Gynecologic Cancer:

G. J. Rustin, M. E. van der Burg on behalf of MRC and EORTC Collaborators

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)
J Clin Oncol (Meeting Abstracts) 2009 27: 1. [Abstract]  

M. W. Audeh, R. T. Penson, M. Friedlander, B. Powell, K. M. Bell-McGuinn, C. Scott, J. N. Weitzel, J. Carmichael, and A. Tutt

Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5500. [Abstract]  

J. A. Ledermann, G. J. Rustin, A. Hackshaw, S. B. Kaye, G. Jayson, H. Gabra, L. E. James, S. Bell, and G. Temple

A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5501. [Abstract]  

M. Zweifel, G. Jayson, N. Reed, R. Osborne, B. Hassan, G. Shreeves, L. Poupard, P. A. Walicke, J. Balkissoon, D. Chaplin, and G. Rustin

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
J Clin Oncol (Meeting Abstracts) 2009 27: 5502. [Abstract]  

W. K. Huh, J. M. Straughn, Jr., and D. E. Cohn

In vitro chemoresponse assay results and population chemotherapy response rates in endometrial cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5503. [Abstract]  

A. Karam, J. Wang Chiang, E. Fung, V. Nossov, and B. Y. Karlan

Influence of residual disease and extreme drug resistance assays on outcome in patients with epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5504. [Abstract]  

C. F. Levenback, C. Tian, R. L. Coleman, M. A. Gold, J. M. Fowler, and P. L. Judson

Sentinel node (SN) biopsy in patients with vulvar cancer: A Gynecologic Oncology Group (GOG) study
J Clin Oncol (Meeting Abstracts) 2009 27: 5505. [Abstract]  

F. Lecuru, A. Bats, P. Mathevet, D. Querleu, E. Leblanc, P. Morice, E. Darai, H. Marret, C. Collin, G. Chatellier, and F. Gilaizeau

Impact of sentinel lymph node biopsy on staging of early cervical cancer: Results of a prospective, multicenter study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA5506. [Abstract]  

A. Dueñas-González, J. J. Zarba, J. C. Alcedo, P. Pattarunataporn, S. Beslija, F. Patel, L. Casanova, H. Barraclough, and M. Orlando

A phase III study comparing concurrent gemcitabine (Gem) plus cisplatin (Cis) and radiation followed by adjuvant Gem plus Cis versus concurrent Cis and radiation in patients with stage IIB to IVA carcinoma of the cervix
J Clin Oncol (Meeting Abstracts) 2009 27: CRA5507. [Abstract]  

S. Pignata, G. Scambia, A. Savarese, R. Sorio, E. Breda, G. Ferrandina, V. Gebbia, P. Musso, C. Gallo, and F. Perrone

Carboplatin plus paclitaxel (CP) versus carboplatin plus stealth liposomal doxorubicin (CLD) in patients with advanced ovarian cancer (AOC): Activity and safety results of the MITO-2 randomized multicenter trial
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5508. [Abstract]  

E. Pujade-Lauraine, S. Mahner, J. Kaern, V. Gebski, M. Heywood, P. Vasey, A. Reinthaller, I. Vergote, S. Pignata, and A. Ferrero

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5509. [Abstract]  

J. Herrstedt, J. Huober, F. Priou, H. Müller, M. Baekelandt, C. Kurzeder, J. Pfisterer, A. Stähle, I. Ray-Coquard, and A. du Bois

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin (TCG) versus paclitaxel-carboplatin (TC) as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients
J Clin Oncol (Meeting Abstracts) 2009 27: LBA5510. [Abstract]  

J. E. Dodge, H. Mackay, S. Klachook, M. Bernardini, P. Shaw, K. J. Murphy, E. Lo, B. P. Rosen, and O. Freedman

What is the optimal strategy to confirm the diagnosis of epithelial ovarian carcinoma (EOC) prior to neoadjuvant chemotherapy (NAC)?
J Clin Oncol (Meeting Abstracts) 2009 27: 5511. [Abstract]  

D. de Jong, J. E. Dodge, O. Freedman, E. Lo, B. P. Rosen, and H. Mackay

Predictors for optimal cytoreduction following neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5512. [Abstract]  

C. Zamagni, P. De Iaco, M. Rosati, N. Cacciari, F. Rosati, D. Rubino, and A. A. Martoni

Effect of six courses of neoadjuvant chemotherapy on pathological complete remission in advanced ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5513. [Abstract]  

S. Mahner, A. Staehle, C. zu Eulenburg, K. Wegscheider, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, J. Pfisterer, and A. du Bois

Prognostic impact of the time interval between primary surgery and start of first-line chemotherapy in patients with advanced ovarian cancer: Analysis of prospective randomized phase III trials
J Clin Oncol (Meeting Abstracts) 2009 27: 5514. [Abstract]  

M. A. Powell, V. L. Filiaci, P. G. Rose, R. S. Mannel, P. Hanjani, K. DeGeest, B. E. Miller, N. Susumu, and F. R. Ueland

A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study
J Clin Oncol (Meeting Abstracts) 2009 27: 5515. [Abstract]  

L. A. Cantrell, L. Havrilesky, D. O'Malley, M. Liotta, A. A. Secord, C. Nagel, A. N. Fader, A. Wallace, P. Rose, and P. A. Gehrig

Effect of treatment of patients with early-stage uterine carcinosarcoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5516. [Abstract]  

C. Kosmas, N. Mylonakis, G. Tsakonas, G. Vorgias, N. Pantelis, P. Politis, N. Kalinoglou, N. Tsavaris, T. Akrivos, and A. Karabelis

Paclitaxel (T), ifosfamide (I), and carboplatin (Cb) (TICb) combination chemotherapy in advanced uterine and adnexal malignant mixed mullerian tumors (MMMTs)
J Clin Oncol (Meeting Abstracts) 2009 27: 5517. [Abstract]  

D. M. O'Malley, C. Nagel, L. A. Cantrell, L. Havrilesky, M. Liotta, A. Alvarez Secord, A. Nickles, D. E. Cohn, A. Wallace, P. Rose, and P. Gehrig

Improved outcomes in advanced stage uterine carcinosarcoma (mixed mullerian tumor [MMT])
J Clin Oncol (Meeting Abstracts) 2009 27: 5518. [Abstract]  

S. Movva, H. Arias-Pulido, A. Chavez, N. Joste, L. Lomo, S. J. Lee, and C. F. Verschraegen

Expression of the epidermal growth factor receptor (EGFR) pathway in cervical cancer (CC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2009 27: 5519. [Abstract]  

B. Monk, L. Mas, J. J. Zarba, A. Oaknin, C. Tarpin, W. Termrungruanglert, J. A. Alber, J. Ding, N. W. Stutts, and L. N. Pandite

A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5520. [Abstract]  

J. H. Farley, M. Sill, J. L. Walker, R. J. Schilder, J. T. Thigpen, R. L. Coleman, and B. E. Miller

Phase II evaluation of cisplatin plus cetuximab in the treatment of recurrent and persistent cancers of the cervix: A limited access phase II study of the Gynecologic Oncology Group
J Clin Oncol (Meeting Abstracts) 2009 27: 5521. [Abstract]  

G. Oskay-Oezcelik, A. du Bois, P. A. Fasching, S. Mahner, C. Liebrich, A. Glaβ, S. Schmidt-Wetze, L. Sepp, K. Münstedt, W. Lichtenegger, and J. Sehouli

What do patients think about CA-125 monitoring in the follow-up? Results from a multicenter trial in 1,060 patients with ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5522. [Abstract]  

D. Chi, O. Zivanovic, V. Kolev, C. Yu, D. A. Levine, Y. Sonoda, N. R. Abu-Rustum, J. Huh, R. R. Barakat, and M. W. Kattan

Nomogram for predicting 5-year survival after primary surgery for epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5523. [Abstract]  

T. C. Chua, G. Robertson, R. Farrell, W. Liauw, T. D. Yan, and D. L. Morris

Systematic review of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian peritoneal carcinomatosis: A more efficacious way of delivering intraperitoneal chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: 5524. [Abstract]  

C. S. Awtrey, K. E. Greenawalt, J. M. Colt, R. L. Corazzini, M. Philbrook, M. R. Santos, and R. E. Bristow

Tissue levels of cisplatin in previously traumatized tissue without adhesion formation in a rabbit sidewall adhesion and intraperitoneal delivery model
J Clin Oncol (Meeting Abstracts) 2009 27: 5525. [Abstract]  

C. N. Krasner, A. Poveda, T. Herzog, J. Vermorken, B. Monk, P. Zintl, J. Li, Y. Su, R. Dhawan, and S. Kaye

Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone
J Clin Oncol (Meeting Abstracts) 2009 27: 5526. [Abstract]  

J. E. Carser, J. E. Quinn, C. O. Michie, W. G. McCluggage, A. R. Williams, P. B. Mullan, C. M. Gourley, and D. P. Harkin

BRCA1 protein expression as a predictor of outcome following chemotherapy in sporadic epithelial ovarian cancer (EOC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5527. [Abstract]  

B. Hennessy, K. Timms, M. S. Carey, A. Gutin, R. Broaddus, A. Gonzalez-Angulo, J. Lanchbury, K. Lu, and G. B. Mills

Somatic BRCA status in ovarian tumors
J Clin Oncol (Meeting Abstracts) 2009 27: 5528. [Abstract]  

M. Smoter, B. Grala, L. Bodnar, and C. Szczylik

Tau expression as a predictive marker in ovarian cancer patients (pts) treated with platinum/paclitaxel chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: 5529. [Abstract]  

K. D. Steffensen, M. Waldstrøm, and A. Jakobsen

Association of ERCC1 protein expression to platinum resistance in epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5530. [Abstract]  

C. Aghajanian, M. W. Sill, K. Darcy, B. Greer, D. S. McMeekin, P. G. Rose, J. Rotmensch, M. N. Barnes, P. Hanjani, and K. Leslie

A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study
J Clin Oncol (Meeting Abstracts) 2009 27: 5531. [Abstract]  

G. Emons, A. Guenthert, F. Thiel, O. Camara, H. Strauss, G. Breitbach, H. Koelbl, T. Reimer, D. Finas, and K. Rensing

Results from a phase II study to assess the efficacy and tolerability of fulvestrant 250 mg/month as treatment of recurrent or metastatic endometrial carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5532. [Abstract]  

J. Qian, D. Weber, R. Cochran, D. Hossain, and D. G. Bostwick

Detection of chromosomal anomalies in uterine endometrial carcinoma using fluorescence in situ hybridization (UteroFISH)
J Clin Oncol (Meeting Abstracts) 2009 27: 5533. [Abstract]  

H. Mackay, S. Gallinger, M. Tsao, C. M. McLachlin, K. Kieser, E. Eisenhauer, D. Tu, and A. Oza

Microsatellite instability and loss of PTEN expression in early versus late-stage endometrial cancer: Results from studies of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG)
J Clin Oncol (Meeting Abstracts) 2009 27: 5534. [Abstract]  

Y. Aoki, M. Inamine, M. Hirakawa, W. Kudaka, and Y. Nagai

Heparanase expression and angiogenesis in endometrial cancer: Analyses of RT-PCR and immunohistochemistry
J Clin Oncol (Meeting Abstracts) 2009 27: 5535. [Abstract]  

S. S. Dawood, C. Albaracin, A. Gonzalez-Angulo, M. Markman, and B. Hennessy

Effect of introduction of paclitaxel on survival among women with stage III and IV ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5536. [Abstract]  

S. B. Kaye, P. Vasey, G. Rustin, S. Pledge, C. Williams, H. Gabra, G. Skailes, A. Lamont, L. Lewsley, J. Paul, and Scottish Gynaecological Cancer Trials Group

Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4)
J Clin Oncol (Meeting Abstracts) 2009 27: 5537. [Abstract]  

M. E. Burg, J. T. Janssen, P. B. Ottevanger, L. G. Kerkhofs, F. Valster, J. M. Stouthard, W. Onstenk, F. Termorshuizen, and J. Verweij

Multicenter randomized phase III trial of 3-weekly paclitaxel/platinum (PC3w) versus weekly paclitaxel/platinum (PCw) induction therapy followed by PC3w maintenance therapy in advanced epithelial ovarian cancer (EOC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5538. [Abstract]  

J. A. Konner, D. Grabon, S. Pezzulli, A. Iasonos, P. Sabbatini, M. Hensley, K. Bell-McGuinn, W. Tew, D. Spriggs, and C. Aghajanian

A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5539. [Abstract]  

D. D. McMeekin, G. Lanneau, J. Curiel, K. Moore, J. Walker, and R. Mannel

Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 5540. [Abstract]  

W. P. Tew, R. O'Cearbhaill, Q. Zhou, H. Thaler, J. Konner, M. L. Hensley, P. Sabbatini, D. Spriggs, C. Aghajanian, and S. M. Lichtman

Intraperitoneal chemotherapy (IPC) in older women with epithelial ovarian cancer (EOC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5541. [Abstract]  

J. Bereder, O. Glehen, J. Habre, M. Desantis, E. Cotte, N. Mounier, I. Ray-Cocquard, B. Karimdjee, N. Bakrin, J. Bernard, D. Benchimol, and F. Gilly

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: A multiinstitutional study of 246 patients
J Clin Oncol (Meeting Abstracts) 2009 27: 5542. [Abstract]  

A. Tiersten, M. Sill, F. Muggia, C. Elera, A. Garcia, P. Fracasso, R. Swensen, D. Warshal, R. Mannel, and Gynecologic Oncology Group

Phase I/feasibility trial of dose-dense carboplatin (C) and paclitaxel (P) in patients (pts) with ovarian cancer: A Gynecologic Oncology Group study
J Clin Oncol (Meeting Abstracts) 2009 27: 5544. [Abstract]  

A. Reyners, W. M. Smit, M. S. Schaapveld, K. Hoekman, F. Erdkamp, R. Lalisang, H. Graaf, M. A. Wymenga, M. Polee, and P. H. Willemse

Adding the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin in first line for stage IC-IV epithelial ovarian cancer: A randomized phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: 5545. [Abstract]  

P. G. Rose, R. Drake, P. S. Braly, M. C. Bell, R. M. Wenham, J. H. Hines, A. Alvarez-Secord, E. Soltes-Rak, B. H. Childs, and T. J. Herzog

Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
J Clin Oncol (Meeting Abstracts) 2009 27: 5546. [Abstract]  

Y. Kikuchi, Sr., H. Kouta, R. Kikuchi, M. Takano, T. Kita, K. Kudoh, D. Aoki, T. Sugiyama, and S. Isonishi

Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5547. [Abstract]  

F. M. Muggia, L. Boyd, L. Liebes, A. Downey, C. Muller, B. Pothuri, S. Blank, T. Rutledge, D. Fishman, and C. Verschraegen

Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome results
J Clin Oncol (Meeting Abstracts) 2009 27: 5548. [Abstract]  

R. L. Coleman, A. Kamat, R. Iyer, V. Kundra, M. Garcia, R. B. Jaffe, and A. K. Sood

Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5549. [Abstract]  

T. J. Herzog, J. B. Vermorken, E. Pujade-Lauraine, J. Li, E. Bayever, J. Gomez, A. Yovine, and B. J. Monk

Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone
J Clin Oncol (Meeting Abstracts) 2009 27: 5550. [Abstract]  

A. Poveda, S. B. Kaye, R. T. McCormack, S. Wang, D. Ricci, E. Broderick, T. Parekh, C. Lebedinsky, J. C. Tecero, and B. J. Monk

Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD
J Clin Oncol (Meeting Abstracts) 2009 27: 5551. [Abstract]  

I. Vergote, N. J. Finkler, J. B. Hall, O. Melnyk, R. P. Edwards, M. Jones, L. Meng, G. L. Brown, E. M. Rankin, J. J. Burke, II, and P. G. Rose

Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5552. [Abstract]  

J. Sehouli, G. Oskay-Oezcelik, D. Stengel, P. Harter, C. Kurzeder, A. Belau, A. Belau, S. Markmann, R. Lorenz, L. Mueller, and W. Lichtenegger

Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO)
J Clin Oncol (Meeting Abstracts) 2009 27: 5553. [Abstract]  

C. Choi, Y. Lee, C. Kim, H. Kang, T. Kim, J. Lee, J. Lee, D. Bae, and B. Kim

Phase II study of CKD602, a camptothecin analog, in combination with carboplatin for the treatment of recurrent ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5554. [Abstract]  

F. Joly, B. Weber, P. Pautier, M. Fabbro, F. Selle, S. Krieger, A. Leconte, H. Bourgeois, and M. Henry-Amar

Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum-based chemotherapy: A French FEDEGYN-FNCLCC phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: 5555. [Abstract]  

N. LaNatra, H. Hochster, F. Muggia, S. V. Blank, J. Curtin, D. Fishman, I. E. Shapira, G. L. Goldberg, S. Parise, and A. Tiersten

Oxaliplatin plus continuous infusion topotecan: First stage of an ongoing phase II study for recurrent ovarian cancer: A New York Cancer Consortium study (#N01-CM62204)
J Clin Oncol (Meeting Abstracts) 2009 27: 5556. [Abstract]  

L. Gladieff, A. Lortholary, R. Largillier, B. Weber, J. Alexandre, X. Durando, B. Slama, J. Dauba, D. Paraiso, and E. Pujade-Lauraine

Weekly paclitaxel (wP) as single agent or in combination with weekly topotecan (wT) or carboplatin (C) in patients with resistant ovarian cancer (ROC): The phase II CARTAXHY randomized trial from GINECO
J Clin Oncol (Meeting Abstracts) 2009 27: 5557. [Abstract]  

S. Kumagai, T. Shoji, Y. Yokoyama, T. Takano, H. Mizunuma, N. Yaegashi, and T. Sugiyama

A phase II trial of combination irinotecan and oral etoposide chemotherapy in recurrent ovarian cancer: A Tohoku Gynecologic Cancer Unit (TGCU) study
J Clin Oncol (Meeting Abstracts) 2009 27: 5558. [Abstract]  

H. W. Hirte, W. McGuire, R. Edwards, A. Husain, P. Hoskins, J. Michels, U. Matulonis, C. Sexton, and G. Michelson

A phase II trial of voreloxin in women with platinum-resistant ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5559. [Abstract]  

I. B. Vergote, N. Colombo, E. Kutarska, J. Del Campo, C. Pippitt, A. Casado, E. Lengyel, K. Gilder, S. Ho, and R. J. Schilder

Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5560. [Abstract]  

M. L. Hensley, S. Kravetz, C. Sima, W. Tew, L. Pereira, P. Sabbatini, C. Whalen, C. A. Aghajanian, C. Zarwan, and S. Berlin

Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PR-EOC): A CTEP-sponsored phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: 5561. [Abstract]  

R. M. Glasspool, M. Gore, G. Rustin, I. McNeish, R. Wilson, S. Pledge, J. Paul, M. Mackean, S. Halford, S. Kaye, and on behalf of the Scottish Gynaecological Cancer Trials Group

Randomized phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5562. [Abstract]  

W. M. Smit, J. Sufliarsky, T. L. Werner, D. Dizon, M. Wagnerova, H. W. Hirte, R. Delaney, J. Li, D. Weber, and J. H. Schellens

A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5563. [Abstract]  

A. Montes, S. K. Sandhu, C. Rothermundt, I. Coombes, R. A'Hern, C. Keyzor, A. Thomas, S. Kaye, and M. Gore

Phase I feasibility study of carboplatin plus capecitabine followed by maintenance capecitabine in patients (pts) with recurrent platinum-sensitive epithelial ovarian cancer (EOC)
J Clin Oncol (Meeting Abstracts) 2009 27: 5564. [Abstract]  

R. T. Morris, D. E. Cohn, J. Fowler, L. A. Solomon, A. Vay, S. Seward, L. Heilbrun, D. Smith, and A. R. Munkarah

Combined weekly docetaxel (D) and gemcitabine (G) for relapsed ovarian cancer (OC) and peritoneal cancer (PC): A multi-institutional phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: 5565. [Abstract]  

L. Chen, H. D. Homesley, D. R. Scribner, Jr., G. H. Cantuaria, Q. He, R. L. Cheek, C. M. Whitehead, H. Doobay, and T. J. Fischer

Performance of a biomarker panel to identify malignancy within a pelvic mass population
J Clin Oncol (Meeting Abstracts) 2009 27: 5566. [Abstract]  

K. M. Darcy, C. Tian, C. B. Ambrosone, T. C. Krivak, D. K. Armstrong, M. A. Bookman, W. Davis, H. Zhao, K. Moysich, and J. A. DeLoia

A Gynecologic Oncology Group study of associations between polymorphisms in ABC transporter genes (ABCB1, ABCC2, and ABCG2) and outcome in advanced stage epithelial ovarian cancer treated with platinum and taxane chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: 5567. [Abstract]  

P. Figueroa, Sr., C. Castro Hernández, M. Santibáñez Andrade, M. Díaz Romero, F. Morales Vázquez, D. Gallardo Rincón, and L. A. Herrera Montalvo

Association between Mad1 G558A and ERCC1 C8092A polymorphisms and response to induction chemotherapy in advanced ovarian carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5568. [Abstract]  

L. R. Boyd, A. P. Novetsky, and J. P. Curtin

Ovarian cancer treatment in the New York City municipal hospital system
J Clin Oncol (Meeting Abstracts) 2009 27: 5569. [Abstract]  

M. Kuhberg, Sr., P. Skowronek, F. Chen, G. Oskay-Oezcelik, G. Oskay-Oezcelik, W. Lichtenegger, W. Lichtenegger, and J. Sehouli

Prediction of nutritional status and intestinal tumor involvement in patients with primary or recurrent ovarian cancer: Results of a prospective study
J Clin Oncol (Meeting Abstracts) 2009 27: 5570. [Abstract]  

T. Pua, A. P. Novetsky, and S. V. Blank

Use of Child-Pugh score to assess perioperative outcome in epithelial ovarian cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 5571. [Abstract]  

J. Alexandre, I. Ray-Coquard, F. Selle, A. Floquet, P. Cottu, B. Weber, C. Falandry, D. Lebrun, E. Pujade-Lauraine for the GINECO-Group

Clinical presentation and sensitivity to platinum-based chemotherapy (CT) of mucinous advanced epithelial ovarian carcinoma (M-AEOC): The GINECO-Group experience
J Clin Oncol (Meeting Abstracts) 2009 27: 5572. [Abstract]  

P. Morice, C. Uzan, A. Kane, A. Rey, S. Gouy, P. Pautier, S. Camatte, C. Lhomme, C. Haie-Meder, and P. Duvillard

Prognostic factors of patients with advanced stage serous borderline tumors of the ovary
J Clin Oncol (Meeting Abstracts) 2009 27: 5573. [Abstract]  

X. Tao, A. K. Sood, M. T. Deavers, K. M. Schmeler, A. M. Nick, R. L. Coleman, D. M. Gershenson, and J. Brown

Antiangiogenic therapy for granulosa cell tumors of the ovary
J Clin Oncol (Meeting Abstracts) 2009 27: 5574. [Abstract]  

J. Brown, M. T. Deavers, A. M. Nick, L. Milojevic, D. M. Gershenson, and A. K. Sood

Clinical relevance of angiogenesis and lymphangiogenesis in patients with sex cord-stromal ovarian tumors
J Clin Oncol (Meeting Abstracts) 2009 27: 5575. [Abstract]  

S. Welch, H. J. Mackay, H. Hirte, G. F. Fleming, R. Morgan, L. Wang, C. Blattler, S. P. Ivy, and A. M. Oza

A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium
J Clin Oncol (Meeting Abstracts) 2009 27: 5576. [Abstract]  

C. Elser, H. Hirte, L. Kaizer, H. Mackay, S. Bindra, L. Tinker, K. MacAlpine, L. Wang, C. Sidor, and A. Oza

Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5577. [Abstract]  

K. Matsuo, M. L. Eno, A. M. Abouzied, D. D. Im, and N. B. Rosenshein

Different expression of progesterone receptor between uterine serous carcinoma and ovarian serous carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5578. [Abstract]  

K. K. Shih, K. Garg, D. A. Levine, N. Kauff, N. R. Abu-Rustum, R. A. Soslow, and R. R. Barakat

DNA mismatch repair protein defects and endometrial cancer in women age 40 and younger
J Clin Oncol (Meeting Abstracts) 2009 27: 5579. [Abstract]  

A. Mendivil, T. J. Vogel, V. L. Bae-Jump, and P. A. Gehrig

A survival comparison between women with uterine serous and/or clear cell carcinoma with and without a history of breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5580. [Abstract]  

D. Robbins, D. Garg, J. Li, and H. Melkonyan

Detection of high-risk HPV in urine of high- and low-risk populations in India
J Clin Oncol (Meeting Abstracts) 2009 27: 5581. [Abstract]  

C. Chen, F. Campbell, J. Patruno, S. Kimmel, R. Boulay, C. Meyers, and M. Martino

Factors associated with regression of cervical dysplasia in adolescents: A retrospective study
J Clin Oncol (Meeting Abstracts) 2009 27: 5582. [Abstract]  

M. W. Kilpatrick, G. R. Jalali, J. Scamporino, A. Menzin, T. Tafas, R. Walat, and P. Tsipouras

Predictive value of gain of 3q for cervical dysplasia and potential utility in the clinical management of LSIL
J Clin Oncol (Meeting Abstracts) 2009 27: 5583. [Abstract]  

A. Fyles, M. Pintilie, D. Hedley, R. Bristow, B. Wouters, R. Hill, and M. Milosevic

High interstitial fluid pressure (IFP) and hypoxia as biomarkers of cisplatin chemoradiation response in advanced cervix cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5584. [Abstract]  

M. Shimada, J. Kigawa, R. Nishimura, M. Hiura, M. Hatae, K. Takehara, A. Sato, H. Kurachi, H. Mizunuma, and T. Sugiyama

Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy after radical surgery: SGSG/TGCU Intergroup Surveillance
J Clin Oncol (Meeting Abstracts) 2009 27: 5585. [Abstract]  

M. McCormack, J. A. Ledermann, M. A. Hall-Craggs, R. P. Symonds, V. Warwick, H. Simonds, I. Fernando, and A. Hackshaw

A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5586. [Abstract]  

M. Marinaccio, E. De Marino, E. Mele, R. Catacchio, C. Pellegrino, V. Pinto, and S. Schonauer

Paclitaxel, ifosfamide, and cisplatin regimen as neoadjuvant chemotherapy in young women with locally advanced squamous cervical cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 5587. [Abstract]  

M. Tanioka, N. Katsumata, T. Hirata, M. Yunokawa, K. Yonemori, T. Kouno, C. Shimizu, K. Tamura, M. Andoh, and Y. Fujiwara

Secondary platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: 5588. [Abstract]  

L. dos Santos, K. Garg, J. P. Diaz, R. A. Soslow, M. L. Hensley, K. M. Alektiar, R. R. Barakat, and M. M. Leitao, Jr.

Incidence of adnexal and lymph node metastases in endometrial stromal sarcoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5589. [Abstract]  

R. O'Cearbhaill, Q. Zhou, A. Iasonos, R. A. Soslow, M. M. Leitao, Jr., C. A. Aghajanian, and M. L. Hensley

Evaluation of the role of aromatase inhibitors (AIs) in the treatment of uterine leiomyosarcoma (uLMS)
J Clin Oncol (Meeting Abstracts) 2009 27: 5590. [Abstract]  

C. Townsley, H. Hirte, P. Hoskins, R. Buckanovich, H. Mackay, S. Welch, L. Wang, R. Polintan, A. Chen, and A. M. Oza

A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium
J Clin Oncol (Meeting Abstracts) 2009 27: 5591. [Abstract]  

C. E. Hill-Kayser, C. Vachani, M. K. Hampshire, L. A. Jacobs, and J. M. Metz

Utilization of Internet-based survivorship care plans by survivors of gynecologic cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 5592. [Abstract]  

F. Murakami, N. Ogawa, A. Yamazaki, S. Sakurai, T. Ishiya, K. Katase, Y. Shimizu, and S. Tanada

Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5593. [Abstract]  

V. E. Von Gruenigen, H. Frasure, N. Fusco, E. Eldermire, S. Eaton, and S. Waggoner

A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmar-plantar erythrodysesthesia
J Clin Oncol (Meeting Abstracts) 2009 27: 5594. [Abstract]  

C. Touboul, C. Uzan, S. Gouy, A. Rey, A. Maugen, Y. Delpech, O. Chanelles, P. Pautier, C. Lhomme, P. Duvillard, C. Haie-Meder, and P. Morice

Postoperative morbidity after completion surgery in patients undergoing chemoradiotherapy for locally advanced cervical carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 5595. [Abstract]  

P. T. Soliman, J. Celestino, S. Finklelstein, R. Broaddus, S. Westin, K. M. Schmeler, K. H. Lu, and R. L. Coleman

Molecular profiling in the diagnosis of synchronous primary cancers of the endometrium and ovary
J Clin Oncol (Meeting Abstracts) 2009 27: e16500. [Abstract]  

C. Morrison, D. Gaile, K. Darcy, S. Liu, L. Shepherd, D. Cohn, S. McMeekin, N. Nowak, and L. Maxwell

A Gynecologic Oncology Group study of frequent copy number aberrations in African American versus Caucasian women with stage I versus stage IIIC/IV endometrioid endometrial cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16501. [Abstract]  

A. Santin, S. Bellone, K. El-Sahwi, N. Buza, F. A. Tavassoli, D. Silasi, M. Azodi, P. E. Schwartz, T. J. Rutherford, and S. Pecorelli

Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16502. [Abstract]  

A. Nickles Fader, P. G. Rose, H. Frasure, P. A. Gehrig, K. N. Moore, L. J. Havrilesky, W. K. Huh, A. E. Axtell, D. M. O'Malley, and K. M. Zanotti

Can primary recurrences in surgical stage I-II uterine papillary serous carcinoma (UPSC) patients be salvaged?
J Clin Oncol (Meeting Abstracts) 2009 27: e16503. [Abstract]  

T. Pejovic, D. P. Gaile, K. M. Darcy, S. Liu, L. Shepherd, W. H. Rodgers, E. Kohn, R. Mannel, M. J. Birrer, and N. Nowak

A Gynecologic Oncology Group study of frequent copy number aberrations in DNA repair genes and other genomic regions in stage I serous ovarian cancers
J Clin Oncol (Meeting Abstracts) 2009 27: e16504. [Abstract]  

L. Randall-Whitis, R. A. Burger, M. Sill, B. J. Monk, B. Buening CCRC, and J. I. Sorosky

Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: e16505. [Abstract]  

P. M. Grimley, R. Matsuno, and W. F. Anderson

Population profiles of extra-ovarian and ovarian serous adenocarcinomas: Comparisons with grade stratification
J Clin Oncol (Meeting Abstracts) 2009 27: e16506. [Abstract]  

D. S. Miller, J. A. Blessing, C. N. Krasner, R. D. Drake, R. Higgins, D. S. McMeekin, and L. V. Puneky

A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
J Clin Oncol (Meeting Abstracts) 2009 27: e16507. [Abstract]  

M. E. Szajnik, M. J. Szczepanski, M. Czystowska, E. Elishaev, M. Mandapathil, E. Nowak-Markwitz, M. Spaczynski, and T. L. Whiteside

Expression and signaling of Toll-like receptor 4 (TLR4) and MyD88 in ovarian carcinoma cells
J Clin Oncol (Meeting Abstracts) 2009 27: e16508. [Abstract]  

H. Kim, W. Ju, B. Jee, J. Kim, Y. Song, and H. Lee

The efficacy of systemic lymphadenectomy for overall survival in epithelial ovarian cancer: A systematic review and meta-analysis by KOGYMAG
J Clin Oncol (Meeting Abstracts) 2009 27: e16509. [Abstract]  

D. L. Richardson, F. J. Backes, L. G. Seamon, L. G. Seamon, J. D. Hurt, D. E. Cohn, J. M. Fowler, L. J. Copeland, and D. M. O'Malley

Does repeat usage of bevacizumab in patients with progressive recurrent ovarian cancer offer a survival advantage?
J Clin Oncol (Meeting Abstracts) 2009 27: e16510. [Abstract]  

K. M. Bermudez Wagner, M. B. Thomas, C. Miyamoto, B. Micaily, and E. Hernandez

Tailored surgical staging and radiation therapy in clinical stage I endometrioid endometrial adenocarcinoma (EEA)
J Clin Oncol (Meeting Abstracts) 2009 27: e16511. [Abstract]  

V. Kolev, S. Mironov, O. Mironov, C. Moskowitz, N. M. Ishill, G. J. Gardner, D. A. Levine, H. Hricak, R. R. Barakat, and D. S. Chi

The prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced stage epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16512. [Abstract]  

I. Beyer, G. J. Bauerschmitz, M. Breidenbach, A. Dragoi, D. Niederacher, W. Janni, and D. T. Rein

Gene therapy for pretreated ovarian cancer via a novel fiber modified mdr1 targeting conditionally replicating adenovirus
J Clin Oncol (Meeting Abstracts) 2009 27: e16513. [Abstract]  

S. Isonishi, R. Matsumoto, M. Hirama, K. Ochiai, T. Tachibana, H. Ishikawa, M. Yasuda, and T. Tanaka

Differential mitochondrial scoring associated with chemotherapeutic effect on ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16514. [Abstract]  

A. Al-Niaimi, B. Manuelli, N. Safdar, R. Chappell, S. Seo, D. Kushner, J. Connor, and E. Hartenbach

Survival with surgical versus medical treatment of patients with bowel obstruction secondary to ovarian cancer recurrence: A 15-year experience
J Clin Oncol (Meeting Abstracts) 2009 27: e16515. [Abstract]  

S. B. Ingersoll, P. Yue, S. Ahmad, J. Turkson, J. R. Edwards, and R. W. Holloway

Molecular characterization of highly tumorigenic cell lines used in a xenograph model to investigate cellular therapy for the treatment of refractory ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16516. [Abstract]  

H. Tsubamoto, R. Wada, R. Kanazawa, S. Komori, H. Maeda, S. Hirota, and S. Adachi

Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16518. [Abstract]  

C. Mercado, D. Zingmond, B. Y. Karlan, E. Sekaris, J. Gross, M. Maggard-Gibbons, J. S. Tomlinson, and C. Y. Ko

Quality of care in advanced ovarian cancer: How important is provider specialty?
J Clin Oncol (Meeting Abstracts) 2009 27: e16519. [Abstract]  

P. H. Thaker, F. Gao, I. Zighelboim, M. A. Powell, J. S. Rader, D. G. Mutch, and N. Kizer

The effects of body mass index on curative radiation therapy in cervical carcinoma: An analysis of complications and survival
J Clin Oncol (Meeting Abstracts) 2009 27: e16520. [Abstract]  

F. AbuShain, P. Escobar, S. Shahabi, C. Michener, R. Drake, P. G. Rose, and P. E. Schwartz

The relevance of rising CA-125 levels within the normal range in predicting recurrence in patients with advanced stage ovarian cancer: A validation study
J Clin Oncol (Meeting Abstracts) 2009 27: e16521. [Abstract]  

D. Reimer, M. Hubalek, S. Riedle, S. Skvortsov, M. Erdel, E. Mueller-Holzner, C. Marth, P. Altevogt, and A. G. Zeimet

Regulation of the EGFR-E2F3a axis by the interferon regulatory factor (IRFs) and by promoter methylation of miR-34a in ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16522. [Abstract]  

D. Vicus, M. Beiner, S. Klachook, L. Le, O. Ginsburg, S. Laframboise, and H. Mackay

Dysgerminoma of the ovary 35 years on: A single institutional experience
J Clin Oncol (Meeting Abstracts) 2009 27: e16523. [Abstract]  

E. Espino-Strebel and J. T. Luna

Correlation between preoperative serum CA 125 and surgicopathologic prognostic factors in endometrial cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16524. [Abstract]  

E. Nugent, A. S. Case, I. Zighelboim, L. DeWitt, P. H. Thaker, L. S. Massad, M. A. Powell, D. G. Mutch, K. Trinkhaus, and J. S. Rader

Chemoradiation in locally advanced cervical carcinoma: An analysis of cisplatin administration and other clinical prognostic factors
J Clin Oncol (Meeting Abstracts) 2009 27: e16525. [Abstract]  

E. Tominaga, H. Tsuda, T. Arao, S. Nishimura, T. Chiyoda, H. Nomura, F. Kataoka, N. Susumu, D. Aoki, and K. Nishio

Use of amplification of the 8q24 and 20q11–13 loci to predict progression-free survival of advanced epithelial ovarian cancer patients receiving standard therapy
J Clin Oncol (Meeting Abstracts) 2009 27: e16526. [Abstract]  

K. El Khalfaoui, G. Oskay-Ozcelik, R. Richter, K. Pietzner, P. Harter, K. Münstedt, S. Mahner, A. Hasenburg, P. Wimberger, and J. Sehouli

Prognostic factors in ovarian cancer patients with brain metastases: Results of a German multicenter study
J Clin Oncol (Meeting Abstracts) 2009 27: e16527. [Abstract]  

M. Schlumbrecht, D. Urbauer, D. Gershenson, and R. Broaddus

Prognostic significance of obesity in high-grade serous carcinoma of the ovary
J Clin Oncol (Meeting Abstracts) 2009 27: e16528. [Abstract]  

L. Elit, A. Lee, J. Julian, P. Hoskins, D. Julian, S. Parpia, and M. Levine

Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study
J Clin Oncol (Meeting Abstracts) 2009 27: e16529. [Abstract]  

U. Gueth and E. Wight

Sequential or combination therapy in the management of recurrent ovarian carcinoma: Clinical experience beyond clinical trials
J Clin Oncol (Meeting Abstracts) 2009 27: e16530. [Abstract]  

K. Odunsi, S. Ghamande, M. Macfee, A. Yin Chieh Yu, S. B. Lele, K. J. Rodabaugh, B. Thomas, and W. C. Zamboni

A phase II, pharmacokinetic (PK), and pharmacodynamic (PD) study of weekly docetaxel (DOC) in patients with platinum-resistant ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16531. [Abstract]  

K. Takehara, K. Miyamoto, Y. Kawakami, M. Kumagai, O. Samura, M. Egawa, H. Nakamura, T. Mizunoe, K. Taniyama, and F. Saji

Epigenetic alteration of BRCA1 in human ovarian tumors
J Clin Oncol (Meeting Abstracts) 2009 27: e16532. [Abstract]  

A. Tibau, I, B. Ojeda, I, R. Nadal, I, J. Pérez Altozano, I, I. Boguña, I, V. Artigas, I, A. Gallardo, I, C. Pérez, I, J. Lopez, I, and A. Barnadas, I

The predictive and prognostic value of serum CA 125 kinetics and CA 125 nadir during paclitaxel/platinum based chemotherapy in patients with advanced ovarian carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16534. [Abstract]  

B. Nayl, X. Durando, C. Pomel, P. Dubray, M. Mouret-Reynier, G. Le Bouedec, P. Gimbergues, P. Chollet, J. Dauplat, and H. Cure

Six versus nine cycles of paclitaxel-carboplatin as first-line chemotherapy in patients with newly diagnosed epithelial advanced ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16535. [Abstract]  

M. Takano, M. Kato, T. Yoshikawa, J. Hirata, M. Takahashi, H. Yokota, N. Kino, T. Goto, R. Konno, and H. Fujiwara

A pharmacogenetic UGT1A1 dose-escalation study for recurrent and refractory gynecologic cancer patients treated with combination therapy of irinotecan and cisplatin
J Clin Oncol (Meeting Abstracts) 2009 27: e16536. [Abstract]  

C. Davies, K. Garson, F. LeBoeuf, J. Bell, and J. Weberpals

Susceptibility of ascites tumor cells to ex-vivo killing by the oncolytic virus JX-963 in epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16537. [Abstract]  

D. S. Dizon, A. Stuckey, and J. Schwartz

Pegylated liposomal doxorubicin in recurrent serous carcinoma of the uterus
J Clin Oncol (Meeting Abstracts) 2009 27: e16538. [Abstract]  

N. Walji, A. Zachariah, C. Yap, S. A. Hussain, C. J. Poole, A. El-Modir, R. Ganesan, and I. N. Fernando

Carboplatin, ifosfamide, and mesna (CIM) for the treatment of gynecological carcinosarcoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16539. [Abstract]  

M. Friedrich, W. Poleska, J. Baltzer, and D. Salehin

Treatment of pseudomyxoma peritonei by intraoperative and intraperitoneal chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e16540. [Abstract]  

B. Gil, G. Oskay-Oezcelik, R. Richter, U. Neumann, P. Neuhaus, W. Lichtenegger, and J. Sehouli

Do patients with recurrent ovarian cancer benefit from relative tumor reduction? Results from a prospective study
J Clin Oncol (Meeting Abstracts) 2009 27: e16541. [Abstract]  

K. K. Leslie, M. W. Sill, K. M. Darcy, A. T. Baron, J. A. Wilken, A. K. Godwin, L. Cook, R. J. Schilder, J. M. Schilder, and N. J. Maihle

Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16542. [Abstract]  

A. L. Chue, N. Walji, L. J. Rogers, S. A. Hussain, K. K. Chan, K. Singh, and I. N. Fernando

Adjuvant hysterectomy following unsuccessful intracavitary brachytherapy in cervical carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16543. [Abstract]  

D. P. Gaile, L. Shepherd, S. Liu, K. Darcy, M. Brady, and C. Morrison

iGenomicViewer, a Gynecologic Oncology Group software library for the creation of highly customizable, portable, interactive, and linked visualizations of high throughput genomic data
J Clin Oncol (Meeting Abstracts) 2009 27: e16544. [Abstract]  

U. P. Neumann, C. Fotopoulou, P. Neuhaus, and J. Sehouli

Clinical outcome of resection of liver metastasis in patients with ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16545. [Abstract]  

S. Williams, D. Gupta, S. Dahlk, K. E. Dzike, G. M. Lambert, and C. A. Lammersfeld

Significance of changes in serum CA125 level on overall survival in ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16546. [Abstract]  

M. Rollins-Raval, R. Byler Dann, R. P. Edwards, and M. Chivukula

Clinical outcome in patients with endometrial papillary serous and endometrioid carcinomas as related to WT-1, Pax-2, and p16 immunohistochemical expression profiles
J Clin Oncol (Meeting Abstracts) 2009 27: e16547. [Abstract]  

H. Kiyohara, S. Kato, T. Ohno, Y. Ohkubo, T. Tamaki, and T. Kamada

Carbon ion radiotherapy for malignant melanoma of female genital organs
J Clin Oncol (Meeting Abstracts) 2009 27: e16548. [Abstract]  

S. Nagao, R. Oishi, N. Iwasa, M. Shimizu, K. Hasegawa, T. Goto, and K. Fujiwara

A feasibility study of intravenous (IV) paclitaxel, intraperitoneal (IP) carboplatin, and IP paclitaxel in patients with epithelial ovarian carcinoma, fallopian tube carcinoma, or peritoneal carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16549. [Abstract]  

M. Arenas Prat, A. Rovirosa, S. Sabater, A. Ameijide, I. Henríquez, S. Servitja, I. Cabezas, E. Mur, and J. Gumà

Experience with endometrial carcinoma (EC): A population-based study in Tarragona Province (Spain)
J Clin Oncol (Meeting Abstracts) 2009 27: e16550. [Abstract]  

S. R. Lord, N. Vasudev, S. Knight, V. Speirs, and G. Hall

Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e16551. [Abstract]  

L. Usha, M. L. Larson, N. Kazmi, T. O'Brien, L. A. Winkelman, and J. Rotmensch

Phase II trial of imatinib mesylate (I) in combination with docetaxel (D) in the treatment of patients (pts) with recurrent or persistent epithelial ovarian carcinoma (EOC)
J Clin Oncol (Meeting Abstracts) 2009 27: e16552. [Abstract]  

K. Wright, E. Munro, M. del Carmen, and A. K. Goodman

Prognosis and comorbidities in stage III and IV endometrial cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16553. [Abstract]  

E. Shrestha

The expression and clinical significance of clusterin and ki67 in cervical cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16554. [Abstract]  

X. Matias-guiu, X. Dolcet, D. Llobet, A. Poveda, J. Pallares, N. Eritia, A. Yeramian, A. Sorolla, E. Ortega, and A. Llombart-Cussac

Targeting the extrinsic apoptotic pathway in endometrial carcinoma cell lines and tumor cell explants
J Clin Oncol (Meeting Abstracts) 2009 27: e16555. [Abstract]  

Y. Kawakami, K. Miyamoto, K. Takehara, M. Kumagai, O. Samura, H. Nakamura, T. Mizunoe, H. Yoshida, K. Taniyama, and F. Saji

Down-regulation of MDR1 by epigenetic alteration in human epithelial ovarian cancer cells
J Clin Oncol (Meeting Abstracts) 2009 27: e16556. [Abstract]  

M. Heubner, S. Kasimir-Bauer, D. Errico, D. Herlyn, R. Kimmig, and P. Wimberger

Role of an EpCAM auto-antibody in ovarian cancer patients with special regard to disseminated tumor cells in bone marrow
J Clin Oncol (Meeting Abstracts) 2009 27: e16557. [Abstract]  

Y. Niibe, T. Ariga, T. Kazumoto, T. Kodaira, H. Etou, O. Suzuki, R. Kinoshita, K. Tsujino, M. Takemoto, and K. Hayakawa

Curative intended radiation therapy for young patients with invasive uterine cervical carcinoma: Clinical outcomes in 105 patients in a Japanese multi-institutional study
J Clin Oncol (Meeting Abstracts) 2009 27: e16558. [Abstract]  

H. F. Oliveira, F. M. Peria, J. M. Andrade, H. R. Marana, A. C. Santos, L. M. Mendonça, and J. Elias, Jr

Survival impact of neoadjuvant treatment in cervical cancer stage IIB
J Clin Oncol (Meeting Abstracts) 2009 27: e16559. [Abstract]  

A. M. Oaknin, M. Romeo, F. Pons, X. Perez, P. Barretina, A. Vidal, L. Martí, M. Barahona, J. Germá, and J. Ponce

Behavior of borderline ovarian tumours (BOTs): Single institution experience
J Clin Oncol (Meeting Abstracts) 2009 27: e16560. [Abstract]  

A. Shaharyar, N. Shami, N. Zia, M. Hafeez, H. Rasheed, T. Saleem, S. Zulfiqar, and A. I. Masood

Treatment of advanced chemo-refractory epithelial ovarian cancer with aromatase inhibitor
J Clin Oncol (Meeting Abstracts) 2009 27: e16561. [Abstract]  

J. J. Diaz, Sr., Mr B. Thomas, and E. Hernandez

Outcome analysis of stage II and III cervical carcinoma: Importance of optimal radiation therapy
J Clin Oncol (Meeting Abstracts) 2009 27: e16562. [Abstract]  

R. K. Hanna, A. Shafer, and L. Van Le

Capping the dose of paclitaxel in endometrial cancer patients: Does this affect clinical outcome?
J Clin Oncol (Meeting Abstracts) 2009 27: e16563. [Abstract]  

P. Skowronek, M. Kuhberg, F. Chen, J. Schwarz, W. Lichtenegger, and J. Sehouli

Impact of malnutrition on surgical outcome of patients with ovarian cancer: Results of a prospective study
J Clin Oncol (Meeting Abstracts) 2009 27: e16564. [Abstract]  

J. N. Bottsford-Miller, A. Shafer, A. Deal, L. Filip, and W. Fowler

Hematologic toxicities before and during bevacizumab chemotherapy in women with gynecologic malignancy
J Clin Oncol (Meeting Abstracts) 2009 27: e16565. [Abstract]  

J. S. Ferriss, W. Brix, M. Henretta, K. Hanley, M. Stoler, L. Duska, and S. Modesitt

Extent of cervical involvement in endometrial cancer as a predictor of outcome
J Clin Oncol (Meeting Abstracts) 2009 27: e16566. [Abstract]  

A. P. Novetsky, T. L. Pua, and J. P. Curtin

Effects of ascites on perioperative and postoperative outcome in epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16567. [Abstract]  

R. Chekerov, A. Coumbos, J. Sehouli, D. Schaedel, G. Oskay-Oezcelik, W. Lichtenegger, and W. Kuehn

Current management of borderline ovarian tumors: A multicenter survey of 323 clinics in Germany, on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO)
J Clin Oncol (Meeting Abstracts) 2009 27: e16568. [Abstract]  

C. K. Basu, A. Mukhopadhyay, R. Pandey, and S. Dey

Pegylated liposomal doxorubicin in ovarian cancer patients with renal compromise
J Clin Oncol (Meeting Abstracts) 2009 27: e16569. [Abstract]  

J. Pariyar

Gestational trophoblastic disease in Nepalese women managed in B. P. Koirala Memorial Cancer Hospital
J Clin Oncol (Meeting Abstracts) 2009 27: e16570. [Abstract]  

T. Sawasaki and Y. Katsube

The Ep-CAM: A potential candidate for diagnosis in ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16571. [Abstract]  

S. Sirop, S. Saha, M. Soni, B. Chkravarty, A. Korant, N. Dutt, D. Wilson, P. Ng, M. Arora, and T. Singh

A second peritoneal cytology instead of the initial cytology as a prognostic factor in epithelial ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16572. [Abstract]  

F. Morales-Vasquez, D. Gallardo, L. Tirado, H. N. López-Basave, D. Cantú, and C. Mendez

Retrospective analysis: Patients with ovarian cancer at National Cancer Institute of Mexico
J Clin Oncol (Meeting Abstracts) 2009 27: e16573. [Abstract]  

R. Scheusan, S. Curescu, D. Stanculeanu, and P. Curescu

Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16574. [Abstract]  

G. Dangal

Surgical treatment for early cervical cancer: Experience at a cancer hospital in Nepal
J Clin Oncol (Meeting Abstracts) 2009 27: e16575. [Abstract]  

K. Y. Terada, J. Davis, J. Kitayama, and D. Shimizu

Hormonal treatment of metastatic endometrial stromal sarcoma
J Clin Oncol (Meeting Abstracts) 2009 27: e16576. [Abstract]  

M. A. Seoud, K. M. Seoud, S. Lindely, and S. Anis

Human papilloma virus (HPV): Burden of the disease in cervical cancer in the Extended Middle East and North Africa (EMENA). A comprehensive review
J Clin Oncol (Meeting Abstracts) 2009 27: e16577. [Abstract]  

J. De La Mota, B. Thomas, W. Fengwei, B. Micaily, H. Yajue, and E. Hernandez

Surgical and immunohistochemical (IC) risk factors for metastatic disease in stage IB1 cervical cancer (CC)
J Clin Oncol (Meeting Abstracts) 2009 27: e16578. [Abstract]  

A. Chudecka-Glaz, D. Zielinska, and I. Rzepka-Górska

YKL-40 and CA 125 serum levels in patients with ovarian cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e16579. [Abstract]  

D. Uddin, K. N. Begum, H. Akthar, and M. Faruqui

Carcinoma of uterine cervix: Top ranking in our country
J Clin Oncol (Meeting Abstracts) 2009 27: e16580. [Abstract]  

Special Awards:

Clara D. Bloomfield

Importance of genetic heterogeneity in curing adult acute leukemia (AL)
J Clin Oncol (Meeting Abstracts) 2009 27: s1. [Abstract]  

Bert Vogelstein

Cancer genomes and their implications for understanding and managing cancer
J Clin Oncol (Meeting Abstracts) 2009 27: s1a. [Abstract]  

Olufunmilayo Olopade

A family-based approach to primary prevention of breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: s2. [Abstract]  

Martine Extermann

Geriatric oncology: The ultimate personalized cancer care
J Clin Oncol (Meeting Abstracts) 2009 27: s2a. [Abstract]  

William E. Evans and Mary V. Relling

Pharmacogenomics of childhood acute lymphoblastic leukemia (ALL)
J Clin Oncol (Meeting Abstracts) 2009 27: s3. [Abstract]  

Developmental Therapeutics: Immunotherapy:

S. J. Schuster, S. S. Neelapu, B. L. Gause, F. M. Muggia, J. P. Gockerman, E. M. Sotomayor, J. N. Winter, C. R. Flowers, A. M. Stergiou, L. W. Kwak for the BiovaxID Phase III Study Investigators

Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results
J Clin Oncol (Meeting Abstracts) 2009 27: 2. [Abstract]  

M. L. Disis, L. G. Salazar, A. Coveler, J. Waisman, D. Higgins, J. Childs, N. Bates, and Y. Dang

Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
J Clin Oncol (Meeting Abstracts) 2009 27: 3000. [Abstract]  

E. G. Iliopoulou, P. Kountourakis, M. V. Karamouzis, D. Doufexis, A. Ardavanis, C. N. Baxevanis, G. Rigatos, M. Papamichail, and S. A. Perez

A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2009 27: 3001. [Abstract]  

D. W. O'Neill, S. Adams, J. D. Goldberg, J. B. Escalon, L. M. Rolnitzky, C. M. Cruz, A. Angiulli, L. Old, A. C. Pavlick, and N. Bhardwaj

Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines
J Clin Oncol (Meeting Abstracts) 2009 27: 3002. [Abstract]  

J. E. Castro, J. D. Sandoval-Sus, J. Melo-Cardenas, D. Darrah, M. Urquiza, R. S. Pakbaz, C. E. Prussak, and T. J. Kipps

Phase I study of intranodal direct injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with chronic lymphocytic leukemia
J Clin Oncol (Meeting Abstracts) 2009 27: 3003. [Abstract]  

H. H. Soliman, S. Antonia, D. Sullivan, N. Vanahanian, and C. Link

Overcoming tumor antigen anergy in human malignancies using the novel indeolamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT)
J Clin Oncol (Meeting Abstracts) 2009 27: 3004. [Abstract]  

D. Tabagari, G. Nemsadze, M. Jincharadze, M. Janjalia, and J. S. Shan

Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3005. [Abstract]  

M. Morse, R. Chapman, J. Powderly, T. Keler, L. He, V. Ramakrishna, L. Vitale, T. Clay, J. Green, and T. Davis

Phase I clinical results of an APC-targeted hCGβ vaccine (CDX-1307) with TLR agonists
J Clin Oncol (Meeting Abstracts) 2009 27: 3006. [Abstract]  

M. Noguchi, H. Uemura, H. Kumon, Y. Nasu, Y. Hirao, K. Matsuoka, T. Kakuma, A. Yamada, and K. Itoh

A randomized trial of personalized peptide vaccine (PPV) plus low-dose estramustine (EMP) versus full-dose EMP in patients with hormone-refractory prostate cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3007. [Abstract]  

C. L. Slingluff, Jr, G. R. Petroni, W. C. Olson, M. E. Smolkin, M. I. Ross, N. B. Haas, W. W. Grosh, M. E. Boisvert, J. M. Kirkwood, and K. A. Chianese-Bullock

Effect of granulocyte-macrophage colony stimulating factor (GM-CSF) administered with a multipeptide vaccine on circulating CD8⁺ and CD4⁺ T-cell responses: Outcome of a multicenter randomized trial
J Clin Oncol (Meeting Abstracts) 2009 27: 3008. [Abstract]  

C. G. Wood, P. Srivastava, L. Lacombe, A. I. Gorelov, S. Gorelov, P. Mulders, H. Zielinski, F. Teofilovici, L. Isakov, and B. Escudier

Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence
J Clin Oncol (Meeting Abstracts) 2009 27: 3009. [Abstract]  

L. G. Salazar, V. Goodell, M. O'Meara, K. Knutson, Y. Dang, C. dela Rosa, K. A. Guthrie, and M. L. Disis

Persistent immunity and survival after immunization with a HER2/neu (HER2) vaccine
J Clin Oncol (Meeting Abstracts) 2009 27: 3010. [Abstract]  

S. A. Perez, S. Bisias, N. L. Kallinteris, A. Ardavanis, K. G. Georgakopoulou, N. Apostolikas, A. Thanos, M. Papamichail, E. von Hofe, and C. N. Baxevanis

Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3011. [Abstract]  

P. Andrade, A. Deleo, C. Visus, L. Butterfield, A. Argiris, and R. L. Ferris

Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A preliminary report
J Clin Oncol (Meeting Abstracts) 2009 27: 3012. [Abstract]  

H. Fakhrai, A. Tong, J. Nemunaitis, and D. L. Shawler

Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3013. [Abstract]  

H. Lindhofer, A. Schoberth, D. Pelster, J. Hess, J. Herold, and M. Jäger

Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study
J Clin Oncol (Meeting Abstracts) 2009 27: 3014. [Abstract]  

N. Vey, J. Bourhis, H. Dombret, D. Bordessoule, T. Prebet, A. Charbonnier, P. Squiban, B. Damholt, D. Blaise, and D. Olive

A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1–7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML)
J Clin Oncol (Meeting Abstracts) 2009 27: 3015. [Abstract]  

L. Andritsos, R. Furman, I. W. Flinn, A. Foreno-Torres, J. M. Flynn, S. C. Stromatt, and J. C. Byrd

A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL
J Clin Oncol (Meeting Abstracts) 2009 27: 3017. [Abstract]  

J. R. Brahmer, S. L. Topalian, J. Powderly, I. Wollner, J. Picus, C. G. Drake, E. Stankevich, A. Korman, D. Pardoll, and I. Lowy

Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies
J Clin Oncol (Meeting Abstracts) 2009 27: 3018. [Abstract]  

P. Sharma, D. Tsavachidou, A. Kamat, D. Ng Tang, H. Chen, T. Fu, P. Troncoso, J. Wolchok, C. J. Logothetis, and J. P. Allison

Immunologic impact of anti-CTLA-4 therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 3019. [Abstract]  

D. M. Berman, J. Wolchok, J. Weber, O. Hamid, S. O'Day, and S. D. Chasalow

Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
J Clin Oncol (Meeting Abstracts) 2009 27: 3020. [Abstract]  

V. R. Peddareddigari, P. W. Miller, B. B. Nebiyou, W. W. Overwijk, M. I. Ross, J. E. Lee, J. E. Gershenwald, V. G. Prieto, P. Hwu, and L. Radvanyi

Effect of clinical status and previous treatment of melanoma patients on expansion of TIL for adoptive T-cell therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 3021. [Abstract]  

J. Baurain, M. Stas, F. Hammouch, A. Gillain, A. Feyens, N. Van Baren, I. Tromme, R. Van Wijck, M. Garmyn, and P. G. Coulie

Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor-specific antigenic peptides
J Clin Oncol (Meeting Abstracts) 2009 27: 3022. [Abstract]  

S. Bhatia, E. Heath, I. Puzanov, W. Miller, Jr, B. Curti, M. Gordon, M. Ernstoff, D. Hausman, N. Hunder, and J. Thompson

Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results
J Clin Oncol (Meeting Abstracts) 2009 27: 3023. [Abstract]  

J. F. Spicer, M. B. Jameson, P. Savage, D. Jodrell, S. M. Rudman, F. Erlandsson, G. Acton, and M. McKeage

A phase I study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma (MM) or renal cell carcinoma (RCC)
J Clin Oncol (Meeting Abstracts) 2009 27: 3024. [Abstract]  

S. J. Clarke, J. T. Smith, C. Gebbie, C. Sweeney, and N. Olszewski

A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3025. [Abstract]  

R. Amato, J. Hernandez-McClain, R. Harrop, P. Cen, and G. Doshi

Vaccination of renal cell cancer (RCC) patients with modified vaccinia Ankara (MVA) delivering tumor antigen 5T4 administered alone or with interleukin 2 (IL-2) or interferon-alpha (IFN)
J Clin Oncol (Meeting Abstracts) 2009 27: 3026. [Abstract]  

B. Acres, E. Quoix, R. Ramlau, G. Lacoste, B. Marie Bastien, A. Tavernaro, S. Bettinger, N. Bizouarne, J. M. Limacher, and J. Y. Bonnefoy

Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010
J Clin Oncol (Meeting Abstracts) 2009 27: 3027. [Abstract]  

J. Nesselhut, D. R. Lorenzen, D. Marx, R. Y. Chang, C. Matthes, B. Hildenbrand, E. M. Schneider, and T. Nesselhut

Cellular immune suppression in cancer patients and its implication for dendritic cell therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 3028. [Abstract]  

M. Jäger, A. Schoberth, B. Theissen, J. Hess, H. Friccius-Quecke, and H. Lindhofer

Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study
J Clin Oncol (Meeting Abstracts) 2009 27: 3029. [Abstract]  

D. Ma, H. Zhang, B. Kennedy, T. Parsons, and W. C. Olson

Antitumor activity of PSMA ADC after progression on docetaxel in a mouse xenograft model of human prostate cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3030. [Abstract]  

S. Parker, D. Berman, K. L. Bennett, S. Alaparthy, Z. Tsuchihashi, S. D. Chasalow, and P. Zhan

Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab
J Clin Oncol (Meeting Abstracts) 2009 27: 3031. [Abstract]  

D. M. Benson, Jr., F. Romagne, P. Squiban, N. Wagtmann, S. Farag, A. Mita, C. Hofmeister, M. Smith, C. Bakan, and M. Caligiuri

Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results
J Clin Oncol (Meeting Abstracts) 2009 27: 3032. [Abstract]  

M. Ströhlein, F. Lordick, D. Rüttinger, O. Schemanski, M. Jaeger, H. Lindhofer, M. Hennig, A. Lahr, and M. Heiss

Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up
J Clin Oncol (Meeting Abstracts) 2009 27: 3033. [Abstract]  

R. H. Vonderheide, P. M. LoRusso, M. Khalil, E. Heath, D. Khaira, D. Soulieres, P. Dorazio, G. L. Mariani, T. Usari, and S. M. Domchek

Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3034. [Abstract]  

J. C. Byrd, R. Lapalombella, A. Ramanunni, L. A. Andritsos, J. M. Flynn, P. Baum, P. Thompson, and N. Muthusamy

Effect of CD37 small modular immuno-pharmaceutical (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the BH3 family member BIM
J Clin Oncol (Meeting Abstracts) 2009 27: 3035. [Abstract]  

C. Bokemeyer, M. Heiss, H. Gamperl, R. Linke, E. Schulze, H. Friccius-Quecke, H. Lindhofer, and S. Parsons

Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites
J Clin Oncol (Meeting Abstracts) 2009 27: 3036. [Abstract]  

M. Okamoto, S. Yusa, K. Shimamura, T. Ogawa, and T. Tomoda

Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3037. [Abstract]  

I. M. Zitron, O. Norkina, Z. Al-Kadhimi, G. R. Barger, L. G. Lum, and S. Mittal

Targeting of glioblastoma with activated T cells armed with anti-CD3xanti-HER2/neu (HER2Bi) and anti-CD3xanti-EGFR (EGFRBi) bispecific antibodies
J Clin Oncol (Meeting Abstracts) 2009 27: 3038. [Abstract]  

L. Pengying, C. Longbang, and H. Xiang

The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo
J Clin Oncol (Meeting Abstracts) 2009 27: 3039. [Abstract]  

G. Pennock, M. Fishman, R. Gonzalez, J. Thompson, B. Huang, S. Tang, P. Rhode, and H. Wong

Phase I clinical experience of a targeted TCR-IL2 fusion protein in patients with metastatic malignancies
J Clin Oncol (Meeting Abstracts) 2009 27: 3040. [Abstract]  

X. S. Wang, L. A. Williams, V. E. Johnson, L. Mao, S. Krishnan, Z. Liao, G. Mobley, and C. S. Cleeland

Association of sTNF-R1 and the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3041. [Abstract]  

G. Konjevic, S. Stankovic, T. Srdic, S. Jelic, and M. Inic

Investigation of constitutive and cytokine-induced expression of pSTAT 1, 3, and 5 in PBL of breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 3042. [Abstract]  

C. Matuschek, E. Bölke, S. Gripp, W. Budach, D. Hermsen, and M. Peiper

Mediator release during combined radio chemotherapy in rectal carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 3043. [Abstract]  

V. Shankar, C. Haritha, H. L. Trivedi, A. Vanikar, P. M. Modi, P. Shah, and V. Shah

Radiation dose-benefit analysis of hematopoietic stem cell grafting for tolerence induction across MHC barriers in living related donor renal allograft recipients
J Clin Oncol (Meeting Abstracts) 2009 27: 3044. [Abstract]  

P. Correale, P. Tagliaferri, M. T. Del Vecchio, C. Remondo, C. Migali, K. Y. Tsang, M. S. Rotundo, F. Fulfaro, P. Tassone, and G. Francini

Association of immune-regulatory (FoxP3+)-T-cell tumor infiltration status with benefit from chemoimmunotherapy with gemcitabine, oxaliplatin, 5-FU/FA plus GM-CSF and aldesleukine (GOLFIG) in metastatic colon cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 3045. [Abstract]  

C. Underhill, M. Millward, S. Lobb, J. McBurnie, S. Meech, J. Gomez-Navarro, D. Readett, and C. A. Bulanhagui

Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 3046. [Abstract]  

F. Recchia, G. Sica, G. Candeloro, R. Bisegna, S. Necozione, P. Bonfili, V. Tombolini, and S. Rea

Multicenter phase II study of sequential chemotherapy, radiotherapy, and immunotherapy in locally advanced pancreatic (Pa) and biliary tree (Bt) adenocarcinoma (ADK)
J Clin Oncol (Meeting Abstracts) 2009 27: 3047. [Abstract]  

D. Kang, E. Wang, D. Wang, M. Amantea, and P. Hsyu

Population pharmacokinetics (PK) of tremelimumab in patients (pts) with melanoma
J Clin Oncol (Meeting Abstracts) 2009 27: 3048. [Abstract]  

E. Wang, D. Kang, D. Wang, C. Bulanhagui, and P. Hsyu

Relationship between pharmacokinetics and safety of tremelimumab in patients with melanoma
J Clin Oncol (Meeting Abstracts) 2009 27: 3049. [Abstract]  

A. Chatterjee, S. Bhattacharya, A. K. Chatterjee, J. Biswas, and B. Mukhopadhyay

A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 3050. [Abstract]  

F. K. Fuh, R. Fuji, K. A. Poon, W. Manning, Jr., K. K. Berry, V. Ramakrishnan, A. Polson, A. Ebens, S. Prabhu, and M. Williams

Pharmacodynamic effects of administration of maytansine conjugated anti-CD22 monoclonal antibodies to cynomolgus monkeys
J Clin Oncol (Meeting Abstracts) 2009 27: 3051. [Abstract]  

E. Bromley, B. Owczarczak, L. Keltner, S. Wang, and S. O. Gollnick

Characterization of an antitumor immune response after light-activated drug therapy using talaporfin sodium in a spontaneously metastasizing mammary tumor model
J Clin Oncol (Meeting Abstracts) 2009 27: 3052. [Abstract]  

E. Godefroy, Y. Guilloux, F. Jotereau, and N. Bhardwaj

MMP-2: A novel target for antitumor immune therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 3053. [Abstract]  

L. G. Salazar, M. Slota, D. Wallace, D. Higgins, A. L. Coveler, Y. Dang, J. Childs, N. Bates, J. Waisman, and M. L. Disis

A phase I study of a DNA plasmid based vaccine encoding the HER2/neu (HER2) intracellular domain (ICD) in subjects with HER2+ breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3054. [Abstract]  

C. Butts, H. Anderson, A. Maksymiuk, D. Vergidis, D. Soulières, Y. Cormier, M. Davis, E. Marshall, M. Falk, and G. Goss

Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2009 27: 3055. [Abstract]  

J. Xia, Sr. and J. Zhou

Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and clinical responses
J Clin Oncol (Meeting Abstracts) 2009 27: 3056. [Abstract]  

L. G. Salazar, D. Wallace, P. Mukherjee, D. Higgins, J. Childs, N. Bates, A. L. Coveler, and M. L. Disis

HER2/neu (HER2) specific T-cell immunity in patients with HER2+ inflammatory breast cancer (IBC) and prognosis
J Clin Oncol (Meeting Abstracts) 2009 27: 3057. [Abstract]  

R. Harrop, W. H. Shingler, M. Goonewardena, J. de Belin, M. Kelleher, N. Drury, P. Treasure, and S. Naylor

Analysis of immunological and clinical data resulting from four phase I and II trials of MVA-5T4 in colorectal cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 3058. [Abstract]  

D. Wallace, M. Disis, A. Coveler, D. Higgins, J. Childs, N. Bates, L. Salazar, M. Slota, Y. Dang, and J. Waisman

Association of the level of HER2/neu (HER2) gene amplification in breast cancer and the magnitude of antigen specific T-cell immunity achieved after HER2 vaccination
J Clin Oncol (Meeting Abstracts) 2009 27: 3059. [Abstract]  

E. Fabre, J. Medioni, M. Dosset, M. Dosset, E. Tartour, S. Oudard, M. Riquet, and O. Adotevi

T-lymphocyte responses to the human telomerase reverse transcriptase (hTERT) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
J Clin Oncol (Meeting Abstracts) 2009 27: 3061. [Abstract]  

J. Giannios, J. Peristeris, N. Alexandropoulos, T. Kononas, and P. Ginopoulos

Effect on humoral and cellular immunity and on apoptosis in CIN2, CIN3, and HPV16+ cervical cancer of therapeutic divalent genetic vaccination with CMV replicon system (CRS) delivering HPV16 recombinantly mutated E6 and E7 viral oncogenes targeting p53 and Rb, respectively
J Clin Oncol (Meeting Abstracts) 2009 27: 3062. [Abstract]  

R. Conforti, Y. Ma, Y. Morel, C. Paturel, M. Terme, S. Viaud, N. Chaput, F. Andre, G. Kroemer, and L. Zitvogel

Anticancer effects of polyadenylic-polyuridylic acid (poly[A:U]) and uncoupling of chemokine receptor signaling: Role of CCR5 and CXCR3
J Clin Oncol (Meeting Abstracts) 2009 27: 3063. [Abstract]  

D. C. Chade, R. Borra, K. R. Leite, F. E. Villanova, I. Nascimento, L. C. Liete, M. Srougi, and P. M. Andrade

Evaluation of recombinant bacillus Calmette-Guerin expressing pertussis toxin in bladder cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3064. [Abstract]  

D. M. Lubaroff, D. A. Vaena, R. D. Williams, F. N. Joudi, M. C. Smith, P. S. Zehr, J. Eastman, K. Griffith, T. M. Madsen, and K. Johnson

A phase II trial of an adenovirus/PSA vaccine for prostate cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3065. [Abstract]  

W. Wu, D. Jin, W. Lou, J. Fan, D. Wang, and X. Qin

A novel recombinant tandem repeat DNA vaccine targeting at MUC1
J Clin Oncol (Meeting Abstracts) 2009 27: 3066. [Abstract]  

K. Yoshimatsu, H. Yokomizo, T. Otani, G. Osawa, and K. Ogawa

Phase I study of peptide vaccine with chemotherapy in patients with unresectable colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 3067. [Abstract]  

S. Parsons, M. Hennig, R. Linke, A. Klein, A. Lahr, H. Lindhofer, and M. Heiss

Clinical benefit of catumaxomab in malignant ascites in patient subpopulations in a pivotal phase II/III trial
J Clin Oncol (Meeting Abstracts) 2009 27: e14000. [Abstract]  

Breast Cancer:

J. O'Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, and C. Bradley

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: 3. [Abstract]  

A. Tutt, M. Robson, J. E. Garber, S. Domchek, M. W. Audeh, J. N. Weitzel, M. Friedlander, and J. Carmichael

Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: CRA501. [Abstract]  

V. C. Tjan-Heijnen, M. J. Pepels, M. de Boer, G. F. Borm, J. A. van Dijck, C. H. van Deurzen, E. M. Adang, M. B. Menke-Pluymers, P. J. van Diest, and P. Bult

Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN): Results from the MIRROR study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA506. [Abstract]  

R. E. Aubert, E. J. Stanek, J. Yao, J. R. Teagarden, M. Subar, R. S. Epstein, T. C. Skaar, Z. Desta, and D. A. Flockhart

Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors
J Clin Oncol (Meeting Abstracts) 2009 27: CRA508. [Abstract]  

V. Dezentje, N. J. Van Blijderveen, H. Gelderblom, H. Putter, M. P. Van Herk-Sukel, M. K. Casparie, A. C. Egberts, J. W. Nortier, and H. J. Guchelaar

Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiologic study
J Clin Oncol (Meeting Abstracts) 2009 27: CRA509. [Abstract]  

L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't Veer, J. Gray, E. Petricoin, K. Conway, N. Hylton, D. Berry I-SPY Investigators

Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA515. [Abstract]  

A. Valachis, D. Mauri, N. P. Polyzos, D. Mavroudis, V. Georgoulias, and G. Casazza

Partial breast irradiation or whole breast radiotherapy for early breast cancer: A meta-analysis of randomized controlled trials
J Clin Oncol (Meeting Abstracts) 2009 27: CRA532. [Abstract]  

Gastrointestinal (Colorectal) Cancer:

N. Wolmark, G. Yothers, M. J. O'Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O'Reilly, and C. J. Allegra

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4. [Abstract]  

D. Kerr, R. Gray, P. Quirke, D. Watson, G. Yothers, I. C. Lavery, M. Lee, M. J. O’Connell, S. Shak, N. Wolmark, and Genomic Health and QUASAR Colon Teams

A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study
J Clin Oncol (Meeting Abstracts) 2009 27: 4000. [Abstract]  

S. Tejpar, F. Bosman, M. Delorenzi, R. Fiocca, P. Yan, D. Klingbiel, D. Dietrich, E. Van Cutsem, R. Labianca, and A. Roth

Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial)
J Clin Oncol (Meeting Abstracts) 2009 27: 4001. [Abstract]  

A. D. Roth, S. Tejpar, P. Yan, R. Fiocca, D. Dietrich, M. Delorenzi, R. Labianca, D. Cunningham, E. Van Cutsem, and F. Bosman

Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4002. [Abstract]  

J. Gerard, D. Azria, S. Gourgou-Bourgade, I. Martel-Laffay, C. Hennequin, P. Etienne, V. Vendrely, T. Conroy, E. Francois, and C. Montoto-Grillot

Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4007. [Abstract]  

C. Aschele, C. Pinto, S. Cordio, G. Rosati, A. Tagliagambe, S. Artale, P. Rosetti, S. Lonardi, L. Boni, L. Cionini, and on behalf of STAR Network Investigators

Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial
J Clin Oncol (Meeting Abstracts) 2009 27: CRA4008. [Abstract]  

R. James, S. Wan, R. Glynne-Jones, D. Sebag-Montefiore, L. Kadalayil, J. Northover, D. Cunningham, H. Meadows, J. Ledermann, and National Cancer Research Institute (NCRI) ACT II Trial Management Group

A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II)
J Clin Oncol (Meeting Abstracts) 2009 27: LBA4009. [Abstract]  

N. A. Jackson McCleary, J. Meyerhardt, E. Green, G. Yothers, A. de Gramont, E. Van Cutsem, M. O’Connell, C. Twelves, L. Saltz, D. Sargent, and The ACCENT Collaborative Group

Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database
J Clin Oncol (Meeting Abstracts) 2009 27: 4010. [Abstract]  

D. J. Sargent, G. Yothers, E. Van Cutsem, J. Cassidy, L. Saltz, N. Wolmark, Q. Shi, M. Buyse, A. de Gramont, and The Adjuvant Colon Cancer Endpoints (ACCENT) Group

Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803
J Clin Oncol (Meeting Abstracts) 2009 27: 4011. [Abstract]  

M. M. Bertagnolli, D. Niedzwiecki, M. Hall, S. D. Jewell, R. J. Mayer, R. M. Goldberg, T. A. Colacchio, R. S. Warren, and M. Redston

Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581
J Clin Oncol (Meeting Abstracts) 2009 27: 4012. [Abstract]  

V. L. Tsikitis, K. Malireddy, E. A. Green, B. Christensen, R. Whelan, J. Hyder, D. Lauter, P. Marcello, S. Larach, D. Sargent, and H. Nelson

Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4013. [Abstract]  

R. Hofheinz, F. Wenz, S. Post, A. Matzdorff, S. Laechelt, L. Mueller, H. Link, M. Moehler, I. Burkholder, and A. Hochhaus

Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo-)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Safety results of a randomized, phase III trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4014. [Abstract]  

P. Piedbois, M. Ychou, A. Zawadi, J. Douillard, V. Guérin-Meyer, T. André, O. Dupuis, P. Rougier, R. Faroux, E. Quinaux, and AERO, GERCOR, FFCD, and FNCLCC Intergroup

Interim efficacy analysis of the French Intergroup R98 trial comparing 5FU-leucovorin alone or with irinotecan (CPT-11) in resected stages II-III rectal cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 4015. [Abstract]  

D. J. Jonker, C. Karapetis, C. Harbison, C. J. O’Callaghan, D. Tu, R. J. Simes, L. Xu, M. J. Moore, J. R. Zalcberg, and S. Khambata-Ford

High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17—A phase III trial of cetuximab versus best supportive care (BSC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4016. [Abstract]  

M. Scartozzi, I. Bearzi, A. Mandolesi, F. Loupakis, A. Zaniboni, R. Berardi, C. Pierantoni, G. Masi, A. Falcone, and S. Cascinu

Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan
J Clin Oncol (Meeting Abstracts) 2009 27: 4017. [Abstract]  

A. Jung, G. Baretton, M. Dietel, H. Gabbert, H. Kreipe, W. Schlake, A. Tannapfel, M. von Knebel Döberitz, and T. Kirchner

The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4018. [Abstract]  

H. Prenen, B. Jacobs, W. De Roock, R. Van Oirbeek, B. Biesmans, J. De Schutter, S. Fieuws, P. Laurent-Puig, E. Van Cutsem, and S. Tejpar

Use of amphiregulin and epiregulin mRNA expression in primary tumors to predict outcome in metastatic colorectal cancer treated with cetuximab
J Clin Oncol (Meeting Abstracts) 2009 27: 4019. [Abstract]  

D. Lambrechts, W. De Roock, H. Prenen, J. De Schutter, B. Jacobs, B. Biesmans, B. Claes, G. De Hertogh, E. Van Cutsem, and S. Tejpar

The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4020. [Abstract]  

F. Loupakis, C. Cremolini, G. Perrone, I. Stasi, L. Salvatore, B. Vincenzi, A. Ruzzo, M. Ronzoni, K. Bencardino, and A. Falcone

Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients
J Clin Oncol (Meeting Abstracts) 2009 27: 4021. [Abstract]  

D. Yang, A. Pohl, W. Zhang, G. Lurje, Y. Ning, A. El-Khoueiry, S. Khambata-Ford, C. Langer, S. Iqbal, and H. Lenz

Pharmacogenetic analysis in metastatic colorectal cancer (mCRC) patients (pts) treated with second-line irinotecan (IR)+/– cetuximab (CB): The EPIC experience
J Clin Oncol (Meeting Abstracts) 2009 27: 4022. [Abstract]  

N. C. Tebbutt, V. Gebski, K. Wilson, M. Cummins, Y. Chua, B. Robinson, A. Broad, D. Cunningham, J. Simes, and T. Price

International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4023. [Abstract]  

A. H. de Gramont Lesparre, B. Chibaudel, O. Bourges, N. Perez-Staub, C. Tournigand, F. Maindrault-Goebel, T. André, A. K. Larsen, P. Afchain, and C. Louvet

Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 4024. [Abstract]  

A. Grothey, D. A. Nikcevich, J. A. Sloan, J. W. Kugler, P. T. Silberstein, T. Dentchev, D. B. Wender, H. E. Windschilt, X. Zhao, and C. L. Loprinzi

Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4025. [Abstract]  

R. Earhart, S. Cheporov, O. Gladkov, M. Biakhov, H. Breitz, and R. De Jager

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy for colorectal cancer (CRC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4026. [Abstract]  

E. P. Mitchell, M. Lacouture, H. Shearer, N. Iannotti, B. Piperdi, M. Pillai, F. Xu, and M. Yassine

Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: CRA4027. [Abstract]  

H. L. McLeod, R. J. Myerson, B. Zehnbauer, K. Trinkaus, R. S. Malyapa, M. G. Mutch, E. E. Abbey, A. Alyasiry, J. W. Fleshman, and B. R. Tan

TYMS genotype-directed neoadjuvant chemoradiation for rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4028. [Abstract]  

I. Sobhani, F. Roudot-Thoraval, F. Mesli, B. Landi, T. Aparicio, C. Louvet, G. DesGuetz, and E. Mitry

Outcome of colon cancer patients with synchronous metastases
J Clin Oncol (Meeting Abstracts) 2009 27: 4029. [Abstract]  

G. A. Poultsides, E. L. Servais, L. B. Saltz, S. Patil, N. E. Kemeny, J. G. Guillem, M. Weiser, L. K. Temple, W. Wong, and P. B. Paty

Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment
J Clin Oncol (Meeting Abstracts) 2009 27: CRA4030. [Abstract]  

N. Wasif, J. S. Tomlinson, M. A. Maggard, A. E. Giuliano, and C. Y. Ko

Polypectomy or surgery for malignant colonic polyps: Do we need to change the NCCN guidelines?
J Clin Oncol (Meeting Abstracts) 2009 27: 4031. [Abstract]  

A. H. Wortham, D. Schreiber, J. Rineer, E. Katsoulakis, R. Sroufe, E. Marienberg, E. Nwokedi, P. Han, K. Choi, and M. Rotman

Overall survival using local excision techniques with and without radiation compared with APR for stage I rectal cancer: A SEER based analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 4032. [Abstract]  

T. Conroy, M. Ducreux, C. Lemanski, E. Francois, M. Giovannini, F. Cvitkovic, X. Mirabel, O. Bouché, C. Montoto-Grillot, and D. Peiffert

Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4033. [Abstract]  

B. Siewert, I. Gareen, D. Vanness, B. Herman, C. D. Johnson, and C. Gatsonis

ACRIN 6664: Patient acceptance and preferance of CT colonography compared to optical colonoscopy for colon cancer screening
J Clin Oncol (Meeting Abstracts) 2009 27: 4034. [Abstract]  

P. F. Lenehan, D. W. Fry, E. R. Heyman, J. F. Eliason, and W. P. Worzel

Generation and validation of a primary-tumor-derived four-gene prognostic signature for recurrence (R) of stages I/II colorectal cancer (CRC) following potentially curative resection
J Clin Oncol (Meeting Abstracts) 2009 27: 4035. [Abstract]  

A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga, P. J. Kuppen, I. Simon, L. J. Van ’t Veer, and R. Tollenaar

Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients
J Clin Oncol (Meeting Abstracts) 2009 27: 4036. [Abstract]  

C. Fuchs, S. Ogino, J. A. Meyerhardt, N. Irahara, D. Niedzwiecki, D. Hollis, L. B. Saltz, R. J. Mayer, and M. M. Bertagnolli

KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803
J Clin Oncol (Meeting Abstracts) 2009 27: 4037. [Abstract]  

J. A. Meyerhardt, N. Jackson McCleary, D. Niedzwiecki, D. Hollis, A. Venook, R. Mayer, and R. Goldberg

Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203
J Clin Oncol (Meeting Abstracts) 2009 27: 4038. [Abstract]  

J. Kim, Y. Chae, S. Sohn, B. Kang, S. Lee, K. Lim, G. Choi, and J. Baek

-93G>A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4039. [Abstract]  

Y. Ning, G. Lurje, K. Danenberg, J. Cooc, D. Yang, A. Pohl, W. Zhang, and H. Lenz

VEGF and VEGFR1 gene expression levels and tumor recurrence in adjuvant colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4040. [Abstract]  

R. D. Kennedy, V. Proutski, A. Tanney, A. Winter, J. M. Black, P. Kerr, P. G. Johnston, and D. P. Harkin

Identification of subtypes in colorectal cancer and their prognostic values
J Clin Oncol (Meeting Abstracts) 2009 27: 4041. [Abstract]  

M. Pierobon, A. Silvestri, V. Calvert, J. Deng, C. Belluco, D. Nitti, A. Colombatti, E. Mammano, L. Liotta, and E. Petricoin

Use of a prognostic pathway signature for colorectal cancer comprised of EGFR/COX2 and imatinib drug target activation to predict occult metastasis in M0 CRC
J Clin Oncol (Meeting Abstracts) 2009 27: 4042. [Abstract]  

M. Tanaka, S. Sethi, D. Li, G. Bland, S. R. Hamilton, J. L. Abbruzzese, and C. Eng

CHFR methylation as an epigenetic marker for recurrence of colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4043. [Abstract]  

S. Gill, C. Loprinzi, H. Kennecke, A. Grothey, G. Nelson, R. Woods, C. Speers, S. Alberts, A. Bardia, and D. Sargent

Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!)
J Clin Oncol (Meeting Abstracts) 2009 27: 4044. [Abstract]  

N. Love, K. Ault Ziel, C. Bylund, M. Elder, L. M. Ellis, A. Grothey, N. J. Meropol, D. Paley, P. M. Ravdin, and L. B. Saltz

Adjuvant therapy report card: Patients with stage II/III colon cancer grade their oncologists
J Clin Oncol (Meeting Abstracts) 2009 27: 4045. [Abstract]  

U. D. Bayraktar, S. Bayraktar, S. Herna, N. Ku, C. Jones, J. Merchan, L. R. Sands, F. Marchetti, A. Montero, and C. M. Rocha-Lima

Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?
J Clin Oncol (Meeting Abstracts) 2009 27: 4046. [Abstract]  

M. E. Valsecchi, J. Leighton, Jr., and W. Tester

Modifiable factors that influence colorectal cancer lymph nodes sampling and examination
J Clin Oncol (Meeting Abstracts) 2009 27: 4047. [Abstract]  

D. Wiese, M. Soni, A. Gayer, A. Korant, S. Sirop, B. Chakravaty, S. Arora, D. Iddings, and S. Saha

Nodal positivity between <12 and >12 lymph nodes harvested in colorectal cancer undergoing SLNM compared with conventional surgery
J Clin Oncol (Meeting Abstracts) 2009 27: 4048. [Abstract]  

M. L. Arora, S. Saha, S. Sirop, B. Chakravarty, A. Korant, M. Soni, D. Wiese, D. Desai, B. Ganatra, S. Kaushal, and D. Iddings

The impact of the number of lymph node metastases on the overall recurrence of colon cancer in the era of sentinel lymph node mapping
J Clin Oncol (Meeting Abstracts) 2009 27: 4049. [Abstract]  

Y. Inoue, K. Tanaka, S. Saigusa, T. Yokoe, H. Yasuda, Y. Toiyama, C. Miki, H. Yanagi, and M. Kusunoki

Evaultion of CD133, VEGF, or EGFR as predictive markers of distant recurrence after preoperative chemoradiotherapy in rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4050. [Abstract]  

H. Lenz, G. Lurje, C. A. Haiman, D. Yang, A. Pohl, Y. Ning, A. El-Khoueiry, S. Iqbal, and W. Zhang

Colorectal cancer susceptibility variants and clinical outcome in adjuvant and metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4051. [Abstract]  

J. M. Jessup, K. Dobbin, S. Hamilton, S. Thibodeau, M. Redston, S. Taube, Z. Wang, J. Benedetti, and Program for the Assessment of Clinical Cancer Tests (PACCT) 18q LOH Team

Interlaboratory assay reproducibility study for loss of heterozygosity on chromosome 18 (18q LOH) in colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4052. [Abstract]  

P. Cejas, M. López-Gómez, R. Madero, J. De Castro, E. Casado, C. Belda, J. Larrauri, J. Barriuso, M. González-Barón, and J. Feliú

Concordance of K-Ras status between colorectal cancer (CRC) primaries and related metastatic samples considering clinicopathological features
J Clin Oncol (Meeting Abstracts) 2009 27: 4053. [Abstract]  

B. A. Costello, J. R. Hecht, and A. Grothey

Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review
J Clin Oncol (Meeting Abstracts) 2009 27: 4054. [Abstract]  

I. Koza, Sr., F. Wrba, D. Vrbanec, J. Ocvirk, T. E. Ciuleanu, S. Beslija, D. Papamichael, D. Messinger, C. C. Zielinski, and T. Brodowicz

Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX+C) or FOLFIRI + cetuximab (FF+C): The CECOG/CORE1.2.001 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4055. [Abstract]  

A. B. El-Khoueiry, A. Pohl, K. Danenberg, J. Cooc, W. Zhang, D. Yang, H. Singh, J. Shriki, S. Iqbal, and H. J. Lenz

Wt Kras and gene expression levels of VEGFR2, EGFR, and ERCC-1 associated with progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
J Clin Oncol (Meeting Abstracts) 2009 27: 4056. [Abstract]  

O. Er, M. Inanc, M. Dikilitas, M. Ozkan, H. Karaca, R. Saraymen, and F. Elmali

VEGF, EGF, HGF, and PDGF levels during chemotherapy in patients with metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4057. [Abstract]  

A. Ruzzo, C. Cremolini, F. Loupakis, L. Fornaro, D. Santini, B. Vincenzi, E. Canestrari, M. Magnani, A. Falcone, and F. Graziano

Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 4058. [Abstract]  

Y. Yoshida, J. Hasegawa, R. Nezu, Y. Kim, M. Hirota, K. Yoshikawa, K. Kawano, H. Izumi, and K. Kohno

Clinical usefulness of mtTFA expression as a predictive marker in colorectal cancer patients treated with FOLFOX
J Clin Oncol (Meeting Abstracts) 2009 27: 4059. [Abstract]  

J. Maurel, V. Alonso-Espinaco, V. Alonso, P. Escudero, M. Jimeno, X. Garcia-Albeniz, J. Muñoz, C. Fernandez- Martos, E. Carcereny, and S. Castellví-Bel

EGFR polymorphism and KRAS mutational status as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study
J Clin Oncol (Meeting Abstracts) 2009 27: 4060. [Abstract]  

T. Winder, W. Zhang, A. El-Khoueiry, D. Yang, A. Pohl, G. Lurje, E. Rowinsky, S. Khambata-Ford, C. Langer, M. Awad, and H. Lenz

Association of a germ-line variant in the K-ras 3’ untranslated region with response and progression-free survival in patients with mCRC treated with single-agent cetuximab (IMCL-0144) or in combination with cetuximab (EPIC) independent of K-ras mutation status
J Clin Oncol (Meeting Abstracts) 2009 27: 4061. [Abstract]  

A. Pohl, W. Zhang, D. Yang, G. Lurje, Y. Ning, S. Khambata-Ford, C. Langer, M. Kahn, J. L. Teo, and H. J. Lenz

Association of CD133 polymorphisms and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with either first-line 5-FU + bevacizumab (BV) or second-line irinotecan (IR)/cetuximab (CB) or IR alone
J Clin Oncol (Meeting Abstracts) 2009 27: 4062. [Abstract]  

C. Horndler, R. Gallego, V. Alonso, V. Alonso, P. Escudero, M. Jimeno, X. Garcia-Albeniz, C. Fernandez-Martos, S. Castellví-Bel, and J. Maurel

Coexpression of matrix metalloproteinase-7 (MMP7) and phosphorylated insulin growth factor receptor I (pIGF-IR) as predictors of resistance to anti-EGFR therapy in advanced colorectal cancer (ACRC): A GEMCAD study
J Clin Oncol (Meeting Abstracts) 2009 27: 4063. [Abstract]  

W. De Roock, M. Janssens, B. Biesmans, B. Jacobs, J. De Schutter, S. Fieuws, E. Van Cutsem, and S. Tejpar

DUSPs as markers of MEK/Erk activation in primary colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4064. [Abstract]  

E. Mitry, O. Bouché, L. Dahan, F. Bonnetain, P. Laurent-Puig, T. Aparicio, P. L. Etienne, C. Lecaille, J. P. Lafargue, J. L. Jouve, and Fédération Francophone de Cancérologie Digestive (FFCD)

Phase II trial of chemotherapy with high-dose FOLFIRI plus bevacizumab in the front-line treatment of patients with metastatic colorectal cancer (mCRC) and genotype UGT1A1*1/ UGT1A1*1 or UGT1A1*1/ UGT1A1*28 (FFCD 0504 trial). Results of a planned interim analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 4065. [Abstract]  

E. Martinez-Balibrea, A. Abad, M. Valladares, M. Martinez-Villacampa, E. Aranda, E. Marcuello, M. Benavides, A. Martinez-Cardús, A. Ginés, J. L. Manzano, and Spanish Group for the Treatment of Digestive Tumors

Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil
J Clin Oncol (Meeting Abstracts) 2009 27: 4066. [Abstract]  

A. L. Cohn, D. A. Smith, M. A. Neubauer, G. Houston, P. Khandelwal, R. G. Wiggans, K. Zhang, and M. Yassine

Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status
J Clin Oncol (Meeting Abstracts) 2009 27: 4067. [Abstract]  

C. Kohne, D. Stroiakovski, C. Chang-chien, R. Lim, T. Pintér, G. Bodoky, C. Stroh, I. Celik, P. Rougier, and E. Van Cutsem

Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4068. [Abstract]  

M. Etienne-Grimaldi, J. Bennouna, J. Formento, J. Douillard, M. Francoual, E. François, R. Faroux, C. El Hannani, J. Jacob, and G. Milano

Prospective pharmacogenetic analysis in advanced colorectal cancer (CRC) patients receiving first-line cetuximab-UFT-irinotecan therapy: Importance of gene polymorphisms related to antibody-dependent cellular cytotoxicity (ADCC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4069. [Abstract]  

H. Singh, A. Pohl, A. El-Khoueiry, G. Lurje, W. Zhang, D. Yang, Y. Ning, J. Shriki, S. Iqbal, and H. Lenz

Use of genetic variants to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line 5-FU or capecitabine in combination with oxaliplatin and bevacizumab (FOLFOX/BV or XELOX/BV)
J Clin Oncol (Meeting Abstracts) 2009 27: 4070. [Abstract]  

F. Farace, J. Mendiboure, A. Adenis, E. Boucher, J. Pierga, T. Conroy, C. Montoto-Grillot, J. Pignon, M. Ducreux, D. Malka, and FNCLCC

Circulating endothelial cell (CEC) monitoring in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line bevacizumab (BEV)-based combination regimens: Results of the randomized phase II FNCLCC-ACCORD 13/0503 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4071. [Abstract]  

J. R. Hecht, M. Pillai, R. Gollard, L. Dreiling, M. Mo, and I. Malik

Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study
J Clin Oncol (Meeting Abstracts) 2009 27: 4072. [Abstract]  

B. Chibaudel, C. Tournigand, N. Perez-Staub, O. Bourges, F. Maindrault-Goebel, T. André, G. Lledo, C. Louvet, F. Bonnetain, and A. de Gramont

Duration of disease control (DDC) or time to failure of strategy (TFS) to evaluate a chemotherapy strategy in advanced colorectal cancer (ACC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4073. [Abstract]  

E. D. Powell, T. Asmis, D. Jonker, D. Tu, C. Karapetis, M. Jeffery, and C. O’Callaghan

Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)—Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4074. [Abstract]  

C. Truong, S. Kempton, S. Lum, J. W. Morgan, J. H. Wong, and S. Roy-Chowdhury

The impact of young age on outcome in colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4075. [Abstract]  

G. Folprecht, M. Nowacki, I. Lang, S. Cascinu, I. Shchepotin, J. Maurel, P. Rougier, D. Cunningham, A. Zubel, and E. Van Cutsem

Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial
J Clin Oncol (Meeting Abstracts) 2009 27: 4076. [Abstract]  

C. Tournigand, B. Samson, W. Scheithauer, C. Louvet, T. Andre, G. Lledo, J. Latreille, F. Viret, B. Chibaudel, and A. de Gramont

mFOLFOX-bevacizumab or XELOX-bevacizumab then bevacizumab (B) alone or with erlotinib (E) in first-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety analysis of DREAM study
J Clin Oncol (Meeting Abstracts) 2009 27: 4077. [Abstract]  

H. Hurwitz, Y. Z. Patt, D. Henry, L. Garbo, E. P. Mitchell, J. Kohles, and D. Spigel

Phase III study of standard triweekly versus dose-dense biweekly capecitabine (C) + oxaliplatin (O) + bevacizumab (B) as first-line treatment for metastatic colorectal cancer (mCRC): XELOX-A-DVS (dense versus standard): Interim analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 4078. [Abstract]  

L. Saltz, J. Infante, L. Schwartzberg, J. Stephenson, C. Rocha-Lima, F. Galimi, K. Dillingham, M. Hsu, J. Wiezorek, and C. Fuchs

Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4079. [Abstract]  

K. E. Bullock, H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell

Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4080. [Abstract]  

S. Vukelja, D. Richards, L. T. Campos, C. Bedell, C. Hagenstad, W. Hyman, J. Letzer, L. Gardner, P. Sportelli, and J. Nemunaitis

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4081. [Abstract]  

J. Maroun, D. Jonker, C. Cripps, R. Goel, T. Asmis, H. Marginean, and G. Chiritescu

Phase I study of the IXO regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), as first-line therapy for metastatic colorectal cancer: Final survival results
J Clin Oncol (Meeting Abstracts) 2009 27: 4082. [Abstract]  

M. G. Fakih, L. Pendyala, M. J. Egorin, G. Fetterly, I. Espinoza-Delgado, M. Ross, J. Phelan, Z. Kramer, B. Yirinec, and R. Diasio

A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors
J Clin Oncol (Meeting Abstracts) 2009 27: 4083. [Abstract]  

T. S. Yang, D. Y. Oh, R. Guimbaud, J. Szanto, T. Salek, L. Thurzo, J. M. Vieitez, G. M. Pover, and T. W. Kim

Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: 4084. [Abstract]  

R. Greil, H. Letocha, E. Gamelin, J. Thaler, R. Hofheinz, L. Mineur, E. Fernebro, M. Karthaus, L. Wright, C. Köhne, and 20060314 Study Group

Updated analysis of a phase II study (20060314) of panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4085. [Abstract]  

M. Ducreux, A. Adenis, J. Mendiboure, E. François, E. Boucher, B. Chauffert, M. Ychou, J. Pierga, C. Montoto-Grillot, and T. Conroy

Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study)
J Clin Oncol (Meeting Abstracts) 2009 27: 4086. [Abstract]  

N. H. Segal, D. Reidy-Lagunes, M. Capanu, N. Kemeny, K. Chung, D. Kelsen, E. Hollywood, N. Goodman-Davis, and L. B. Saltz

Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)
J Clin Oncol (Meeting Abstracts) 2009 27: 4087. [Abstract]  

L. Rimassa, A. F. Sobrero, A. Santoro, V. Andretta, V. Gregorc, F. Sclafani, F. Caprioni, F. Caligaris-Cappio, A. Lambiase, and C. Bordignon

Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
J Clin Oncol (Meeting Abstracts) 2009 27: 4088. [Abstract]  

S. K. Geevarghese, A. Chen, D. A. Geller, H. A. de Haan, A. Iagaru, A. Knoll, J. Nemunaitis, T. R. Reid, D. Y. Sze, and K. Tanabe

Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4089. [Abstract]  

J. Xu, Y. Zhong, W. Niu, X. Qin, Y. Wei, L. Ren, J. Wang, J. Chen, and S. Qian

Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery
J Clin Oncol (Meeting Abstracts) 2009 27: 4090. [Abstract]  

W. O. Bechstein, H. Lang, C. Köhne, F. Parisi, H. R. Raab, A. Frilling, R. Konopke, J. Weitz, C. Stroszczynski, and G. Folprecht

Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases
J Clin Oncol (Meeting Abstracts) 2009 27: 4091. [Abstract]  

C. Aliberti, G. Benea, M. Tilli, and G. Fiorentini

Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients
J Clin Oncol (Meeting Abstracts) 2009 27: 4092. [Abstract]  

R. Adam, D. A. Wicherts, R. J. de Haas, F. Lévi, B. Paule, D. Azoulay, and D. Castaing

Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab
J Clin Oncol (Meeting Abstracts) 2009 27: 4093. [Abstract]  

Y. Becouarn, S. Mathoulin-Pélissier, M. Rivoire, A. Ayav, J. Arnaud, A. Sa Cunha, R. Brunet, M. Fonck, C. Bellera, and S. Evrard

Efficacy of intraoperative radiofrequency ablation (IRFA) combined or not with resection to treat unresectable colorectal metastases, with or without preoperative chemotherapy: The ARF2003 Study (NTC 00210106): Preliminary results
J Clin Oncol (Meeting Abstracts) 2009 27: 4095. [Abstract]  

M. Van Den Eynde, A. Hendlisz, M. Peeters, L. Defreyne, G. Maleux, J. Vannoote, P. Delatte, M. Paesmans, J. Van Laethem, and P. Flamen

Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT)
J Clin Oncol (Meeting Abstracts) 2009 27: 4096. [Abstract]  

D. A. Wicherts, R. J. de Haas, M. Sebagh, O. Ciacio, F. Lévi, B. Paule, D. Azoulay, H. Bismuth, D. Castaing, and R. Adam

Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases
J Clin Oncol (Meeting Abstracts) 2009 27: 4097. [Abstract]  

D. Keizman, N. Maimon, M. Ish-Shalom, D. Buchbut, M. Inbar, B. Klein, J. Bernheim, I. Goldiner, A. Leikin- Frenkel, S. Shpigel, and F. Konikoff

An animal model for chemotherapy-associated steatohepatitis (CASH) and its prevention by the oral administration of fatty acid bile acid conjugate (FABAC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4098. [Abstract]  

E. Morris, J. Thomas, D. Forman, P. Quirke, B. Cottier, and G. J. Poston

The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases
J Clin Oncol (Meeting Abstracts) 2009 27: 4099. [Abstract]  

M. Nogue, A. Salud, P. Vicente, C. Pericay, A. Arriví, J. M. Roca, F. Losa, J. Ponce, M. J. Safont, and I. Guasch

Addition of bevacizumab to induction plus concomitant capecitabine-oxaliplatin (XELOX) chemoradiotherapy (CRT) in MRI poor prognosis locally advanced rectal cancer: Avacross study
J Clin Oncol (Meeting Abstracts) 2009 27: 4100. [Abstract]  

D. Hompes, A. D’Hoore, E. Van Cutsem, W. Ceelen, M. Peeters, K. Van der Speeten, C. Bertrand, J. Kerger, and H. Legendre

Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A Belgian multicenter prospective phase II clinical study
J Clin Oncol (Meeting Abstracts) 2009 27: 4101. [Abstract]  

O. Glehen, D. Elias, F. N. Gilly, F. Boutitie, J. M. Bereder, F. Quenet, L. Sideris, B. Mansvelt, G. Lorimier, and Association Française de Chirurgie

Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients
J Clin Oncol (Meeting Abstracts) 2009 27: 4102. [Abstract]  

C. Fernandez-Martos, J. Aparicio, A. Salud, V. Alonso, B. Massuti, M. Safont, R. Vera, P. Escudero, J. Maurel, and C. Pericay

Multicenter randomized phase II study of chemoradiation (CRT) followed by surgery (S) and chemotherapy (CT) versus induction CT followed by CRT and S in high-risk rectal cancer: GCR-3 final efficacy and safety results
J Clin Oncol (Meeting Abstracts) 2009 27: 4103. [Abstract]  

E. Gamelin, L. Mineur, C. Chevelle, P. Cailleux, L. Martin, L. Bastit, B. Roullet, A. Hasbini, J. Savary, and P. Cellier

Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study
J Clin Oncol (Meeting Abstracts) 2009 27: 4104. [Abstract]  

T. Dipetrillo, V. Pricolo, J. Lagares-Garcia, W. Sikov, M. Vrees, B. McNulty, B. O'Connor, A. Klipfel, H. Khurshid, and H. Safran

Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4105. [Abstract]  

L. S. Blaszkowsky, T. S. Hong, A. X. Zhu, E. L. Kwak, H. J. Mamon, P. C. Shellito, J. C. Cusack, D. Berger, K. Horgan, and D. P. Ryan

A phase I/II study of bevacizumab (beva), erlotinib (erl), and 5-fluorouracil (5-FU) with concurrent external beam radiation therapy (RT) in locally advanced rectal cancer (LARC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4106. [Abstract]  

E. Casado, Sr., P. Cejas, J. Sanchez, M. Blanco, J. Maurel, B. Castelo, J. Feliu, R. Miquel, J. De Castro, M. Sereno, and M. Gonzalez Baron

Screening candidate targets by SAGE evaluation of rectal cancer transcriptome after chemoradiotherapy: Association of trefoil factor-family 3 (TFF3) expression with patients prognosis
J Clin Oncol (Meeting Abstracts) 2009 27: 4107. [Abstract]  

L. F. Lobato, L. Stocchi, A. da Luz Moreira, M. Kalady, D. Dietz, D. Geisler, I. Lavery, and V. Fazio

Effect of downstaging without complete pathologic response after neoadjuvant treatment on cancer outcomes for cIII and cII rectal cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 4108. [Abstract]  

W. M. Eisterer, A. De Vries, D. Oefner, R. Greil, H. Rabl, J. Tschmelitsch, R. Schmid, K. Kapp, F. Zehentmayr, and J. Thaler

Neoadjuvant chemoradiation therapy with capecitabine (X) plus cetuximab (C), and external beam radiotherapy (RT) in locally advanced rectal cancer (LARC): ABCSG trial R03
J Clin Oncol (Meeting Abstracts) 2009 27: 4109. [Abstract]  

C. Pinto, F. Di Fabio, E. Maiello, P. Di Tullio, S. Pini, C. Aschele, C. Garufi, A. Bochicchio, G. Pinotti, T. Latiano, and A. Martoni

Phase II study of preoperative panitumumab, 5-fluorouracil, and oxaliplatin with concurrent radiotherapy in locally advanced rectal cancer: Preliminary safety results (StarPan /STAR-02 Study)
J Clin Oncol (Meeting Abstracts) 2009 27: 4110. [Abstract]  

A. D. Sasse, E. C. Sasse, L. V. dos Santos, J. S. Lima, C. M. Nascente, H. P. Saito, M. S. Tariki, V. C. Conceicao, A. M. Carvalho, and N. S. Siqueira

Oral fluoropyrimidines versus 5-fluorouracil for colorectal cancer: Results of a systematic review and meta-analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 4111. [Abstract]  

F. Levi, P. Innominato, A. Poncet, T. Moreau, S. Iacobelli, C. Focan, C. Garufi, G. Bjarnason, R. Adam, S. Giacchetti, and for the ARTBC Chronotherapy Group

Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT)
J Clin Oncol (Meeting Abstracts) 2009 27: 4112. [Abstract]  

L. H. Jensen, L. Dysager, J. Lindebjerg, S. Kølvraa, L. Byriel, and D. G. Crüger

Molecular biology from bench-to-bedside: Which colorectal cancer patients to refer for genetic counseling
J Clin Oncol (Meeting Abstracts) 2009 27: 4113. [Abstract]  

D. J. Renouf, H. J. Lim, C. Speers, D. Villa, S. Gill, C. D. Blanke, S. E. O’Reilly, and H. Kennecke

Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study
J Clin Oncol (Meeting Abstracts) 2009 27: 4114. [Abstract]  

K. Shitara, K. Matsuo, D. Takahari, T. Yokota, T. Ura, and K. Muro

Neutropenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX
J Clin Oncol (Meeting Abstracts) 2009 27: 4115. [Abstract]  

C. Eng, G. J. Chang, P. Das, M. Rodriguez-Bigas, J. M. Skibber, W. Qiao, G. L. Rosner, L. T. Ukegbu, R. A. Wolff, and C. H. Crane

Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal
J Clin Oncol (Meeting Abstracts) 2009 27: 4116. [Abstract]  

A. Swampillai, M. Williams, M. Osborne, S. Mawdsley, R. Hughes, M. Harrison, and R. Glynne-Jones

A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT)
J Clin Oncol (Meeting Abstracts) 2009 27: 4117. [Abstract]  

N. Perez-Staub, B. Chibaudel, F. Paye, J. Taieb, B. Gayet, O. Bourges, T. André, C. Tournigand, C. Louvet, and A. de Gramont

Survival after surgery in patients with initially resectable metastasis receiving adjuvant/neoadjuvant FOLFOX therapy and in patients who had surgery after FOLFOX therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 4118. [Abstract]  

J. Feliu, M. Safont, A. Salud, F. Losa, C. García-Girón, C. Bosch, P. Escudero, R. López, C. Madroñal, and M. González-Barón

Phase II study to evaluate the efficacy of capecitabine combined with bevacizumab as first-line treatment in elderly patients with advanced or metastatic colorectal adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: 4119. [Abstract]  

G. P. Hess, P. F. Wang, D. Quach, and B. Barber

Metastatic colorectal cancer (mCRC): Recent patterns of chemotherapy and monoclonal antibody (MoAb) therapy in clinical practice
J Clin Oncol (Meeting Abstracts) 2009 27: 4120. [Abstract]  

G. Des Guetz, B. Uzzan, P. Nicolas, K. Chouahnia, G. Perret, L. Zelek, and J. Morere

Does microsatellite instability predict the effect of adjuvant chemotherapy in stage III colorectal cancer? A meta-analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 4121. [Abstract]  

C. Vale, J. F. Tierney, A. Meade, D. Fisher, R. Kaplan, R. A. Adams, T. S. Maughan, and M. K. Parmar

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs)
J Clin Oncol (Meeting Abstracts) 2009 27: 4122. [Abstract]  

K. P. Raj, A. Ziogas, A. R. Barleben, M. J. Stamos, and J. A. Zell

Use of tumor site as a prognosticator: Population-based analysis of rectosigmoid and rectum cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 4123. [Abstract]  

T. Yeung, J. Wilding, and W. Bodmer

Colorectal cancer stem cells: Characterization and functional analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 4124. [Abstract]  

A. Santomaggio, E. Ricevuto, K. Cannita, G. Bruera, M. Tudini, P. Lanfiuti Baldi, M. Mancini, G. Porzio, P. Marchetti, and C. Ficorella

"Poker" schedule of weekly alternating 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIR-B/FOX) in advanced colorectal cancer: A phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: 4125. [Abstract]  

V. Catalano, F. Loupakis, R. Bisonni, U. Torresi, D. Santini, R. R. Silva, L. Giustini, A. Falcone, S. D’Emidio, M. Rocchi, and F. Graziano

Impact of mucinous histology on prognosis for patients with radically resected stage Dukes B2 and C colon cancer: Preliminary results
J Clin Oncol (Meeting Abstracts) 2009 27: 4126. [Abstract]  

D. J. Watkins, J. Tabernero, H. J. Schmoll, T. Trarbach, F. J. Ramos, K. Hsu, M. Gates, J. Clark, P. LeVan, and D. Cunningham

A phase II study of the anti-IGFR antibody MK-0646 in combination with cetuximab and irinotecan in the treatment of chemorefractory metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4127. [Abstract]  

S. Tommasi, N. Silvestris, D. Petriella, R. Pinto, B. Pilato, R. Lacalamita, A. Gernone, A. Paradiso, F. A. Zito, and G. Colucci

Epigenetic alterations of primary tumor and metastatic site of colorectal carcinoma (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: 4128. [Abstract]  

L. Yee, H. A. Burris, M. Kozloff, Z. Wainberg, M. Pao, S. Skettino, W. Novotny, B. Durbin, J. Weston, and H. Hurwitz

Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results
J Clin Oncol (Meeting Abstracts) 2009 27: 4129. [Abstract]  

P. Rougier, J. Infante, J. Van Laethem, J. J. Stephenson, H. Uronis, L. Schwartzberg, L. Chen, C. Wu, D. Smethurst, and M. Peeters

A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): Safety results
J Clin Oncol (Meeting Abstracts) 2009 27: 4130. [Abstract]  

S. Saglam, D. Bugra, E. Kaytan Saglam, S. Yamaner, O. Asoglu, E. Balik, E. N. Oral, B. Sakar, A. Kizir, Y. Kapran, and H. Camlica

Prospective randomized study comparing fourth-week surgery versus eighth- week surgery after neoadjuvant concomitant radiotherapy and infusional 5-FU in T3–4/N0+ rectal cancer: Istanbul R-01 Study
J Clin Oncol (Meeting Abstracts) 2009 27: 4131. [Abstract]  

R. Melcher, T. Kudlich, H. Luehrs, T. Katzenberger, B. Illert, O. Al-Taie, H. Einsele, W. Scheppach, and M. Scheurlen

Prognostic impact of allelic losses in 1p32–36 (HYTM1), 4p15.2 (D4S2397), 5q22.2 (D5S346), 8p22 (D8S254), 18q12.3 (D18S474), and microsatellite instability for colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4132. [Abstract]  

J. Brady, M. Middleton, R. S. Midgley, M. K. Mallath, P. Corrie, B. Sirohi, I. Chau, R. Digumarti, J. Botbyl, and J. J. Lager

A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 4133. [Abstract]  

S. Saha, S. Sirop, A. Korant, B. Chakravarty, N. Krishnaiah, D. Wiese, M. Soni, M. Arora, S. Nagpal, and T. Singh

The number of lymph node metastases as a prognostic indicator of disease-specific survival in the era of sentinel lymph node mapping in colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15000. [Abstract]  

A. N. Freedman, M. L. Slattery, R. Ballard-Barbash, G. Willis, B. J. Cann, D. Pee, M. H. Gail, and R. M. Pfeiffer

Colorectal cancer risk prediction tool for men and women without known susceptibility
J Clin Oncol (Meeting Abstracts) 2009 27: e15002. [Abstract]  

D. Kandioler, N. Pilat, S. Kappel, T. Gruenberger, F. Laengle, M. Mittlboeck, B. Herberger, I. Kuehrer, R. Jakesz, and F. Muehlbacher

A prospective study of the interaction between p53 genotype and overall survival in patients with colorectal cancer liver metastases (CRCLM) with and without neoadjuvant therapy (oxaliplatin and capecitabine/5-FU): A p53 research group study
J Clin Oncol (Meeting Abstracts) 2009 27: e15003. [Abstract]  

E. M. Quinaux, I. Baumgaertner, A. Khalil, C. Louvet, M. E. Buyse, A. de Gramont, and T. André

Comparison of l and dl forms of folinic acid in Gercor C96.1 trial (A phase III trial comparing bimonthly LV5FU2 to monthly high-dose 5FU-leucovorin in patients with Dukes’ B2 and C colon cancer)
J Clin Oncol (Meeting Abstracts) 2009 27: e15004. [Abstract]  

T. J. Price, M. Peeters, J. Douillard, E. Mitchell, A. Cohn, A. H. Strickland, F. Rivera, F. Xu, J. Gansert, and S. Siena

Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15005. [Abstract]  

E. Barrajon, A. Lopez, G. Esquerdo, and J. M. Cervera

Cure rate in early colorectal cancer estimated from disease-free survival curves from phase III comparative clinical trials: Necessity of long follow-up
J Clin Oncol (Meeting Abstracts) 2009 27: e15006. [Abstract]  

F. Giuliani, F. De Vita, V. Lorusso, S. Cinieri, I. Nugnes, M. Orditura, E. Maiello, S. Del Prete, S. Leo, and G. Colucci

FOLFIRI + bevacizumab as first-line treatment in advanced colorectal cancer (ACC): Final results (prot. GOIM 2601)
J Clin Oncol (Meeting Abstracts) 2009 27: e15007. [Abstract]  

I. Ahmed, M. Howard, Z. Rehman, F. Ofar, P. Marley, E. O’Doherty, and M. J. Martin

A comparison of overall and disease-specific survivals following adjuvant radiotherapy with neo-adjuvant radiotherapy for rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15008. [Abstract]  

A. Artinyan, E. Castillo, B. Foster, and L. Wagman

Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases
J Clin Oncol (Meeting Abstracts) 2009 27: e15009. [Abstract]  

F. Rojas Llimpe, F. Di Fabio, G. Ercolani, E. Giampalma, C. Serra, P. Castellucci, S. Pini, V. Mutri, R. Golfieri, C. Pinto, and A. Martoni

Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study)
J Clin Oncol (Meeting Abstracts) 2009 27: e15010. [Abstract]  

P. Pfeiffer, T. L. Joergensen, B. V. Jensen, C. Qvortrup, K. Skougaard, J. K. Bjerregaard, T. P. Hansen, E. Høgdal, and D. Nielsen

Addition of bevacizumab or sunitinib to biweekly cetuximab and irinotecan as salvage therapy in patients with metastatic colorectal cancer after failure to CetIri
J Clin Oncol (Meeting Abstracts) 2009 27: e15011. [Abstract]  

Z. Zhou, W. V. Walsh, V. G. Bathini, and B. Piperdi

Anti-VEGF and anti-EGFR monoclonal antibodies (Mabs) in the first-line therapy for metastatic colorectal cancer: A meta-analysis
J Clin Oncol (Meeting Abstracts) 2009 27: e15012. [Abstract]  

S. A. Barroso, E. Sanches, M. Ferreira, M. Passos, A. Sá, R. Nabiço, C. Sotto-Mayor, J. Espírito Santo, and R. San- Bento

Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: e15013. [Abstract]  

S. Pant, G. Hostetter, B. Armstrong, M. Bittner, S. Shack, S. Savage, G. J. Weiss, H. Ozer, and R. Ramanathan

Use of independent genome-wide assays to discover HOXA signature in colon and rectal cancers and validate a role in tumorigenesis
J Clin Oncol (Meeting Abstracts) 2009 27: e15014. [Abstract]  

D. Goere, Sr., I. Dsehais, T. de Baere, V. Boige, D. Malka, S. Bonnet, C. Dromain, D. Elias, and M. Ducreux

Hepatic resection of initially unresectable liver metastases from colorectal cancer after hepatic arterial infusion of oxaliplatin and systemic 5-fluorouracil and leucovorin
J Clin Oncol (Meeting Abstracts) 2009 27: e15015. [Abstract]  

K. L. Foley, J. A. Tooze, E. Y. Song, H. D. Klepin, and A. M. Geiger

Receipt of chemotherapy among Medicaid-enrolled patients diagnosed with regional colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15016. [Abstract]  

M. G. Zalis, F. M. Vieira, I. Zalcberg-Renault, M. H. Bonamino, C. G. Ferreira, and S. Oliveira

KRAS mutation profile in colorectal cancer patients in Brazil: A cohort of 989 individuals
J Clin Oncol (Meeting Abstracts) 2009 27: e15017. [Abstract]  

Y. Yuan, H. Ma, D. J. Cohen, T. Ryan, H. Choi, E. Love‘, M. Awad, S. Khambata-Ford, D. Mauro, and H. Hochster

Activity and tolerance of biweekly CapeOx-cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): Relation to K-ras mutation status
J Clin Oncol (Meeting Abstracts) 2009 27: e15018. [Abstract]  

E. X. Chen, S. Welch, M. Krzyzanowska, H. MacKay, J. Knox, R. Feld, J. Petronis, C. Blatter, L. Wang, and M. J. Moore

A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15019. [Abstract]  

C. Garufi, A. Torsello, S. Tumolo, M. Mottolese, C. Campanella, M. Zeuli, G. Lo Re, I. Sperduti, G. Pizzi, and G. M. Ettorre

POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM)
J Clin Oncol (Meeting Abstracts) 2009 27: e15020. [Abstract]  

V. Vaccaro, F. Cuppone, F. Loupakis, M. Milella, P. Carlini, C. Nisticò, A. Falcone, E. Terzoli, F. Cognetti, and E. Bria

Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials
J Clin Oncol (Meeting Abstracts) 2009 27: e15021. [Abstract]  

F. Fostira, C. Panopoulos, K. Papademitriou, G. Lypas, G. Lypas, V. Barbounis, A. Efremidis, and D. Yannoukakos

A novel mutation in MUTYH-associated polyposis (MAP) syndrome
J Clin Oncol (Meeting Abstracts) 2009 27: e15022. [Abstract]  

Y. Choi, T. Kim, S. Lee, J. Lee, H. Chang, H. Kim, J. Shin, J. Lee, and Y. Kang

A phase I/II study of combination therapy of S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15023. [Abstract]  

G. Bastian, B. Chibaudel, F. Maindrault-Goebel, C. Garcia-Hejl, F. Bonnetain, C. Rebischung, M. Hebbar, Y. Yataghene, and A. de Gramont

Relation between long-term blood pharmacokinetics (PK), pharmacogenomics (PG), and severe neurotoxicity in patients undergoing an oxaliplatin (O)-based regimen
J Clin Oncol (Meeting Abstracts) 2009 27: e15024. [Abstract]  

T. Trarbach, K. Schuette, J. Stoehlmacher, E. Goekkurt, H. Guenther, U. Ubbelohde, C. Stroszczynski, G. Ehninger, and G. Folprecht

Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15025. [Abstract]  

A. Fora, M. Fakih, S. Scheib, T. Hanna, C. Raczyk, A. Hutson, and R. Gottlieb

New CT treatment response score for predicting survival in patients with metastatic colorectal carcinoma: A pilot study
J Clin Oncol (Meeting Abstracts) 2009 27: e15026. [Abstract]  

N. Bouganim, P. Kavan, M. Eid, P. Metrakos, P. Chaudhury, and G. Batist

Perioperative chemotherapy with bevacizumab (BV) for liver metastases (LM) in colorectal cancer (CRC): McGill University pilot study
J Clin Oncol (Meeting Abstracts) 2009 27: e15027. [Abstract]  

M. Mano, A. Hendlisz, J. Machiels, E. Ehrnrooth, H. Aladdin, and J. Van Laethem

Phase I trial of zalutumumab and irinotecan in metastatic colorectal cancer patients who have failed irinotecan- and cetuximab-based therapy
J Clin Oncol (Meeting Abstracts) 2009 27: e15028. [Abstract]  

V. Velenik, J. Ocvirk, I. Oblak, and F. Anderluh

Neoadjuvant cetuximab, capecitabine, and radiotherapy (RT) in locally advanced resectable rectal cancer: results of a phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: e15029. [Abstract]  

A. F. Sobrero, E. Bennicelli, A. Pessino, A. Guglielmi, S. Mammoliti, F. Caprioni, G. Fornarini, D. Comandini, S. Sciallero, and F. Ansaldi

Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15030. [Abstract]  

A. Bardia, C. Loprinzi, A. Grothey, G. Nelson, S. Alberts, S. Patiyil, S. Thome, S. Gill, and D. Sargent

Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators
J Clin Oncol (Meeting Abstracts) 2009 27: e15031. [Abstract]  

T. Hansen, K. G. Spindler, D. A. Olsen, R. F. Andersen, J. Lindebjerg, I. Brandslund, and A. Jakobsen

Functional and prognostic influence of receptor polymorphisms in the vascular endothelial growth factor system in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15032. [Abstract]  

S. Aamdal, S. G. Larsen, K. H. Hole, K. K. Grøholt, S. Dueland, S. Aamdal, and K. Giercksky

Extended TME- and MRI-assisted pathology show high incidence of pt4 after neoadjuvant treatment
J Clin Oncol (Meeting Abstracts) 2009 27: e15033. [Abstract]  

S. M. Allegro, C. Rowsell, C. Law, and Y. Ko

Histological hepatic changes in patients undergoing liver resection for colorectal metastasis: A retrospective cohort study
J Clin Oncol (Meeting Abstracts) 2009 27: e15034. [Abstract]  

T. Doi, K. Shirao, H. Uetake, K. Hatake, Y. Takahashi, S. Nihira BV Appropriate Use Review Committee

Final safety results from the post-marketing survey (PMS) of bevacizumab (BV) in Japanese colorectal cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e15035. [Abstract]  

D. Azuara, F. Rodriguez-Moranta, A. Soriano-Izquierdo, J. Guardiola, J. de Oca, S. Biondo, I. Blanco, M. Esteller, and G. Capella

Evaluation of stool melting curve analysis of methylated CpG island promoters as an alternative for early noninvasive diagnosis of colorectal tumors
J Clin Oncol (Meeting Abstracts) 2009 27: e15036. [Abstract]  

P. A. Philip, S. Gupta, L. Heilbrun, D. Smith, B. El-Rayes, and A. Shields

¹⁸F-Fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15037. [Abstract]  

S. Hazama, Y. Okuyama, T. Kato, N. Okayama, Y. Hinoda, J. Sakamoto, H. Mishima, Y. Fujita, Y. Hamamoto, and M. Oka

Use of genotype subset selections of multi-UGT1As polymorphisms to predict severe neutropenia and tumor responses of metastatic CRC patients received FOLFIRI regimen
J Clin Oncol (Meeting Abstracts) 2009 27: e15038. [Abstract]  

M. Soni, S. Saha, A. Korant, B. Chakravarty, S. Arora, D. Iddings, S. Sirop, R. Bisnoi, D. Wiese, and T. Singh

Correlation of bone marrow micrometastasis to TNM stage of colorectal tumors
J Clin Oncol (Meeting Abstracts) 2009 27: e15039. [Abstract]  

A. Chajut, S. Benjamin, S. Gilad, Y. Goren, H. Dan, O. Zion, M. Kushnir, Y. Kundel, Y. Niv, and B. Brenner

Circulating microRNAs as potential blood-based biomarkers for detection of colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15040. [Abstract]  

A. Martinez Cardús, E. Martinez-Balibrea, E. Musulén, A. Ginés, J. L. Manzano, L. Layos, V. Quiroga, E. Aranda, and A. Abad

In vitro-acquired resistance gene expression profile and in vivo response to oxaliplatin-based treatment
J Clin Oncol (Meeting Abstracts) 2009 27: e15041. [Abstract]  

R. A. Tracy, S. T. Chuang, J. Kim, and D. Coppola

Correlation of expression of pro-apoptotic proteins bax and bak with lymph node metastasis in colonic adenocarcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e15042. [Abstract]  

A. Castiglioni, K. Bencardino, A. M. Tamburini, A. Monno, L. Albarello, C. Staudacher, M. Ronzoni, C. Doglioni, P. Rovere-Querini, and A. Manfredi

Characterization of innate responses elicited by neoadjuvant radio-chemotherapy for rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15044. [Abstract]  

I. Isufi, E. James, K. Keley, J. Peccerillo, and M. W. Saif

Pregabalin (PGB) in treatment of oxaliplatin-induced neuropathy
J Clin Oncol (Meeting Abstracts) 2009 27: e15045. [Abstract]  

S. Ananda, S. Kosmider, L. Lim, F. Barnett, J. Desai, and P. Gibbs

Adjuvant chemotherapy for stage II and stage III colon cancer—What is happening in routine practice?
J Clin Oncol (Meeting Abstracts) 2009 27: e15046. [Abstract]  

J. A. Posey, S. Koya, V. R. Katkoori, D. E. Davis, and U. Manne

Prognostic significance of VDR, DKK-1, and DKK-4 expression in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15047. [Abstract]  

T. Yokota, K. Muro, N. Shibata, T. Ura, D. Takahari, K. Shitara, and Y. Yatabe

Development of an assay for KRAS mutation as a predictive marker for cetuximab in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15048. [Abstract]  

S. Stintzing, R. T. Hoffmann, V. Heinemann, M. Kufeld, and A. Muacevic

Robotic radiosurgery of liver metastases of solid tumors
J Clin Oncol (Meeting Abstracts) 2009 27: e15049. [Abstract]  

G. Aprile, M. Miscoria, P. Baldin, A. Casetta, M. Pandolfi, C. Di Loreto, S. Pizzolitto, S. Pizzolitto, L. Foltran, G. Fasola, and F. Puglisi

Chemotherapy-induced thymidine phosphorylase modulation in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15050. [Abstract]  

M. J. Lamas, E. Balboa, G. Duran, P. Rana, A. Gomez, B. Bernardez, R. Lopez, A. Carracedo, and F. Barros

Analysis of pharmacogenetic biomarkers in rectal patients trated with chemoradiotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e15051. [Abstract]  

I. R. Quispe, Sr., F. J. Ramos, I. Bilbao, T. Macarulla, S. Cedres, R. Charco, J. Lázaro, M. Moreiras, M. Moreiras, and J. Tabernero

Long-term overall survival (os) and prognostic factors of patients (pts) with surgery of liver metastases from colorectal cancer origin (lm/crc): Retrospective analysis of a Spanish single institution
J Clin Oncol (Meeting Abstracts) 2009 27: e15052. [Abstract]  

C. Grande, Sr., G. Quintero, J. R. Mel, G. Huidobro, B. Campos, S. Candamio, J. C. Méndez, M. Salgado, E. Álvarez, and J. Casal

Phase II study of biweekly XELOX (capecitabine and oxaliplatin) as first line chemotherapy in elderly patients with metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15053. [Abstract]  

E. Song, N. Lee, J. Kwak, H. Yhim, K. Lee, H. Roh, M. Sohn, and C. Yim

High- versus low-dose leucovorin in 5-fluorouracil-based oxaliplatin- or irinotecan-containing regimen in metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15054. [Abstract]  

C. Bengala, S. Bettelli, A. Fontana, F. Bertolini, G. Sartori, N. Malavasi, L. Losi, C. Del Giovane, G. Luppi, and P. Conte

EGFR gene copy number, KRAS and BRAF status, PTEN and AKT expression analysis in patients with metastatic colon cancer treated with anti-EGFR monoclonal antibodies ± chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e15055. [Abstract]  

M. Nishioka, M. Shimada, N. Kurita, T. Utsunomiya, T. Iwata, K. Yoshikawa, and J. Higashijima

The effects of Gosha-jinki-gan on oxaliplatin-related neurotoxicity: A prospective randomized study
J Clin Oncol (Meeting Abstracts) 2009 27: e15056. [Abstract]  

D. Arnold, M. Kindler, V. Petersen, D. Tummes, M. Moelle, C. Schoeberl, S. Srock, A. Kutscheidt, and W. Grothe

Bevacizumab (BV) plus chemotherapy (CT) as first-line treatment of patients with metastatic colorectal cancer (mCRC): First results from a large community-based observational cohort study in Germany
J Clin Oncol (Meeting Abstracts) 2009 27: e15057. [Abstract]  

L. Kowalczyk, P. Shah, T. George, L. Lu, G. Sarosi, R. Beyth, and S. Sultan

Impact of a simple intervention that improves colon cancer lymph node yield and assessement
J Clin Oncol (Meeting Abstracts) 2009 27: e15058. [Abstract]  

E. Al-sukhni, P. F. Ridgway, B. O’Connor, R. S. McLeod, and C. J. Swallow

Extent of resection for curable colorectal cancer in young patients: A 27-year experience at a tertiary care centre
J Clin Oncol (Meeting Abstracts) 2009 27: e15059. [Abstract]  

L. Ubillos, N. Berois, D. Mazal, V. Braña, C. Yacoel, A. Masllorens, E. Berriel, M. Rondan, L. Carriquiry, and E. Osinaga

Involvement of ppGalNAc-T6, a new colon cancer marker, in the molecular basis of simple mucin-type O-glycosylated antigen expression
J Clin Oncol (Meeting Abstracts) 2009 27: e15060. [Abstract]  

M. E. Tamayo, G. H. Cornelio, J. B. Bautista, M. L. Flores, M. R. Kurman, M. M. Paul, M. A. Gargano, and M. L. Patchen

A phase Ib/2, dose-escalating, safety, and efficacy study of imprime PGG, cetuximab and irinotecan in patients with advanced colorectal cancer (CRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15062. [Abstract]  

W. Chua, S. Randall, M. J. McKay, L. Horvath, S. J. Clarke, and M. P. Molloy

Targeted plasma proteome profiling for early prediction of chemotherapy response and toxicity in colorectal cancer (CRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15063. [Abstract]  

S. Beslija, M. Banjin, S. Jungic, N. Obralic, G. Kecman-Malcic, I. Rakita, B. Salkic, A. Pasic, L. Tinjic, and V. Smoljanovic

Updated phase II study results of capecitabine (X) + irinotecan (I) + bevacizumab (A) as first-line therapy for metastatic colorectal cancer (MCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15064. [Abstract]  

Y. Deng, L. Wang, Q. Tian, C. Miller, T. Lin, A. J. Chien, C. M. Ulrich, W. M. Grady, C. A. Blau, and E. H. Lin

Regulation of expression of cd133, a colon cancer stem cell marker and other stemness genes/pathways, by celecoxib: Clues from clinical observations
J Clin Oncol (Meeting Abstracts) 2009 27: e15065. [Abstract]  

P. Fedele, G. Di Maggio, S. Leo, L. Nanni, F. Giuliani, M. Biglietto, V. Lorusso, S. Cinieri, G. Colucci, E. Maiello Gruppo Oncologico Italia Meridionale (GOIM)

Bi-weekly administration of capecitabine + oxaliplatin (Xelox-2) in first-line treatment of advanced colorectal cancer (ACRC): A phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM)
J Clin Oncol (Meeting Abstracts) 2009 27: e15066. [Abstract]  

P. Comella, B. Massidda, D. Natale, G. Filippelli, A. Farris, G. Condemi, S. Palmeri, S. Tafuto, G. Vessia, and G. Barberis

Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience
J Clin Oncol (Meeting Abstracts) 2009 27: e15067. [Abstract]  

M. Gil-Delgado, G. Bastian, J. Spano, B. Paule, G. Des-Guetz, A. Bardier-Dupas, and D. Khayat

Oxaliplatin/Capecitabine combination (Xelox) with or without targeted therapies in advanced colorectal cancer (ACRC) and pharmacokinetic analysis
J Clin Oncol (Meeting Abstracts) 2009 27: e15068. [Abstract]  

N. Halama, S. Michel, M. Kloor, I. Zoernig, T. Pommerencke, P. Schirmacher, M. von Knebel-Döberitz, J. Weitz, N. Grabe, and D. Jäger

Immune infiltrates in liver metastases of colorectal cancer and response to chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e15069. [Abstract]  

D. S. Ksienski, M. Levesque, and S. Gill

Predictors of adjuvant chemotherapy (AT) decision-making in referred patients (pts) with stage II and III colon cancer (CC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15070. [Abstract]  

H. Kuramochi, K. Hayashi, G. Nakajima, H. Kamikozuru, and M. Yamamoto

Evaluation of thymidylate synthase and ERCC1 mRNA levels as predictive markers in colorectal cancer patients treated with S-1 and oxaliplatin
J Clin Oncol (Meeting Abstracts) 2009 27: e15071. [Abstract]  

J. C. Yap, G. Y. Yang, M. Fakih, T. Mashtare, K. Bullard Dunn, B. W. Kuvshinoff, J. Smith, N. I. Khushalani, and J. F. Gibbs

Primary adenocarcinoma of the anus: a 22-year SEER population database analysis
J Clin Oncol (Meeting Abstracts) 2009 27: e15072. [Abstract]  

H. Albrecht, F. Boxberger, K. Wolff, N. Ostermeier, U. Reulbach, G. Maennlein, T. Meyer, W. Hohenberger, E. G. Hahn, and A. Wein

Palliative first-line treatment with weekly high-dose 5-fluorouracil and sodium folinic acid (s-FA) (AIO-schedule) as 24h-infusion plus biweekly oxaliplatin (ox) in patients with definitively non-resectable metastatic colorectal cancer (CRC) following secondary (sec.) metastatic resection: An interdisciplinary phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: e15073. [Abstract]  

E. Vrdoljak, T. Omrcen, and A. Hrabar

Phase II study of bevacizumab in combination with capecitabine as first line treatment in elderly patients with metastatic colorectal cancer (MCC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15074. [Abstract]  

E. Assenat, A. Kramar, S. Poujol, C. Gestin-Boyer, P. Senesse, E. Samalin, F. Portales, S. Thezenas, J. Bleuse, and M. Ychou

A phase I trial of a bi-weekly combination of capecitabine/irinotecan (XELIRI) then capecitabine/irinotecan/oxaliplatin (XELIRINOX) in solid tumors
J Clin Oncol (Meeting Abstracts) 2009 27: e15075. [Abstract]  

S. Iqbal, D. Yang, S. Cole, A. B. El-Khoueiry, W. Boswell, R. Agafitei, R. Lujan, and H. J. Lenz

Phase II study of capecitabine and gemcitabine in patients with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15077. [Abstract]  

Y. Chae, J. Kim, S. Sohn, S. Kim, S. Lee, J. Moon, S. Jeon, Y. Cho, G. Choi, and S. Jun

RIPK1 gene polymorphism as a prognostic marker for survival in patients with colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15078. [Abstract]  

N. B. Pandya, K. R. Tkaczuk, N. Tait, O. Ioffe, M. Tan, D. A. Van Echo, M. J. Sutula, S. A. Lesko, S. F. Deamond, and P. O. Ts’o

A predictive test for therapeutic treatment outcomes of advanced gastrointestinal cancer patients (AGC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15079. [Abstract]  

A. Viudez, R. Zárate, M. Garrido, J. Rodríguez, A. Chopitea, I. Fernández-Troconiz, F. Pardo, and J. García-Foncillas

Dose escalation of capecitabine in combination with biweekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: Preliminary clinical results
J Clin Oncol (Meeting Abstracts) 2009 27: e15080. [Abstract]  

J. Vieitez, P. Jiménez Fonseca, M. Fernandez de Sanmamed, A. S. Pitiot, G. Crespo, J. Berros, C. Muriel, M. Izquierdo, P. Pardo, and A. Lacave

Incidence and significance of K-RAS mutation in first line treatment of colorectal cancer (cc): Experience of a single institution (Hospital Universitario Central de Asturias (HUCA))
J Clin Oncol (Meeting Abstracts) 2009 27: e15081. [Abstract]  

A. Antonacopoulou, A. Argyriou, A. E. Kottorou, C. D. Scopa, and H. P. Kalofonos

Association of integrin beta-3 polymorphism and chronic oxaliplatin-induced peripheral neuropathy: Preliminary results
J Clin Oncol (Meeting Abstracts) 2009 27: e15082. [Abstract]  

P. Kavan, N. Bouganim, M. Eid, P. Metrakos, P. Chaudhury, and G. Batist

Safety of bevacizumab when given perioperatively for colorectal cancer with liver metastases: McGill University pilot study
J Clin Oncol (Meeting Abstracts) 2009 27: e15083. [Abstract]  

L. Xie, R. Lai, X. Wu, S. Zhang, X. Tang, and T. Chen

Correlation between K-ras mutations status and benefit from cetuximab treatment in advanced colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15084. [Abstract]  

S. Deva and M. B. Jameson

Systematic review of histamine type 2 receptor antagonists as an adjunct to curative surgical resection in gastrointestinal malignancies
J Clin Oncol (Meeting Abstracts) 2009 27: e15085. [Abstract]  

A. E. Kottorou, A. G. Antonacopoulou, L. Skarlas, P. D. Grivas, C. D. Scopa, T. Makatsoris, and H. P. Kalofonos

Nfy-c expression in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15086. [Abstract]  

J. Ocvirk and M. Rebersek

Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream
J Clin Oncol (Meeting Abstracts) 2009 27: e15087. [Abstract]  

B. A. Carneiro, N. Bahary, B. Lembersky, M. Fakih, S. S. Krishnamurthi, S. Lancaster, R. Pinkerton, T. Crandall, D. Potter, and R. K. Ramanathan

Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15088. [Abstract]  

M. B. Jameson, M. Head, and S. Deva

Colorectal cancer survival following adjuvant chemotherapy with weekly i.v. fluorouracil 425 mg/m² and folinic acid 50mg
J Clin Oncol (Meeting Abstracts) 2009 27: e15089. [Abstract]  

Q. Lu, A. Zhao, and L. Shen

Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome
J Clin Oncol (Meeting Abstracts) 2009 27: e15090. [Abstract]  

M. M. Moore, W. Chua, J. Zhao, S. J. Clarke, and L. Horvath

Evaluation of plasma total and cleaved cytokeratin 18 as predictive markers of chemotherapy in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15091. [Abstract]  

M. Oukkal, F. Kara, S. Difi, D. Bouzidi, K. Bentabak, A. Graba, N. Smail, N. Ait Kaci, R. Baba Ahmed, and K. Bouzid

Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15092. [Abstract]  

E. C. Marginean, G. Torlakovic, H. Neufeld, and E. Torlakovic

Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors
J Clin Oncol (Meeting Abstracts) 2009 27: e15093. [Abstract]  

R. Joubert, U. Raeth, and T. Moehler

Variation in enrollment of colorectal cancer patients in clinical trials
J Clin Oncol (Meeting Abstracts) 2009 27: e15094. [Abstract]  

B. Yu, M. Zhang, W. Wu, L. Chen, L. Peng, G. Bian, J. Fu, and C. Fei

Neoadjuvant chemoradiotherapy for locally advanced low-lying rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15095. [Abstract]  

G. Melmed, C. Becerra, G. Saracino, E. Bowman, and A. D. McCollum

Chemotherapy-free interval following initial chemotherapy in patients with stage IV colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15096. [Abstract]  

J. E. Littlejohn, D. Jupiter, X. Cao, L. Zhang, M. Shabahang, and W. R. Smythe

BNIP3L (Nix) expression in colon cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15097. [Abstract]  

S. Madajewicz, D. M. Waterhouse, P. Ritch, M. Khan, D. Higby, C. G. Leichman, S. K. Malik, P. Hentschel, L. Zhao, and S. J. Nicol

Phase II trial comparing folinic acid, fluorouracil, and gemcitabine (FFG) and FOLFOX4 regimens with added bevacizumab (B) in metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15098. [Abstract]  

H. Matthes, W. E. Friedel, and P. R. Bock

Long-term supportive treatment with fermented mistletoe (viscum album L.) extract in primary nonmetastatic colorectal cancer: Best time to start with for optimal effectiveness
J Clin Oncol (Meeting Abstracts) 2009 27: e15099. [Abstract]  

S. Sukumaran, N. Pavlakis, K. B. Pittman, K. Patterson, and T. J. Price

Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): A systematic review of controlled clinical trials
J Clin Oncol (Meeting Abstracts) 2009 27: e15100. [Abstract]  

J. Gasent Blesa, V. Alberola Candel, O. Juan, M. Provencio Pulla, V. Giner Marco, C. Gravalos, I. Fernandez, and C. Llorca

Neoadjuvant chemoradiotherapy in rectal cancer patients (pt) with oxaliplatin (Ox) and capecitabine (Cp): Results of a phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: e15101. [Abstract]  

S. S. Kazmi, M. Azfar, A. A. Syed, and M. A. Yusuf

Oxaliplatin-based neoadjuvant chemoradiation for locally advanced rectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15102. [Abstract]  

J. Metges, E. Gamelin, R. Faroux, V. Klein, G. Ganem, J. Douillard, C. Stampfli, S. Corbinais, C. Riche, and F. Grude

AVASTERB OUEST: A prospective cohort study of unresectable metastatic colon cancer treated successively by FOLFIRI bevacizumab and cetuximab irinotecan
J Clin Oncol (Meeting Abstracts) 2009 27: e15103. [Abstract]  

H. Malik and G. Poston

Do predictive scoring systems have any role in determining treatment strategy for colorectal liver metastases at the individual patient level?
J Clin Oncol (Meeting Abstracts) 2009 27: e15104. [Abstract]  

C. Mucciarini, S. Bellentani, G. Razzini, I. Bernardini, F. Artioli, A. Iop, and S. Blanzieri

The role of contrast-enhanced ultrasound in detection of liver metastases from colorectal cancer: A prospective monocentric study
J Clin Oncol (Meeting Abstracts) 2009 27: e15105. [Abstract]  

W. Li, W. Zhang, S. Cai, J. Yin, and J. Li

Prognostic factors for colorectal cancer patients with pulmonary metastases
J Clin Oncol (Meeting Abstracts) 2009 27: e15107. [Abstract]  

L. Djellali, B. Larbaoui, A. Boukerche, S. Ghazi, I. Chaiba, N. Meziane, D. Yekrou, and D. F. Youcef

Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e15108. [Abstract]  

E. Pineda, C. Pericay, X. García-Albéniz, J. Augé, V. Alonso, P. Escudero, C. Fernández-Martos, R. Gallego, and J. Maurel

Serum IGFBP3, IGF-I, and MMP7 changes in advanced colorectal cancer (ACRC) patients (pts) treated with anti-EGFR therapy: A GEMCAD study
J Clin Oncol (Meeting Abstracts) 2009 27: e15109. [Abstract]  

T. Ochiai, K. Nishimura, T. Watanabe, M. Kitajima, N. Nakayama, S. Mashiko, R. Yamazaki, N. Kaneko, S. Futagawa, and I. Nagaoka

Evaluation of the distinction between responder and non-responder in FOLFOX/FOLFIRI based on the alteration of serum iron level
J Clin Oncol (Meeting Abstracts) 2009 27: e15110. [Abstract]  

A. Takeda

Use of anti-neuropilin 1, 2 antibodies to predict colorectal cancer prognosis
J Clin Oncol (Meeting Abstracts) 2009 27: e15111. [Abstract]  

E. Torlakovic, E. C. Marginean, G. Torlakovic, R. Geyer, H. Neufeld, and J. Decoteau

Downregulation of RIZ1 protein expression in left-sided versus right-sided primary colorectal carcinomas and their distant metastases and the association with NF-B activation
J Clin Oncol (Meeting Abstracts) 2009 27: e15112. [Abstract]  

S. Lee, J. Lee, H. Ahn, J. Park, J. Kim, K. Park, H. Lim, W. Kang, B. Kim, and Y. Park

The role of oophorectomy for colon cancer with ovarian metastasis
J Clin Oncol (Meeting Abstracts) 2009 27: e15113. [Abstract]  

B. Ardalan, M. Feagans, D. Mezentsev, C. Jones, P. R. Subbarayan, G. Walker, M. Sapp, K. Stephenson, J. Ness, D. Franceschi, and A. Livingstone

Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL)
J Clin Oncol (Meeting Abstracts) 2009 27: e15114. [Abstract]  

S. Sharma, T. Reid, S. Hoosen, C. Garrett, J. Beck, S. Davidson, M. MacKenzie, U. Brandt, and J. Hecht

Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15115. [Abstract]  

S. Oh, S. Kim, and K. Jun Suk

The relationship and optimal cutoff value between dual phase corrected whole body uptake ratio (CUR) and serum CEA level in recurrent/metastatic colorectal carcinoma: Dual phase whole body protocol using time of flight (TOF) imaging
J Clin Oncol (Meeting Abstracts) 2009 27: e15116. [Abstract]  

J. M. Kovar, H. X. Bui, J. P. Reynolds, H. Al-Ghawi, G. Luo, N. Abdel Karim, S. Samaan, A. Mehta, and M. Molloy

A closer look at the number of lymph nodes examined in colorectal cancer: A VAMC experience
J Clin Oncol (Meeting Abstracts) 2009 27: e15117. [Abstract]  

S. Lin, E. Chiang, Y. Tsai, S. Lee, B. Kuo, and R. Lin

Effect of AbGn-7, a glycotope-specific monoclonal antibody, on apoptosis in colon cancer cells and tumor growth in xenograft models
J Clin Oncol (Meeting Abstracts) 2009 27: e15118. [Abstract]  

R. Lai, Sr., L. Feng, L. Liu, L. Xie, X. Wu, S. Zhang, X. Tang, J. Geng, and T. Chen

The clinical pathogensis significance associated with mutation of APC MCR in colorectal neoplasms
J Clin Oncol (Meeting Abstracts) 2009 27: e15119. [Abstract]  

K. Sasaki, K. Oono, K. Harada, T. Someya, Y. Takada, Department of Surgery, Sapporo Medical University, T. Furuhata, and K. Hirata

Can Kampo medicine prolong the life of metastatic colorectal cancer (MCRC) patients with chemotherapy?
J Clin Oncol (Meeting Abstracts) 2009 27: e15120. [Abstract]  

G. Carlsson, H. Bjökqvist, G. Kurlberg, S. Torbjörn, M. Casillas, M. Holmqvist, C. Stoffregen, and B. Gustavsson

Feasibility of treatment of resectable rectal cancer with neoadjuvant treatment with pemetrexed
J Clin Oncol (Meeting Abstracts) 2009 27: e15121. [Abstract]  

J. Hasegawa, Y. Yoshida, T. Mizushima, M. Fujii, H. Mizuno, K. Tamagawa, and R. Nezu

Outcome of initially unresectable advanced and metastatic colorectal cancer patients treated with first-line mFOLFOX6 followed by surgical tumor removal of metastases: Preliminary results of a phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: e15122. [Abstract]  

R. P. Junghans, M. Abedi, A. Bais, E. Gomes, Q. Ma, E. Beaudoin, and P. Davol

Phase I trial of advanced generation anti-CEA designer T cells in gastrointestinal and breast cancers
J Clin Oncol (Meeting Abstracts) 2009 27: e15123. [Abstract]  

J. B. Blitzer, I. Shbeeb, A. Neoman, K. Azaren, M. Paulsen, S. Evans, and R. Nagourney

Functional profiling in stage IV colorectal cancer: A phase II trial of individualized therapy
J Clin Oncol (Meeting Abstracts) 2009 27: e15124. [Abstract]  

R. Xu none, Y. Li, H. Luo, and F. Wang

Phase II study of capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e15125. [Abstract]  

E. Mak, C. Townsley, R. Buckman, E. Chen, L. Lopez, L. Wang, M. Moore, and A. M. Oza

Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory colorectal carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e15126. [Abstract]  

S. D. Rice, P. R. Ervin, and S. L. Brower

Use of an in vitro chemoresponse assay to define a subset of colorectal carcinomas responsive to cetuximab
J Clin Oncol (Meeting Abstracts) 2009 27: e15127. [Abstract]  

K. Iqbal

Positive expression and correlation of chemokine receptor CXCR4 with nodal metastasis and prognosis in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15128. [Abstract]  

T. Oshima, N. Yamamoto, T. Sato, Y. Nagano, S. Fujii, C. Kunisaki, M. Shiozawa, M. Akaike, Y. Rino, M. Masuda, and T. Imada

Overexpression of EphA4 gene and reduced expression of EphB2 gene: Correlation with liver metastasis in colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15129. [Abstract]  

S. D. Glisson, R. V. LaRocca, J. B. Hargis, A. Cervera, G. Goldsmith, B. Cornell, D. D. Repishti, and J. E. Sunderland

A phase II clinical trial utilizing maximum medical and surgical cytoredutive treatments for patients with metastatic colorectal cancer to the liver
J Clin Oncol (Meeting Abstracts) 2009 27: e15130. [Abstract]  

S. Subramonia Iyer and A. Akl

A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004
J Clin Oncol (Meeting Abstracts) 2009 27: e15131. [Abstract]  

M. V. Phadke, L. H. Stocks, and Y. G. Phadke

New "sutureless" technique of ileostomy and colostomy
J Clin Oncol (Meeting Abstracts) 2009 27: e15132. [Abstract]  

C. Mello, T. B. Oliveira, T. F. Paiva, Junior, M. J. Silva, S. M. Sanches, M. R. Cruz, U. R. Nicolau, and M. F. Fanelli

Safety profile of first-line bevacizumab and chemotherapy in patients with unresected primary colorectal cancer and synchronous metastases
J Clin Oncol (Meeting Abstracts) 2009 27: e15133. [Abstract]  

B. Larbaoui

Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma
J Clin Oncol (Meeting Abstracts) 2009 27: e15134. [Abstract]  

H. Astudillo, J. Sanchez-Guillen, P. Romero-Garcia, J. Bastarrachea-ortiz, G. Morgan-Villela, J. M. Salazar, V. M. Vazquez-Rivera, H. Ruiz-Calzada, and P. Cortes-Esteban

Polymorphism detection of K-Ras mutations using high-resolution melting analysis in Mexican patients with metastatic colorectal cancer (mCRC)
J Clin Oncol (Meeting Abstracts) 2009 27: e15135. [Abstract]  

C. Lin and Y. Chen

Protective role of silibinin on matrix metalloproteinase-2 and activator protein-1 on LoVo cells
J Clin Oncol (Meeting Abstracts) 2009 27: e15136. [Abstract]  

K. H. Khan

Retrospective analysis of resected primary colorectal cancer revealed
J Clin Oncol (Meeting Abstracts) 2009 27: e15137. [Abstract]  

S. Tomao, Sr., G. Spinelli, L. Rossi, G. Pasciuti, G. Arcangeli, M. D’Aprile, E. Veltri, and G. Baiano

Safety, efficacy, and time to clinical response with bevacizumab plus FOLFIRI regimen in metastatic colorectal cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e15138. [Abstract]  

M. Piperdi, V. Velagapudi, G. Ayata, J. Simons, J. F. Tseng, and B. Piperdi

Rectal prognostic index (RPI) to predict outcome of patients with locally advanced rectal cancer (LARC) treated with preoperative chemo-radiation (preop-CRT)
J Clin Oncol (Meeting Abstracts) 2009 27: e15139. [Abstract]  

T. Sasatomi and Y. Ogata

DWIBS (diffusion weighted whole body imaging with background signal suppression) scan for colorectal cancer and its evaluation: Comparison with CT or PET scans
J Clin Oncol (Meeting Abstracts) 2009 27: e15140. [Abstract]  

M. Shibata, N. Yumiko, T. Hirano, S. Matsuo, H. Abe, and Y. Yajima

Efficacy of FOLFOX4 in patients with hypoalbuminemia or immune impairment
J Clin Oncol (Meeting Abstracts) 2009 27: e15141. [Abstract]  

C. L. Martel and M. V. McNamara

The use of panitumumab (Pan) in patients (pts) with metastatic colorectal carcinoma (CRC) whose disease has progressed through treatment (Rx) with cetuximab (Cet)
J Clin Oncol (Meeting Abstracts) 2009 27: e15142. [Abstract]  

G. F. Samelis, A. Tsiakou, M. Karamanidi, M. Pelechrini, A. Zaganides, and K. Ekmektzoglou

Effect of continuation of bevacizumab following disease progression in patients with metastatic colorectal cancer on survival
J Clin Oncol (Meeting Abstracts) 2009 27: e15143. [Abstract]  

J. Gomez Rangel, Sr., O. Alvarez Ordorica, R. Villalobos Valencia, and J. A. Silva

Utility of concomitant chemoradiotherapy with 5-fluorouracil (5-FU) single agent as neoadjuvant treatment regimen in mexican patients with stage III rectal cancer: Experience in the Oncology Hospital
J Clin Oncol (Meeting Abstracts) 2009 27: e15144. [Abstract]  

N. Srinivasaiah, III, B. Joseph, J. Gunn, J. Hartley, and J. Monson

A qualitative analysis of a focus group discussion on patient decision making in cancer care
J Clin Oncol (Meeting Abstracts) 2009 27: e15145. [Abstract]  

H. Mahfouf, H. Djeddi, S. Belhadef, K. Bouzid, and K. Bentabak

Capecitabine combined with oxaliplatin (XELOX) as first-line chemotherapy in colorectal cancer with liver metastases
J Clin Oncol (Meeting Abstracts) 2009 27: e15146. [Abstract]  

D. Hwang, E. Jung, and S. Cho

Expression of EGFR, VEGF, and K-ras mutation as predictors for response of cetuximab in colorectal cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e15147. [Abstract]  

Breast Cancer—Local-Regional and Adjuvant Therapy:

J. A. Sparano, L. J. Goldestin, B. H. Childs, S. Shak, S. Badve, F. L. Baehner, N. E. Davidson, G. W. Sledge, Jr., R. Gray North American Breast Cancer Intergroup

Genotypic characterization of phenotypically defined triple-negative breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 500. [Abstract]  

J. Gronwald, T. Byrski, T. Huzarski, R. Dent, V. Bielicka, D. Zuziak, R. Wisniowski, J. Lubinski, and S. Narod

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 502. [Abstract]  

M. Buess, M. Rajski, B. Vogel, R. Herrmann, and C. Rochlitz

Tumor endothelial interaction, CD44+/CD24- stem cell signature, and prognosis in early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 503. [Abstract]  

E. Lim, F. Vaillant, D. Wu, N. Forrest, B. Pal, D. Gyorki, G. K. Smyth, J. Visvader, G. Lindeman kConFab

Investigation of human mammary stem and progenitor subpopulations from BRCA1 mutation carriers and noncarriers
J Clin Oncol (Meeting Abstracts) 2009 27: 504. [Abstract]  

J. M. Reuben, B. Lee, A. Lucci, H. Gao, E. N. Cohen, C. Li, S. Krishnamurthy, G. N. Hortobagyi, W. A. Woodward, and M. Cristofanilli

Disseminated tumor cells in primary breast cancer: Evaluation of the percentage of breast cancer stem cells in bone marrow aspirates of patients receiving neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: 505. [Abstract]  

S. Dawood, A. M. Gonzalez-Angulo, W. Woodward, F. Meric-Bernstam, K. Hunt, A. Buzdar, G. Hortobagyi, and T. Buchholz

Value of adjuvant radiation therapy in breast cancer patients with one to three positive lymph nodes undergoing a modified radical mastectomy and systemic therapy
J Clin Oncol (Meeting Abstracts) 2009 27: 507. [Abstract]  

K. E. Ribi, K. A. Phillips, Z. Sun, A. Stephens, A. Thompson, V. Harvey, B. Thürlimann, F. Cardoso, A. S. Coates, and J. Bernhard

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1–98 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 510. [Abstract]  

N. Harbeck, M. Schmitt, C. Meisner, C. Friedel, M. Untch, M. Schmidt, B. Lisboa, C. Sweep, F. Jänicke, C. Thomssen Chemo N0 Study Group

Final 10-year analysis of prospective multicenter Chemo N0 trial for validation of ASCO-recommended biomarkers uPA/PAI-1 for therapy decision making in node-negative breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 511. [Abstract]  

R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C. Linn, and L. J. Van 't Veer

The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 512. [Abstract]  

T. Watanabe, M. Kuranami, K. Inoue, N. Masuda, K. Aogi, H. Iwata, H. Mukai, S. Tanaka, T. Yamaguchi, and Y. Ohashi

Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 516. [Abstract]  

M. J. Rodrigues, J. Wassermann, L. Albiges-Sauvin, D. Stevens, E. Brain, S. Delaloge, M. Mathieu, E. Guillot, A. Vincent-Salomon, and P. H. Cottu

Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study
J Clin Oncol (Meeting Abstracts) 2009 27: 517. [Abstract]  

M. Knauer, S. Mook, V. Retèl, M. Kok, J. Wesseling, A. M. Glas, E. J. Rutgers, L. J. van 't Veer, and S. C. Linn

Early determination of metastatic potential in breast cancer: The 70-gene signature in small tumors
J Clin Oncol (Meeting Abstracts) 2009 27: 518. [Abstract]  

M. Cheang, S. K. Chia, D. Tu, S. Jiang, L. E. Shepherd, K. I. Pritchard, and T. O. Nielsen

Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF
J Clin Oncol (Meeting Abstracts) 2009 27: 519. [Abstract]  

W. R. Sukov, D. V. Miller, A. C. Dueck, K. S. Tenner, R. B. Jenkins, P. A. Kaufman, N. E. Davidson, S. R. Dakhil, S. Martino, V. Roy, and E. A. Perez

Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial
J Clin Oncol (Meeting Abstracts) 2009 27: 520. [Abstract]  

C. Kurzeder, J. König, A. Woeckel, G. Sauer, M. Wischnewsky, M. Blettner, and R. Kreienberg

Impact of study participation on survival of early-stage breast cancer patients: Results from the BRENDA study, a multicenter clinical cohort on quality of breast cancer care
J Clin Oncol (Meeting Abstracts) 2009 27: 521. [Abstract]  

H. M. Earl, A. Vallier, L. Hiller, N. Fenwick, M. Iddawela, L. Hughes-Davies, E. Provenzano, K. McAdam, T. Hickish, C. Caldas for NeotAnGo Investigators

Neo-tAnGo: A neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): First report of the primary endpoint, pathological complete response (pCR)
J Clin Oncol (Meeting Abstracts) 2009 27: 522. [Abstract]  

C. Desmedt, E. Azambuja, D. Larsimont, G. Rouas, A. Di Leo, S. Delaloge, C. Duhem, V. D'Hondt, M. Piccart, C. Sotiriou on behalf of the investigators of the TOP trial

Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial
J Clin Oncol (Meeting Abstracts) 2009 27: 523. [Abstract]  

J. Huober, G. von Minckwitz, C. Denkert, A. Kleine-Tebbe, E. Weiss, D. Zahm, G. Köhler, K. Mehta, and S. Loib

Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment
J Clin Oncol (Meeting Abstracts) 2009 27: 524. [Abstract]  

F. Marme, C. Sohn, B. Burwinkel, P. Sinn, M. Hahn, P. Lichter, A. Benner, and A. Schneeweiss

Association of the fibroblast growth factor receptor-4 (FGFR4) Gly388Arg polymorphism with clinical and pathological response to primary systemic therapy (PST) for early breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2009 27: 525. [Abstract]  

B. Gerber, H. Stehle, F. Ricardo, N. Maass, D. Fischer, H. L. Sommer, B. Conrad, K. Mehta, and S. Loibl

ZORO: A prospective randomized multicenter study to prevent chemotherapy-induced ovarian failure with the GnRH-agonist goserelin in young hormone-insensitive breast cancer patients receiving anthracycline containing (neo-) adjuvant chemotherapy (GBG 37)
J Clin Oncol (Meeting Abstracts) 2009 27: 526. [Abstract]  

D. A. Yardley, E. Raefsky, R. Castillo, A. Lahiry, R. LoCicero, D. Thompson, M. Shastry, V. Trieu, D. Knauer, and N. Desai

Results of a multicenter pilot study of weekly nab-paclitaxel, carboplatin with bevacizumab, and trastuzumab as neoadjuvant therapy in HER2+ locally advanced breast cancer with SPARC correlatives
J Clin Oncol (Meeting Abstracts) 2009 27: 527. [Abstract]  

R. Le Scodan, G. Cizeron-Clairac, E. Fourme, D. Meseure, S. Vacher, F. Spyratos, F. Cvitkovic, B. de la Lande, R. Lidereau, and I. Bieche

DNA repair gene expression profile and risk of locoregional relapse in locally advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 528. [Abstract]  

N. Hylton, J. Blume, C. Gatsonis, R. Gomez, W. Bernreuter, E. Pisano, M. Rosen, H. Marques, L. Esserman, M. Schnall ACRIN 6657/I-SPY Trial Team

MRI tumor volume for predicting response to neoadjuvant chemotherapy in locally advanced breast cancer: Findings from ACRIN 6657/CALGB 150007
J Clin Oncol (Meeting Abstracts) 2009 27: 529. [Abstract]  

A. B. Chagpar, P. Blumencranz, P. W. Whitworth, K. B. Deck, A. Rosenberg, R. M. Simmons, D. S. Reintgen, P. Beitsch, S. Saha, T. B. Julian GeneSearch Beta and Pivotal Investigators

Use of intraoperative breast cancer sentinel lymph node (SLN) assay to predict of 4 positive (+) lymph nodes (LN)
J Clin Oncol (Meeting Abstracts) 2009 27: 530. [Abstract]  

U. Rudloff, E. Brogi, B. McCormick, J. P. Brockway, J. I. Goldberg, C. A. Wynveen, A. S. Reiner, S. Patil, and K. J. Van Zee

The influence of margin width and volume of disease near margin on benefit of radiation therapy after breast-conserving surgery for DCIS: Results of long-term follow-up
J Clin Oncol (Meeting Abstracts) 2009 27: 531. [Abstract]  

S. Loi, B. Haibe-Kains, F. Lallemand, L. Pusztai, A. Bardelli, C. Gillett, P. Ellis, M. J. Piccart-Gebhart, W. A. Phillips, G. A. McArthur, and C. Sotiriou

Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 533. [Abstract]  

E. Piura, J. W. Chapman, A. Lipton, L. Zhu, K. Leitzel, C. F. Wilson, K. I. Pritchard, L. Shepherd, and M. N. Pollak

Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial
J Clin Oncol (Meeting Abstracts) 2009 27: 534. [Abstract]  

F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, and L. J. Van 't Veer

Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines
J Clin Oncol (Meeting Abstracts) 2009 27: 535. [Abstract]  

M. Mathieu, J. De la Cruz, A. S. Veilllard, S. Koscielny, C. Bourgier, F. Rimareix, M. Spielmann, T. Delozier, F. Andre, and S. Delaloge

Use of progesterone receptor (PR) expression to predict benefit from prolonged adjuvant tamoxifen (TAM) in breast cancer: Results of a biomarker study from the TAM01 randomized Trial
J Clin Oncol (Meeting Abstracts) 2009 27: 536. [Abstract]  

S. X. Yang, J. P. Costantino, D. Nguyen, J. Jeong, E. P. Mamounas, N. Wolmark, C. Kim, K. Kidwell, S. Paik, and S. M. Swain

Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 537. [Abstract]  

F. N. Tanja, O. Hoffmann, B. Aktas, E. Solomayer, D. Wallwiener, S. Becker, R. Kimmig, and S. Kasimir-Baur

Expression profile of CTC and corresponding tumors in primary breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 538. [Abstract]  

A. Moreno-Aspitia, D. W. Hillman, A. C. Dueck, W. P. Carney, W. L. Lingle, K. S. Tenner, J. M. Lafky, M. M. Reinholz, L. A. Kutteh, and E. A. Perez

Baseline and recurrence levels of soluble HER2 (sHER2) in early-stage HER2-neu positive breast cancer (HER2+BC) from the NCCTG adjuvant Intergroup trial N9831
J Clin Oncol (Meeting Abstracts) 2009 27: 539. [Abstract]  

M. J. Procter, T. Suter, E. de Azamuja, S. Muehlbauer, U. Dafni, D. J. van Veldhuisen, M. Muscholl, and M. Piccart-Gebhart

Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) Trial with 3.6 years median follow- up
J Clin Oncol (Meeting Abstracts) 2009 27: 540. [Abstract]  

A. U. Buzdar, M. C. Green, K. R. Broglio, C. D. Carter, V. Valero, N. K. Ibrahim, K. K. Hunt, and G. N. Hortobagyi

Prospective randomized trial evaluating weekly paclitaxel (WP) versus docetaxel in combination with capecitabine (DC) in operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 542. [Abstract]  

N. U. Lin, A. Vanderplas, M. E. Hughes, R. L. Theriault, S. B. Edge, Y. Wong, D. W. Blayney, J. C. Niland, E. P. Winer, and J. C. Weeks

Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN)
J Clin Oncol (Meeting Abstracts) 2009 27: 543. [Abstract]  

C. Thomssen, M. Vetter, M. Schmidt, C. Veyret, C. Meisner, G. von Minckwitz, P. Martin, F. C. Sweep, D. Paepke, N. Harbeck NNBC-3 Trial Group

ASCO-recommended prognostic factors uPA/PAI-1 in node-negative (N0) breast cancer patients (pts) compared to clinicopathological risk assessment within the NNBC 3-Europe trial
J Clin Oncol (Meeting Abstracts) 2009 27: 544. [Abstract]  

K. Zaman, B. Thürlimann, J. Huober, A. Schönenberger, O. Pagani, J. Lüthi, M. Simcock, A. Giobbie-Hurder, C. Genton, S. Aebi on behalf of the Swiss Group for Clinical Cancer Research (SAKK)

Modeling bone mineral density (BMD) evolution in postmenopausal patients treated by letrozole (L), tamoxifen (T), and sequences of T and L (SAKK 21/07)
J Clin Oncol (Meeting Abstracts) 2009 27: 545. [Abstract]  

N. Berrada, R. Conforti, S. Delaloge, M. Spielmann, and F. Andre

Use of molecular classification combined with p53 and topoisomerase IIa expression to identify tumors highly responsive to FEC regimen: A tissue microarray
J Clin Oncol (Meeting Abstracts) 2009 27: 546. [Abstract]  

V. Caggiano, K. R. Bauer, and C. A. Parise

Triple-negative receptor status and the 2007 St. Gallen consensus guidelines for early breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 547. [Abstract]  

S. Shak, G. Palmer, F. L. Baehner, C. Millward, D. Watson, and G. W. Sledge, Jr.

Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers
J Clin Oncol (Meeting Abstracts) 2009 27: 549. [Abstract]  

H. A. McKean, C. Reynolds, T. L. Hoskin, V. J. Suman, C. S. Grant, M. G. Erlander, X. Ma, J. Ingle, and M. P. Goetz

Ductal carcinoma in situ of the breast and gene expression markers for prediction of invasive recurrence
J Clin Oncol (Meeting Abstracts) 2009 27: 550. [Abstract]  

P. D. Ryan, N. M. Tung, S. J. Isakoff, M. Golshan, A. Richardson, A. D. Corben, B. L. Smith, R. Gelman, E. P. Winer, and J. E. Garber

Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy
J Clin Oncol (Meeting Abstracts) 2009 27: 551. [Abstract]  

C. Markopoulos, E. Tzorakoleftherakis, A. Polychronis, V. Venizelos, G. Xepapadakis, K. Kalogerakos, J. Papadiamantis, V. Zobolas, J. Janinis, U. Dafni Hellenic Society of Breast Surgeons

Management of bone loss in breast cancer patients: 24-month results from the ARBI trial of anastrozole with risedronate
J Clin Oncol (Meeting Abstracts) 2009 27: 552. [Abstract]  

W. J. Irvin, Jr., L. A. Carey, O. Olajide, E. C. Dees, J. Peppercorn, W. K. Chiu, C. M. Walko, H. L. McLeod, J. P. Evans, and K. E. Weck

Comprehensive CYP2D6 genotyping in a multiracial U.S. breast cancer population
J Clin Oncol (Meeting Abstracts) 2009 27: 553. [Abstract]  

B. K. Rack, C. Schindlbeck, A. Schneeweiss, I. Schrader, R. Lorenz, M. Beckmann, K. Pantel, W. Lichtenegger, H. Sommer, W. Janni for the SUCCESS Study Group

Persistance of circulating tumor cells (CTCs) in peripheral blood of breast cancer (BC) patients two years after primary diagnosis
J Clin Oncol (Meeting Abstracts) 2009 27: 554. [Abstract]  

G. Lunardi, L. Del Mastro, M. Serra, P. Driol, C. Boni, F. Cognetti, R. Ponzone, M. Porpiglia, M. Venturini, P. Pronzato Gruppo Italiano Mammella (GIM)

Plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment: Association with single nucleotide polymorphisms (SNPs) of CYP19A1
J Clin Oncol (Meeting Abstracts) 2009 27: 555. [Abstract]  

L. Huiart, S. Dell'Aniello, and S. Suissa

Patterns of use of tamoxifen and aromatase inhibitors: A population-based observational study
J Clin Oncol (Meeting Abstracts) 2009 27: 556. [Abstract]  

K. E. Ougari, C. Taneja, O. Sofrygin, S. Kaura, and T. Delea

Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective
J Clin Oncol (Meeting Abstracts) 2009 27: 557. [Abstract]  

E. A. Mittendorf, S. L. Tucker, J. S. Jeruss, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt

Validation of a novel staging system for breast cancer patients treated with neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: 558. [Abstract]  

M. Ono, H. Tsuda, C. Shimizu, S. Yamamoto, T. Shibata, T. Kouno, K. Tamura, M. Ando, N. Katsumata, T. KInoshita, and Y. Fujiwara

Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 559. [Abstract]  

D. Amadori, F. Schittulli, A. Paradiso, E. Scarpi, P. Sismondi, A. Ravaioli, A. Rocca, R. Maltoni, P. Serra, and R. Silvestrini

Randomized phase III trial of adjuvant epicirubicin (E) followed by cyclophosphamide, methotrexate, and fluorouracil (CMF) or CMF followed by E in patients with N^- or 3 N⁺ rapidly proliferating breast cancer (RPBC)
J Clin Oncol (Meeting Abstracts) 2009 27: 560. [Abstract]  

V. Shih, A. Chan, J. Chiang, C. Teo, J. Chen, and Z. Wong

Cardiotoxicity risks of adjuvant trastuzumab in Asian breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 561. [Abstract]  

D. L. Hershman, D. McMahon, K. D. Crew, T. Shao, S. Cremers, L. Brafman, D. Awad, and E. Shane

Evaluation of the protective effects of zoledronic acid on bone mass in premenopausal women undergoing adjuvant chemotherapy following treatment discontinuation
J Clin Oncol (Meeting Abstracts) 2009 27: 562. [Abstract]  

M. Thompson, B. Seal, M. Tangirala, L. Asmar, and S. Jones

Long-term survival benefits of docetaxel plus cyclophosphamide compared to doxorubicin plus cyclophosphamide in the adjuvant treatment of operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 563. [Abstract]  

Y. Park, S. Kim, O. Ok, H. Baek, J. Lee, S. Nam, J. Yang, E. Cho, J. Ahn, and Y. Im

Risk stratification by hormonal receptor (ER, PgR) and HER2 status in small (1cm) invasive breast cancer: Who might be a possible candidate for adjuvant treatment?
J Clin Oncol (Meeting Abstracts) 2009 27: 564. [Abstract]  

N. Masuda, M. Ando, K. Aogi, H. Ino, H. Iwata, Y. Tokuda, S. Nakamura, N. Yamamoto, and Y. Fujiwara

Randomized phase II study of neoadjuvant chemotherapy and trastuzumab for operable breast cancer with overexpression of HER2
J Clin Oncol (Meeting Abstracts) 2009 27: 565. [Abstract]  

L. C. Hanker, T. Karn, A. Rody, E. Ruckhäberle, C. Solbach, and M. Kaufmann

Prognostic value of gene expression of p63 by microarray analysis in estrogen receptor positive and negative breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 566. [Abstract]  

M. D. Gustavson, A. Welsh, C. Jones, J. Mayotte, J. Tu, J. Hopkins, D. Rimm, and J. Christiansen

Evaluation of the false-negative rate of standardized and quantitative measurement of estrogen receptor (ER) in tissue using AQUA technology
J Clin Oncol (Meeting Abstracts) 2009 27: 567. [Abstract]  

V. Möbus, B. Conrad, A. Schneeweis, R. Kreienberg, E. F. Solomayer, M. R. Clemens, H. Tesch, S. Loibl, V. Nekljudova, and G. von Minckwitz

Gain study: A phase III trial to compare ETC versus EC-TX and ibandronate versus observation in patients with node-positive primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 568. [Abstract]  

F. Andre, P. Dessen, B. Job, S. Delaloge, L. Pusztai, and V. Lazar

Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 569. [Abstract]  

A. Frassoldati, V. Guarneri, A. Bottini, K. Cagossi, L. Cavanna, G. Bisagni, R. D'Amico, F. Piacentini, C. Oliva, and P. Conte

Preplanned first-step analysis of LET-LOB neoadjuvant study: A double-blind randomized phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HR+ve operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 570. [Abstract]  

K. D. Crew, J. Capodice, H. Greenlee, L. Brafman, D. Fuentes, D. Awad, and D. L. Hershman

Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 571. [Abstract]  

J. M. Gold, J. S. Najita, S. Lester, A. L. Richardson, D. E. Morganstern, W. Y. Chen, A. H. Partridge, I. E. Krop, E. P. Winer, and H. J. Burstein

Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making
J Clin Oncol (Meeting Abstracts) 2009 27: 572. [Abstract]  

V. Guarneri, A. Frassoldati, A. Bottini, K. Cagossi, L. Cavanna, A. Ravaioli, D. Amadori, G. Giardina, C. Oliva, and P. Conte

Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial
J Clin Oncol (Meeting Abstracts) 2009 27: 573. [Abstract]  

M. Y. Iddawela, Y. Wang, R. Russell, G. Cowley, M. El-Sheemy, J. Eremin, O. Eremin, M. Faham, H. M. Earl, and C. Caldas

Gene expression profiling and copy number analysis to identify predictive molecular markers in breast cancer: Successful use of formalin fixed paraffin embedded tissue (FFPE)
J Clin Oncol (Meeting Abstracts) 2009 27: 574. [Abstract]  

H. C. Moore, J. Kim, C. Rodriguez, G. T. Budd, and L. Rybicki

Predictors of permanent menopause after chemotherapy for early-stage breast cancer in premenopausal women
J Clin Oncol (Meeting Abstracts) 2009 27: 575. [Abstract]  

E. O. Jenkins, A. M. Deal, E. Burrows, A. Drobish, and L. A. Carey

Improved clinical response from neoadjuvant taxane chemotherapy across breast cancer subtypes
J Clin Oncol (Meeting Abstracts) 2009 27: 576. [Abstract]  

G. Papaxoinis, D. Pectasides, R. M. Wirtz, V. Kotoula, C. Papadimitriou, H. Gogas, G. Aravantinos, D. Skarlos, K. T. Kalogeras, and G. Fountzilas

Prognostic significance of PI3K mRNA expression in patients with operable high-risk breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 577. [Abstract]  

Y. Ohashi, T. Watanabe, M. Sano, H. Koyama, H. Inaji, and T. Suzuki

Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial)
J Clin Oncol (Meeting Abstracts) 2009 27: 578. [Abstract]  

C. J. Christy, M. Rishi, J. Schwartz, B. J. Grube, V. Bossuyt, L. Philpotts, M. P. DiGiovanna, F. Tavassoli, and D. R. Lannin

Association between HER2/neu overexpression and calcifications in breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 579. [Abstract]  

J. W. Smith, M. Buyse, P. Rastogi, C. Geyer, Jr., S. Jacobs, E. Patocskai, and N. Wolmark

Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group
J Clin Oncol (Meeting Abstracts) 2009 27: 580. [Abstract]  

N. Dhillon, S. Kaura, G. Dranitsaris, and H. Rugo

Number needed to treat (NNT) to compare benefits of letrozole (LET) with adjuvant chemotherapy (CT) in patients (pts) with node-positive (N+) breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2009 27: 581. [Abstract]  

P. Canney, C. Linsday, A. Wardley, A. Jones, M. Verril, R. Todd, P. Barrett-Lee, M. Keni, S. Robb, and C. Plummer

Cardiac effects when using trial-derived monitoring protocols for adjuvant trastuzumab: Results from a retrospective multicenter UK audit
J Clin Oncol (Meeting Abstracts) 2009 27: 582. [Abstract]  

M. Ionta, F. Atzori, M. Murgia, B. Frau, M. Barca, A. Coinu, A. Trogu, F. Eltrudis, L. Minerba, and B. Massidda

Adding cisplatin to an anthracycline-based primary chemotherapy in triple-negative (TN) and non-triple negative (non-TN) T4 breast cancer patients (pts): Long-term outcomes
J Clin Oncol (Meeting Abstracts) 2009 27: 583. [Abstract]  

P. Rastogi, M. Buyse, S. Swain, S. Jacobs, A. Robidoux, M. Liepman, P. Dy, C. Geyer, Jr., and N. Wolmark

Bevacizumab beginning concurrently with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy followed by postoperative bevacizumab alone for women with HER2-negative locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group
J Clin Oncol (Meeting Abstracts) 2009 27: 584. [Abstract]  

R. J. Paridaens, S. Gelber, B. F. Cole, R. D. Gelber, B. Thürlimann, K. Price, S. Holmberg, D. Crivellari, A. S. Coates, and A. Goldhirsch

Evaluation of Adjuvant! Online to predict the effect of optimal endocrine therapy (ovarian function suppression plus tamoxifen) for premenopausal breast cancer patients with estrogen-receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 585. [Abstract]  

S. C. Linn, M. A. Vollebergh, M. Hauptmann, L. F. Wessels, P. M. Nederlof, E. G. de Vries, S. Rodenhuis, and J. Wesseling

Selective benefit of high-dose, platinum-containing, alkylating chemotherapy with stem cell rescue for patients with breast cancers with an expansive growth pattern on histology
J Clin Oncol (Meeting Abstracts) 2009 27: 587. [Abstract]  

C. M. Walko, Y. A. Yu, S. Bhushan, I. Spasojevic, L. Carey, F. Collichio, D. Armstrong, and E. C. Dees

Effect of aprepitant (AP) on cyclophosphamide (CPA) pharmacokinetics (PK) in early breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 588. [Abstract]  

J. Lemieux, M. Côté, L. Provencher, I. Simard, C. St-Pierre, and E. Demers

Evaluation of the incidence and of risk factors associated with trastuzumab-associated cardiac toxicity in routine clinical practice
J Clin Oncol (Meeting Abstracts) 2009 27: 589. [Abstract]  

P. Drullinsky, M. N. Fornier, S. Sugarman, G. D'Andrea, T. Troso-Sandoval, A. D. Seidman, J. Yuan, S. Patil, L. Norton, and C. Hudis

Dose-dense (DD) cyclophosphamide, methotrexate, and fluorouracil (CMF) at 14-day intervals: A pilot study of every 14- and 10–11-day dosing intervals for women with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 590. [Abstract]  

N. Sato, N. Masuda, S. Saji, H. Takei, Y. Yamamoto, H. Sasano, and M. Toi

Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IIIA breast cancer (JFMC34–0601)
J Clin Oncol (Meeting Abstracts) 2009 27: 591. [Abstract]  

C. H. Arce-Salinas, F. U. Lara, E. Leon Mexican Breast Cancer Collaborative Group

Phase II open clinical trial to evaluate efficacy and safety of neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2009 27: 592. [Abstract]  

R. Kronenwett, U. Stropp, E. Briasoulis, M. Gehrmann, E. Razis, G. Hennig, D. Bafaloukos, R. M. Wirtz, T. Economopoulos, and G. Fountzilas

Utility of a multigene prognostic algorithm in combination with TP53 expression for prediction of benefit from adjuvant taxane-containing chemotherapy in node-positive breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 593. [Abstract]  

S. M. Ali, J. W. Chapman, L. Demers, L. Shepherd, L. Han, C. Wilson, K. Pritchard, K. Leitzel, M. Pollak, and A. Lipton

Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women
J Clin Oncol (Meeting Abstracts) 2009 27: 594. [Abstract]  

L. Blakely, B. Somer, M. Keaton, R. Hermann, F. Schnell, P. Cobb, A. Johns, M. Walker, and L. Schwartzberg

Neoadjuvant dose-dense sequential biweekly epirubicin and cyclophosphamide followed by docetaxel and trastuzumab for HER2+ operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 595. [Abstract]  

D. Rodriguez-Abreu, A. Murias, M. García, V. Vega, C. Garcia, M. Mori, B. Báez-Acosta, A. Diez, and J. Almenarez

Neoadjuvant biweekly dose-dense chemotherapy with fluouracil, epirubicin, and cyclophosphamide (FEC 90), followed by docetaxel in patients with HER2-neu negative primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 596. [Abstract]  

N. Brünner, B. Ejlertsen, M. Jensen, K. V. Nielsen, E. Balslev, B. B. Rasmussen, G. L. Willemoe, P. B. Hertel, A. Knoop, and H. Mouridsen

Prediction of responsiveness to adjuvant anthracyclines in high-risk breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 597. [Abstract]  

S. K. Chia, C. Lohrisch, K. Gelmon, H. Kennecke, G. Pansegrau, M. Taylor, A. Attwell, D. Jepson, M. Hayes, and T. Shenkier

Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel and capecitabine for HER2-negative locally advanced breast cancer (LABC): A multicenter study from British Columbia
J Clin Oncol (Meeting Abstracts) 2009 27: 598. [Abstract]  

T. Safra, R. Bernstein Molho, I. Stephansky, N. Yaal-Hahoshen, M. Inbar, A. Ackerstein, and D. Geffen

Effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole
J Clin Oncol (Meeting Abstracts) 2009 27: 599. [Abstract]  

M. Riggi, E. M. Moreno-Lopez, J. Rolski, P. Petruzelka, J. M. Ferrero, E. Tellez-Bernal, N. Vaissiere, and C. Lucas

Oral vinorelbine (NVBo) and anastrozole (A) as neoadjuvant treatment of locally advanced (LA) breast cancer (BC) in hormone receptor positive (HR+) postmenopausal patients: Results of an international phase II trial
J Clin Oncol (Meeting Abstracts) 2009 27: 600. [Abstract]  

P. Khosravi-Shahi, Y. Izarzugaza Peron, and G. Perez-Manga

Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials
J Clin Oncol (Meeting Abstracts) 2009 27: 601. [Abstract]  

M. N. Dickler, H. L. McArthur, B. Nulsen, S. Patil, J. Sealey, J. Laragh, C. Merali, R. Steingart, C. Hudis, and H. Rugo

Evaluation of the correlation of baseline blood pressure (BP) and plasma renin activity (PRA) with bevacizumab (B)-mediated hypertension in patients with early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 602. [Abstract]  

A. S. Caudle, A. M. Gonzalez-Angulo, H. K. Kelly, P. Liu, L. Pusztai, W. F. Symmans, H. M. Kuerer, E. A. Mittendorf, G. N. Hortobagyi, and F. Meric-Bernstam

Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 603. [Abstract]  

H. Abe, T. Umeda, Y. Kawai, M. Tanaka, T. Shimizu, H. Chou, Y. Kubota, E. Mekata, Y. Kurumi, and T. Tani

Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin, and cyclophosphamide as adjuvant chemotherapy for early-stage breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 604. [Abstract]  

C. Delbaldo, D. Serin, F. Priou, P. Laplaige, S. Greget, E. Angellier, E. Teissier, J. Berdah, M. Fabbro, E. Quinaux Association Européenne de Recherche en Oncologie (AERO)

Analysis of the impact of growth factor on the haematological safety of dose-dense regimen in the randomized phase II adjuvant trial BO3
J Clin Oncol (Meeting Abstracts) 2009 27: 605. [Abstract]  

R. C. Chen, S. E. Hankinson, J. R. Harris, and W. Y. Chen

Coronary heart disease (CHD) and stroke risk associated with breast cancer (CA) irradiation (RT) based on patient baseline cardiac risk profile
J Clin Oncol (Meeting Abstracts) 2009 27: 606. [Abstract]  

E. B. Elkin, A. R. Gonzales, N. M. Ishill, M. L. Klem, D. Hodgson, A. K. Ng, L. B. Marks, J. Weidhaas, G. M. Freedman, R. C. Miller, and J. Yahalom

Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma?
J Clin Oncol (Meeting Abstracts) 2009 27: 607. [Abstract]  

D. Sinha, A. K. Bahadur, K. Singh, and A. K. Rathi

Comparison of neoadjuvant paclitaxel and carboplatin with neoadjuvant letrozole in postmenopausal patients with receptor-positive locally advanced breast cancer (LABC)
J Clin Oncol (Meeting Abstracts) 2009 27: 608. [Abstract]  

F. Di Filippo, M. Mottolese, C. Botti, F. Marandino, A. Psaila, P. Perri, S. Di Filippo, R. Pasqualoni, F. Ferranti, and S. Buglioni

A prospective clinical study for molecular intra-operative detection of lymph node metastasis in breast cancer patients by one step nucleic acid amplification (OSNA) in comparison to intensive histological investigation
J Clin Oncol (Meeting Abstracts) 2009 27: 609. [Abstract]  

A. C. Schmitz, M. A. van den Bosch, C. Loo, J. L. Peterse, M. Gertenbach, W. P. Mali, E. J. Rutgers, and K. G. Gilhuijs

Visualization of invasive breast cancer and its subclinical disease spread within the breast: Precise correlation between MR imaging findings and histopathologic findings
J Clin Oncol (Meeting Abstracts) 2009 27: 610. [Abstract]  

N. P. Reuter, M. R. Bower, C. R. Scoggins, R. C. Martin, K. M. McMasters, and A. B. Chagpar

Optimal timing of radioactive tracer for sentinel node biopsy in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 611. [Abstract]  

B. M. Syed, Jr., S. J. Johnston, D. W. M. Wong, D. A. L. Morgan, I. O. Ellis, and K. L. Cheung

Surgery versus primary endocrine therapy for elderly women with estrogen receptor-positive early operable primary breast cancer: Survival analysis and correlation with oestrogen receptor positivity
J Clin Oncol (Meeting Abstracts) 2009 27: 612. [Abstract]  

M. S. Pugliese, M. M. Stempel, S. M. Patil, M. Hsu, H. S. Cody, III, M. Morrow, and M. L. Gemignani

The clinical impact and outcomes of immunohistochemistry-only metastases in breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 613. [Abstract]  

M. Gemignani, A. Karam, M. Hsu, S. Patil, M. Stempel, T. Traina, A. Ho, H. Cody, III, and M. Morrow

Determinants of outcome in elderly patients with positive sentinel lymph nodes
J Clin Oncol (Meeting Abstracts) 2009 27: 614. [Abstract]  

D. Dionysopoulos, N. Berrada, J. Chevalier, F. Rimareix, M. Mathieu, C. Balleyguier, S. Gouy, F. André, P. Vielh, S. Delaloge, and S. Delaloge

Determinants of therapeutic delays and their impact on axillary node involvement in operable invasive breast cancer (BC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2009 27: 615. [Abstract]  

K. Yamashita, S. Haga, and K. Shimizu

Sentinel and axillary nodes of the breast distinguished from those of the arm by 3D-CT lymphography and selectively dissected by endoscopic surgery
J Clin Oncol (Meeting Abstracts) 2009 27: 616. [Abstract]  

R. Jagsi, P. Abrahamse, J. J. Griggs, and S. J. Katz

Adjuvant radiotherapy use in a population-based sample of breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 617. [Abstract]  

R. C. Inhorn, B. Daniel, D. Daniel, Y. Naot, J. Zubkus, C. Lane, V. Trieu, D. Knauer, N. Desai, and D. A. Yardley

Correlation of SPARC, ER, PR, and HER2 tumor with progression-free survival from a phase II neoadjuvant trial of gemcitabine, epirubicin, and nab-paclitaxel
J Clin Oncol (Meeting Abstracts) 2009 27: 618. [Abstract]  

S. Seitz, A. V. Schally, S. Gluck, F. Rick, L. Szalontay, F. Hohla, A. Papadia, F. Köster, O. Ortmann, and S. Buchholz

Effective treatment of triple-negative breast cancer with targeted cytotoxic somatostatin analogue AN-162 (AEZS-124)
J Clin Oncol (Meeting Abstracts) 2009 27: 619. [Abstract]  

K. Hisamatsu, W. Takiyama, R. Sakabe, Y. Satou, S. Saeki, H. Mukaida, Y. Yamashita, N. Hirabayashi, M. Kaneko, and T. Ono

Factors influencing 3D-MRI diagnosis in preoperative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 620. [Abstract]  

V. Durbecq, S. Majjaj, J. Nogaret, N. Sirtaine, J. Schobbens, D. Noterman, D. Hertens, V. Filipov, D. Larsimont, and I. Veys

Use of quantitative RT-PCR assay to predict metastases size of sentinel node from breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 621. [Abstract]  

J. L. Wagner, C. Warneke, I. Bedrosian, E. Mittendorf, G. Babiera, H. Kuerer, K. Hunt, W. Yang, A. Sahin, and F. Meric-Bernstam

Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: 622. [Abstract]  

H. Apsey, V. Roy, B. Pockaj, D. Northfelt, R. Sticca, D. A. Nikcevich, B. Mattar, T. Fitch, and E. A. Perez

Surgical practice patterns following NCCTG N0338 "Phase II trial of docetaxel and darboplatin administered every two weeks as induction therapy for stage II and stage III breast cancer."
J Clin Oncol (Meeting Abstracts) 2009 27: 623. [Abstract]  

N. Tagaya, A. Abe, M. Tachibana, and K. Kubota

A novel approach for sentinel lymph node identification using fluorescence imaging and image overlay navigation surgery in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 624. [Abstract]  

J. P. Leone, V. Guardiola, A. Venkatraman, M. D. Pegram, C. Welsh, O. Silva, R. Larrieux, D. Franchesci, C. Gomez, and J. Hurley

Neoadjuvant platinum-based chemotherapy (CT) for triple-negative locally advanced breast cancer (LABC): Retrospective analysis of 125 patients
J Clin Oncol (Meeting Abstracts) 2009 27: 625. [Abstract]  

F. K. Wenz, G. Welzel, E. Blank, B. Hermann, V. Steil, M. Suetterlin, and U. Kraus-Tiefenbacher

Intraoperative radiotherapy (IORT) as a boost during breast conserving surgery (BCS) using low kV X-rays: The first 5 years of experience with a novel approach
J Clin Oncol (Meeting Abstracts) 2009 27: 626. [Abstract]  

J. R. Bernard, Jr., L. A. Vallow, R. B. McNeil, S. A. McLaughlin, X. J. Geiger, and E. A. Perez

In newly diagnosed breast cancer, is a contralateral prophylactic mastectomy necessary following a negative MRI?
J Clin Oncol (Meeting Abstracts) 2009 27: 627. [Abstract]  

M. Kurosumi, Y. Kobayashi, and H. Takei

The utility of a real-time RT-PCR assay for the detection of metastases greater than 0.2 mm in sentinel lymph nodes of breast cancer patients confirmed by detailed histological analysis
J Clin Oncol (Meeting Abstracts) 2009 27: 628. [Abstract]  

R. E. Mansel, F. McNeill The NEW START Steering Committee

The final results of the United Kingdom sentinel node training program: New Start
J Clin Oncol (Meeting Abstracts) 2009 27: 629. [Abstract]  

W. Al-Khyatt, B. M. Syed, D. A. Morgan, and K. L. Cheung

Primary endocrine therapy for early operable primary breast cancer in elderly women: A large series from a single institution
J Clin Oncol (Meeting Abstracts) 2009 27: 630. [Abstract]  

K. D. Kiel, T. Refaat, N. Navanandan, and V. Sathiaseelan

Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 631. [Abstract]  

H. Kim, E. Park, W. Lim, J. Sei, B. Koh, B. Son, and S. Ahn

Nipple areola skin-sparing mastectomy with TRAM flap reconstruction: Single-center study
J Clin Oncol (Meeting Abstracts) 2009 27: 632. [Abstract]  

J. D. Schwartz, C. Christy, B. Grube, M. Rishi, F. Tavassoli, V. Bossuyt, L. Harris, M. P. DiGiovanna, and D. R. Lannin

Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology
J Clin Oncol (Meeting Abstracts) 2009 27: 633. [Abstract]  

I. Borget, C. Caramella, C. Balleyguier, V. Suciu, C. Uzan, J. Domont, M. Mathieu, C. Dromain, S. Delaloge, and P. Vielh

Comparison of cytopathological and histological results in 1,053 fine-needle aspiration cytology of breast lesions performed in a one-stop clinic
J Clin Oncol (Meeting Abstracts) 2009 27: 635. [Abstract]  

N. Nabavizadeh, C. Klifa, D. Newitt, Y. Lu, J. Hattangadi, C. Fisher, N. Hylton, and C. Park

MR quantification of abnormal stromal enhancement in the periphery of invasive breast tumors
J Clin Oncol (Meeting Abstracts) 2009 27: 636. [Abstract]  

J. M. Perez Garcia, Sr., C. Saura, E. Muñoz, G. Sanchez-Olle, P. Gomez, V. Peg, D. Sabadell, J. Cortes, J. Baselga, and M. Bellet

Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts)
J Clin Oncol (Meeting Abstracts) 2009 27: 637. [Abstract]  

S. L. Roth

Survival advantage by neoadjuvant radiochemotherapy in locally advanced noninflammatory breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: 638. [Abstract]  

M. Dresse, D. Mayr, V. Heinemann, S. Kahlert, I. Bauerfeind, D. Nagel, D. Seidel, and P. Stieber

HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11500. [Abstract]  

O. Pribylova, L. B. Petruzelka, S. Argalaczova, B. Konopasek, J. Drazdakova, O. Slanar, O. Slanar, and T. Zima

Pharmacogenomic prediction of breast cancer treatment outcome with adjuvant tamoxifen in postmenopausal women with estrogen receptor-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11501. [Abstract]  

P. Dubray, X. Durando, C. Abrial, M. Mouret-Reynier, B. Nayl, E. Thivat, P. Gimbergues, J. Achard, P. Chollet, and F. Penault-Llorca

Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100- docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11502. [Abstract]  

M. J. Piccart-Gebhart and P. L. Bedard

Who benefits from taxanes?
J Clin Oncol (Meeting Abstracts) 2009 27: e11503. [Abstract]  

H. Jinno, T. Onishi, M. Takahashi, M. Sakata, Y. Kitagawa, N. Kitamura, T. Nakahara, and M. Mukai

Non-sentinel lymph node status and prognosis of the breast cancer patients with micrometastatic sentinel lymph nodes
J Clin Oncol (Meeting Abstracts) 2009 27: e11504. [Abstract]  

A. Del Giglio, J. F. Pinto, F. A. Fonseca, S. R. Marsicano, P. O. Delgado, P. G. Coelho, A. L. Sant’Anna, and P. Maeda

Chemotherapy induces microssatelite instability (MIS) in plasma free DNA (pfDNA), peripheral blood mononuclear fraction (PBMNF) cells, and urine free DNA (ufDNA) of breast cancer (BC) patients as well as in normal PBMNF cells in vitro in the absence of amifostine (A)
J Clin Oncol (Meeting Abstracts) 2009 27: e11505. [Abstract]  

L. K. Jacobs, N. Khouri, S. Jeter, P. Powers, M. Rudek, E. Gabrielson, Z. Zhang, S. Sukumar, T. Tsangaris, and V. Stearns

A phase I study assessing the feasibility and safety of intraductal pegylated liposomal doxorubicin (PLD) in women with breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11506. [Abstract]  

L. Favier, M. Liegard, S. Guiu, I. van Praagh, R. Largillier, B. Weber, D. Coeffic, B. Vasseur, B. Coudert TAXHER- S01 & GETN(A) Groups

Long-term follow-up and factors of survival of HER-2 positive breast cancer patients treated either by neoadjuvant trastuzumab docetaxel (TAXHER-S01 study) or by neoadjuvant trastuzumab docetaxel carboplatin (GETN[A]1 study)
J Clin Oncol (Meeting Abstracts) 2009 27: e11507. [Abstract]  

S. Thureau, F. Clatot, J. Pillé, S. Laberge-Le-Couteulx, O. Rigal, C. Veyret, J. Basuyau, and E. Blot

Prognostic value of serum level of HER-2 extracellular domain (ECD) at diagnosis of HER-2 overexpressed primary breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2009 27: e11508. [Abstract]  

E. Raefsky, R. Inhorn, M. Lange, N. Peacock, M. Shastry, E. Vazquez, V. Priego, L. Franco, J. D. Hainsworth, and D. A. Yardley

Preliminary safety results from a multicenter phase II trial of nanoparticle albumin-bound paclitaxel/cyclophosphamide in early stage breast cancer plus trastuzumab in HER-2+ patients (pts)
J Clin Oncol (Meeting Abstracts) 2009 27: e11509. [Abstract]  

T. N. Shenkier, M. Hayes, K. A. Gelmon, S. Chia, C. Bajdik, B. Norris, S. Caroline, P. Hassell, S. E. O’Reilly, S. Allan, and R. Yerushalmi

A phase II trial of a neoadjuvant platinum-containing regimen for locally advanced breast cancer: Pathologic response, long-term follow-up, and correlation with biomarkers
J Clin Oncol (Meeting Abstracts) 2009 27: e11510. [Abstract]  

M. Kusama and Y. Imamura

Impact of radiofrequency ablation therapy for breast cancer in nipple-areolar complex
J Clin Oncol (Meeting Abstracts) 2009 27: e11511. [Abstract]  

S. Paepke, M. Kiechle, D. Paepke, E. Klein, M. Warm, D. Augustin, O. Camara, J. Nährig, R. Kates, and N. Harbeck

Interim analysis of the multicenter phase II HEDON trial evaluating pathological response to pre-operative docetaxel and docetaxel+trastuzumab (T) in locally advanced breast cancer (BR) stratified by HER2-status
J Clin Oncol (Meeting Abstracts) 2009 27: e11512. [Abstract]  

J. B. Choudhury, G. Beadle, and K. Mengersen

Measurement of quality of life in women with breast cancer before and after adjuvant chemotherapy: A structural equation modelling
J Clin Oncol (Meeting Abstracts) 2009 27: e11513. [Abstract]  

H. S. Han, I. Reis, K. Kuroi, M. Toi, E. Suzuki, R. Syme, L. Chow, A. Yip, W. Zhao, R. Nimmagadda, and S. Gluck

Racial differences in acute toxicities of FEC 100 chemotherapy in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11515. [Abstract]  

A. Guerrero-Zotano, Sr., J. Gavila, M. A. Climent, M. J. Juan, V. Guillem, and A. Ruiz

Response to neoadjuvant chemotherapy and outcome based on breast cancer subtype
J Clin Oncol (Meeting Abstracts) 2009 27: e11516. [Abstract]  

P. S. Craft, J. Buckingham, J. E. Dahlstrom, K. Beckmann, Y. Zhang, R. Stuart-Harris, G. Jacob, D. Roder, and N. Tait

Variations in care for operable breast cancer and outcomes between rural and metropolitan centers in Australia
J Clin Oncol (Meeting Abstracts) 2009 27: e11517. [Abstract]  

F. E. Prisco, E. D. Saad, F. M. Carvalho, E. B. Ojopi, and C. E. Bacchi

Potential economic impact of the 21-gene expression panel according to tumor (T) size in lymph-node-negative (LNN), estrogen-receptor (ER)-positive early breast cancer (BC)
J Clin Oncol (Meeting Abstracts) 2009 27: e11518. [Abstract]  

G. Von Minckwitz, I. Bauerfeind, B. Gerber, H. Eidtmann, M. Kaufmann, S. D. Costa, S. Loibl, V. Nekljudova, and M. Untch

Geparquinto: An interim safety analysis of epirubicin/cyclophosphamide followed by docetaxel with or without bevacizumab as neoadjuvant chemotherapy for primary breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e11519. [Abstract]  

K. Fedenko, P. Cortazar, P. Keegan, and R. Pazdur

Trastuzumab cardiotoxicity: FDA review of four adjuvant breast cancer clinical trials leading to trastuzumab marketing approvals
J Clin Oncol (Meeting Abstracts) 2009 27: e11520. [Abstract]  

F. Boccardo, A. Rubagotti, P. Guglielmini, P. Sismondi, A. Farris, D. Amadori, B. Agostara, A. Gambi, G. Catalano, and M. Faedi

Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11521. [Abstract]  

G. G. Kimmick, F. Camacho, W. Hwang, and R. T. Anderson

The relationship between adherence to adjuvant hormonal therapy and survival among low-income, insured women with primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11522. [Abstract]  

J. Picarsic, A. Brufsky, A. Onisko, and M. Chivukula

Predictors of invasive breast cancer or DCIS recurrence in estrogen receptor positive (ER+) and estrogen receptor negative (ER-) ductal carcinoma in situ (DCIS) patients with and without associated invasive carcinoma (IC)
J Clin Oncol (Meeting Abstracts) 2009 27: e11523. [Abstract]  

S. E. Waintraub and V. Tuchman

The role of preoperative neoadjuvant cytoreductive dose-dense bevacizumab plus docetaxel followed by bevacizumab-doxorubicin-cyclophosphamide regimen in locally advanced operable breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11524. [Abstract]  

S. Takao, M. Miyashita, N. Kohno, K. Wakita, M. Konishi, I. Kokufu, H. Yoshimura, Y. Kasahara, S. Kohno, and T. Ienaga

Induction of primary systemic therapy by weekly paclitaxel: Predictive value of hormone receptors, HER-2, topoisomerase II- alpha, and other biological markers in relation to pathological complete response
J Clin Oncol (Meeting Abstracts) 2009 27: e11525. [Abstract]  

H. Jouhadi, Sr. and A. Benider

Adjuvant paclitaxel, capecitabine, and trastuzumab for HER-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11526. [Abstract]  

A. McCullough, A. Dueck, B. Chen, M. Reinholz, A. Wiktor, W. Lingle, R. Jenkins, and E. Perez

HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639
J Clin Oncol (Meeting Abstracts) 2009 27: e11527. [Abstract]  

E. J. Silberfein, K. K. Hunt, K. Broglio, J. Shen, A. Sahin, H. Le-Petross, J. Oh, J. Litton, R. F. Hwang, and E. A. Mittendorf

Clinicopathologic factors associated with involved margins following breast conserving surgery for invasive lobular carcinoma (ILC)
J Clin Oncol (Meeting Abstracts) 2009 27: e11528. [Abstract]  

P. Cortazar, J. Johnson, R. Justice, and R. Pazdur

Adjuvant breast cancer: FDA approval overview
J Clin Oncol (Meeting Abstracts) 2009 27: e11529. [Abstract]  

S. Imoto, S. Morita, M. Kitajima, T. Aikou, Y. Kitagawa Japanese Society Investigators for Sentinel Node Navigation Surgery

Early recurrence of breast cancer after sentinel node navigation surgery: A multicenter prospective study in Japan
J Clin Oncol (Meeting Abstracts) 2009 27: e11530. [Abstract]  

P. Ermacora, P. Driol, S. Russo, C. Andreetta, F. E. Pisa, B. Alessi, A. M. Minisini, M. Mansutti, G. Fasola, and F. Puglisi

Predictors of tumor shrinkage after anthracycline-based preoperative chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11531. [Abstract]  

M. Ravnik, A. Sadikov, N. Snoj, P. Nussdorfer, and T. Cufer

Validation of Adjuvant!Online on Slovenian collective of early breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e11532. [Abstract]  

N. B. Kouzminova, A. Aggarwal, S. Aggarwal, and A. Y. Lin

The impact of residual cancer removed during subsequent surgeries on the outcome of patients with localized breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11533. [Abstract]  

J. Stebbing, H. C. Keun, J. Sidhu, M. Patterson, S. R. Bloom, V. Amber, C. Coombes, H. Marconell, and D. Pshezhetskiy

Serum molecular signatures of weight change during early breast cancer chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11534. [Abstract]  

T. Kinoshita, N. Yamamoto, T. Fujisawa, N. Masuda, T. Hojo, K. Aogi, K. Seki, and H. Tsuda

A phase II trial of image-guided radiofrequency ablation of small breast carcinomas: Results of a multicenter study in Japan
J Clin Oncol (Meeting Abstracts) 2009 27: e11535. [Abstract]  

D. T. Tsoi, M. Inoue, C. M. Kelly, S. Verma, and K. Pritchard

Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11536. [Abstract]  

A. Vicente, E. García-Martínez, E. Gonzalez-Billalabeitia, M. Zafra, C. Castilla-Llorente, T. García-García, J. Macías, E. García-Garre, V. Vicente, and F. Ayala de la Peña

Prognostic value of decrease on blood lymphocytes in breast cancer patients undergoing primary chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11537. [Abstract]  

V. Ozmen, S. Ozkan Gurdal, M. Muslumanoglu, A. Igci, S. S. Tuzlali, B. Ozcinar, E. Canbay, M. Kecer, and T. Dagoglu

Predictive factor for residual tumor after lumpectomy for close margins
J Clin Oncol (Meeting Abstracts) 2009 27: e11538. [Abstract]  

C. Daveau, D. Stevens, O. Berges, S. Zilberman, M. Gardner, S. Villette, E. Brain, S. Lasry, A. Labib, and R. Le Scodan

Locally advanced breast cancer patients with negative pathological lymph node status after neoadjuvant chemotherapy and conservative surgery: Is lymph node irradiation necessary?
J Clin Oncol (Meeting Abstracts) 2009 27: e11539. [Abstract]  

R. A. Macrorie-Fairweather, K. Albuquerque, K. Yao, and J. Sinacore

A decision tree to predict four or more positive axillary lymph nodes in breast cancer patients with positive sentinel node biopsy: Determining necessity for regional nodal irradiation in the absence of axillary dissection
J Clin Oncol (Meeting Abstracts) 2009 27: e11540. [Abstract]  

D. Katz, H. Mazeh, L. Divinsky, M. Temper, I. Ospovat, A. Salah, T. Hamburger, D. Galinsky, B. Uziely, and T. Peretz

Fertility and pregnancy in patients under age 38 following chemotherapy for breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11541. [Abstract]  

A. C. Youssef

A phase II study of docetaxel followed by vinorelbine and doxorubicin in the neoadjuvant treatment of locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11542. [Abstract]  

A. Sever, S. Jones, K. Cox, J. Weeks, P. Mills, D. Fish, and P. Jones

A novel approach to identify sentinel lymph nodes using microbubbles and contrast enhanced ultrasound in preoperative breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e11543. [Abstract]  

S. Giraudi, P. Marroni, L. Boni, C. Bighin, A. Levaggi, G. Bini, P. Taveggia, M. Venturini, P. Pronzato, and L. Del Mastro

Anti-Mullerian hormone (AMH) and ovarian function in young breast cancer (BC) women receiving adjuvant chemoterapy (CT)
J Clin Oncol (Meeting Abstracts) 2009 27: e11544. [Abstract]  

R. Venkitaraman, S. G. Ramanan, K. R. Rajalekshmy, T. G. Sagar, and V. Shanta

Predictors of pathologic response to preoperative chemotherapy and concurrent radiotherapy for locally advanced breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11545. [Abstract]  

S. Lee, S. Kim, H. Kang, E. Lee, E. Kim, K. Ko, and Y. Kwon

Correlation of tumor size on preoperative breast MRI and pathologic tumor size in Asian patients
J Clin Oncol (Meeting Abstracts) 2009 27: e11546. [Abstract]  

T. H. Luu, S. Lau, R. Nelson, M. Ottochian, A. Garcia, and G. Somlo

Is there a survival benefit with adjuvant chemotherapy for patients with stage I (T1N0) triple negative breast cancer?
J Clin Oncol (Meeting Abstracts) 2009 27: e11547. [Abstract]  

T. Osako, R. Nishimura, Y. Okumura, and M. Hayashi

Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population
J Clin Oncol (Meeting Abstracts) 2009 27: e11548. [Abstract]  

J. Silva and A. Martinez-Velasco

Correlating MRI, mammogram, and ultrasonography( USG): Which study most accurately predicts breast cancer size?
J Clin Oncol (Meeting Abstracts) 2009 27: e11549. [Abstract]  

D. Withrow, S. Verma, R. Dent, S. Ahmed, J. Fralick, G. Dranitsaris, and T. Petrella

Trastuzumab-mediated cardiotoxicity in the nontrial setting: Evaluation of patients receiving adjuvant trastuzumab at an academic centre
J Clin Oncol (Meeting Abstracts) 2009 27: e11550. [Abstract]  

P. Li and S. X. Liu

Effects of Shugan-Liangxue prescription combined with anastrozole (ANA) on bone metabolism of ovariectomy (OVX) rats
J Clin Oncol (Meeting Abstracts) 2009 27: e11551. [Abstract]  

Y. Suh, S. Oh, B. Song, and S. Jung

Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemotherapy for node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11552. [Abstract]  

F. N. Rana

A retrospective review of demographics and stage of triple-negative breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11553. [Abstract]  

C. K. Lee, E. Choo, and C. R. Lewis

Pathological characteristics, distant recurrence rates, and survival outcomes of breast cancer with triple-negative phenotype
J Clin Oncol (Meeting Abstracts) 2009 27: e11554. [Abstract]  

S. Graziani, S. Mendes, T. S. Vitório, A. F. Padoveze, R. Hegg, S. P. Bydlowski, and R. C. Maranhão

Uptake by breast carcinoma of a lipidic nanoemulsion after intralesional injection into the patients: A new strategy for neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11555. [Abstract]  

C. Ferrario, A. Wong, N. Bouganim, T. Gao, R. Aloyz, and L. C. Panasci

Trastuzumab and vinorelbine (TV) in early stages of breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11556. [Abstract]  

S. Bayraktar, U. D. Bayraktar, I. M. Reis, M. Pegram, C. Welsh, O. Silva, D. Franchesci, C. R. Gomez, and J. Hurley

Neoadjuvant dose-dense docetaxel, carboplatinum, and trastuzumab (ddTCH) chemotherapy for HER2 overexpressing breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11557. [Abstract]  

X. Hao, Y. Liu, R. Hui, and J. Zhang

Comparison of the sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+ breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11558. [Abstract]  

G. Carillio, R. Aiello, M. Alì, A. Mazzola, G. Scandurra, E. Taibi, M. Chiarenza, G. Fallica, F. Caruso, and M. Caruso

Neoadjuvant trastuzumab in a sequential nonanthracycline-based regimen for patients with stage II-III breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11559. [Abstract]  

P. J. Chollet, P. Dubray, X. Durando, C. Abrial, B. Nayl, M. Mouret-Reynier, C. Pomel, A. Bellière, S. Lemery, and F. Penault-Llorca

Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT)
J Clin Oncol (Meeting Abstracts) 2009 27: e11560. [Abstract]  

S. Li, B. Goins, W. T. Phillips, M. Saenz, P. Otto, and A. Bao

Postlumpectomy loco-regional breast cancer therapy with liposomal therapeutic agents: Retention and distribution in nude rats
J Clin Oncol (Meeting Abstracts) 2009 27: e11562. [Abstract]  

P. W. Whitworth, C. A. Presant, J. Rutledge, A. Hallquist, M. Perree, and D. Agapitos

Chemosensitivity (CS) of patient (pt) breast cancer (BrCa) cells in vitro: Correlation with prior chemotherapy (CT) and implications for personalized treatment planning
J Clin Oncol (Meeting Abstracts) 2009 27: e11563. [Abstract]  

D. Gupta, V. Raina, N. K. Shukla, G. K. Rath, B. K. Mohanti, and D. N. Sharma

Retrospective comparison of response rates and survival with neoadjuvant docetaxel versus anthracycline-based chemotherapy for locally advanced breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e11564. [Abstract]  

M. Almatari, M. Moe, P. Ali, and P. Willshaw

Bone density changes during adjuvant aromatase inhibitor treatment in breast cancer patients: Single center experience
J Clin Oncol (Meeting Abstracts) 2009 27: e11565. [Abstract]  

S. Koya, Y. Li, S. A. McDaniel, A. F. LoBuglio, H. Krontiras, J. Carpenter, L. Nabell, K. Bland, C. Falkson, and A. Forero

Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/III breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11566. [Abstract]  

A. Lipton, C. Campbell-Baird, Y. Chen, R. Dias, and B. Kelly

Frequency of zoledronic acid (ZOL) administration to prevent aromatase inhibitor-associated bone loss (AIBL)
J Clin Oncol (Meeting Abstracts) 2009 27: e11567. [Abstract]  

S. Goyal, T. Puri, D. N. Sharma, P. K. Julka, and G. K. Rath

Lymphedema following irradiation in breast cancer: A cross-sectional study
J Clin Oncol (Meeting Abstracts) 2009 27: e11569. [Abstract]  

V. R. Jacobs, S. C. Mayer, B. Paessens, G. Anker, U. Schwarz-Boeger, S. Paepke, N. Harbeck, R. Bernard, M. Kiechle, and A. Ihbe-Heffinger

Prospective study comparing hospital costs and DRG reimbursement of inpatient treatment of febrile neutropenia during adjuvant anthracycline-based CTX for primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11570. [Abstract]  

S. Stäcker, M. Thill, K. Röder, K. Diedrich, and D. Fischer

Lymphorrea incidences after modified radical mastectomy with auto cut versus spray mode electro coagulation
J Clin Oncol (Meeting Abstracts) 2009 27: e11571. [Abstract]  

C. Von Briel

Radiotherapy for breast cancer: Can the heart be protected with respiratory gating in patients with left-sided breast cancer?
J Clin Oncol (Meeting Abstracts) 2009 27: e11572. [Abstract]  

H. R. Chang, R. Prati, J. A. Gornbein, D. Chung, and J. A. Glaspy

Survival in patients with locally advanced breast cancer after neoadjuvant docetaxel (T), carboplatin (C), and trastuzumab (H)
J Clin Oncol (Meeting Abstracts) 2009 27: e11573. [Abstract]  

Y. Yamane, G. Ishii, K. Goto, M. Kojima, M. Nakao, Y. Shimada, Y. Nishiwaki, K. Nagai, and A. Ochiai

A novel histopathological evaluation method for predicting the outcome of non-small cell lung cancer treated by neoadjuvant therapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11574. [Abstract]  

M. Jean Pierre, J. Extra, J. Jacquemier, M. Buttarelli, E. Lambaudie, M. Bannier, I. Brenot Rossi, and G. Houvenaeghel

Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11575. [Abstract]  

J. Rom, G. von Minckwitz, F. Marme, M. Sievert, D. Kozian, F. Schuetz, A. Scharf, M. Kaufmann, C. Sohn, and A. Schneeweiss

Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11576. [Abstract]  

A. Mato, M. Cappa, K. Fox, G. Policarpo, J. Cohen, H. Wall, S. Rossi, and D. Mintzer

Cardiac safety of docetaxel/cyclophosphamide/trastuzumab (DCH) as adjuvant therapy for HER-2 (+) early stage breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11577. [Abstract]  

K. Shiraishi, K. Nakagawa, H. Yamashita, A. Terahara, K. Ohtomo, and T. Yamaguchi

Long-term results of breast-conservation therapy for Japanese women classified according to intrinsic subtype
J Clin Oncol (Meeting Abstracts) 2009 27: e11578. [Abstract]  

V. Ghai, H. A. Harvey, K. K. Abbi, A. Barochia, C. Bhardwaj, and L. M. Demers

Significance of CA 27.29 (MUC 1 glycoprotein) levels in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11579. [Abstract]  

I. Fujiwara, H. Nakajima, N. Mizuta, K. Sakaguchi, and Y. Hachimine

Video-assisted skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue: Clinical outcomes
J Clin Oncol (Meeting Abstracts) 2009 27: e11580. [Abstract]  

G. Perez Manga, P. Khosravi-Shahi, Y. Izarzugaza Peron, A. Soria Lovelle, R. Gonzalez del Val, M. Palomero Plaza, M. Riesco Martinez, Y. Jerez Gilarranz, J. Adeva Alfonso, and A. Alonso

Phase II study of neoadjuvant treatment with docetaxel, capecitabine, and trastuzumab in HER-2-positive locally advanced or inflammatory breast cancer: TXH trial
J Clin Oncol (Meeting Abstracts) 2009 27: e11581. [Abstract]  

J. Lee, W. Min, S. Kim, and B. Son

Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11582. [Abstract]  

H. Kawaguchi, H. Shigematsu, C. Koga, E. Mori, S. Nishimura, Y. Nakamura, K. Nishiyama, T. Esaki, and S. Ohno

Sentinel node biopsy in Asian breast cancer patients: An observation study of 1,000 consecutive patients treated at a single institute
J Clin Oncol (Meeting Abstracts) 2009 27: e11584. [Abstract]  

S. Al-Sam, S. Al-Ramadhani, S. Jader, J. Singer, and A. Aylwin

Same-day breast core biopsy result: Effect on ER/PR and HER-2 scores
J Clin Oncol (Meeting Abstracts) 2009 27: e11585. [Abstract]  

M. E. Trinkaus, S. Sayed, S. Gakinya, W. Hanna, Z. Moloo, and Y. Rahim

External quality assurance of breast cancer pathologic reporting in Kenya
J Clin Oncol (Meeting Abstracts) 2009 27: e11586. [Abstract]  

S. Iwase, D. Yamamoto, K. Kitamura, H. Odagiri, S. Teramoto, S. Ohtani, T. Doi, K. Kinebuchi, Y. Kuroda, and Y. Nagumo

Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11587. [Abstract]  

T. Sircar, S. Chaudhri, and A. Francis

Effect of neoadjuvant chemotherapy on oestrogen, progesterone, and HER-2 receptor expression in breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11588. [Abstract]  

U. Bohn, M. Pavcovich, P. Jimenez, M. Hernandez, M. Lloret, M. Cazorla, I. Reyes, T. Baratta, and C. Bustos

Effect of primary polychemotherapy after sentinel lymph node biopsy on the necessity for lymphadenectomy in stage II breast cancer patients
J Clin Oncol (Meeting Abstracts) 2009 27: e11589. [Abstract]  

A. Hirano, T. Shimizu, M. Kamimura, N. Goto, O. Watanabe, J. Kinoshita, K. Domoto, M. Aiba, K. Ogawa, and D. Miura

Epirubicin and cyclophosphamide (EC) followed by weekly paclitaxel with/without trastuzumab as primary systemic therapy in locally advanced breast cancer: Phase II study
J Clin Oncol (Meeting Abstracts) 2009 27: e11590. [Abstract]  

S. Troyan, S. Gibbs-Strauss, S. Gioux, R. Oketokoun, F. Azar, A. Khamene, V. Kianzad, M. Rosenberg, B. L. Clough, and J. V. Frangioni

Image-guided near-infrared fluorescent sentinel lymph node mapping in human breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11591. [Abstract]  

C. Jackisch, N. Harbeck, M. Blettner, P. Hadji, H. Lück, D. C. Schmidt, R. Haidinger, B. Gutendorf, and R. Kreienberg

First data from the the Patient's Anastrozole Compliance to Therapy Programme evaluating the influence of a standardized information service on compliance in postmenopausal women with early breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11592. [Abstract]  

J. P. Guastalla, Y. Belkacemi, B. Cutuli, P. Dalivoust, N. Dohollou, A. Hardy Bessard, R. Salmon, and T. Delozier

Management of side effects of aromatase inhibitors (AIs) during adjuvant therapy for postmenopausal women with HR+ breast cancer: Analysis of French practices
J Clin Oncol (Meeting Abstracts) 2009 27: e11593. [Abstract]  

I. K. Komenaka, M. L. Hibbard, and M. E. Bouton

Benefits of preoperative chemotherapy for operable breast cancer in the community hospital setting
J Clin Oncol (Meeting Abstracts) 2009 27: e11594. [Abstract]  

A. C. Barochia, L. Cream, H. Harvey, and J. Sivik

Incidence of peripheral neuropathy in high-risk early-stage breast cancer patients receiving dose-dense paclitaxel in central Pennsylvania
J Clin Oncol (Meeting Abstracts) 2009 27: e11595. [Abstract]  

F. Giovanardi, L. Scaltriti, F. Gibertoni, K. Cagossi, L. Cavanna, F. Artioli, and G. Giovanardi

One-day surgery in breast cancer: Monoinstitutional results (experience during 2. 5 years)
J Clin Oncol (Meeting Abstracts) 2009 27: e11596. [Abstract]  

B. Ozcinar, V. Ozmen, S. A. Guler, B. M. Gulluoglu, N. Kocaman, M. Ozkan, M. E. Muslumanoglu, A. Igci, M. Kecer, and T. Dagoglu

Complications of local/regional treatment of breast cancer and quality of life
J Clin Oncol (Meeting Abstracts) 2009 27: e11597. [Abstract]  

S. Djahansouzi, V. Rostock, D. Niederacher, D. Rein, W. Rath, and H. Bender

Effect of endocrine therapy with tamoxifen on hormone receptor status in patients with breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11598. [Abstract]  

D. J. Bharali, M. Yalcin, U. Dier, S. Mousa, S. Mousa, C. Hanko, P. Phillips, and S. A. Mousa

Nanoparticle-targeted delivery of nonanticoagulant heparin and doxorubicin in doxorubicin-resistant breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11599. [Abstract]  

D. Miura, Y. Saitoh, T. Iwatani, H. Kawabata, and N. Inoshita

Chromosome enumeration probe 17 (CEP) ratio to predict chemosensitivity in HER-2 overexpressing breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11600. [Abstract]  

P. Hadji

An economic analysis of arthralgia/myalgia (A/M) versus recurrence in women with hormone receptor-positive (HR+) breast cancer (BC) on aromatase inhibitors (AIs)
J Clin Oncol (Meeting Abstracts) 2009 27: e11601. [Abstract]  

I. Kuter, E. Anderson, U. Emeribe, P. Finlay, R. Nicholson, and J. Gee

Comparison of methods for detection of fulvestrant-induced changes in breast tumor estrogen and progesterone receptor expression in a neoadjuvant trial (NEWEST)
J Clin Oncol (Meeting Abstracts) 2009 27: e11602. [Abstract]  

R. Maisano, R. Maisano, D. Azzarello, P. Del Medico, R. Giannicola, C. Giuffrè, V. Panuccio, M. Raffaele, M. Zavettieri, A. Falzea, and M. Nardi

Incidence of arthralgia syndrome (AS) related to aromatase inhibitors (AIs) in postmenopausal women with early breast cancer (EBC)
J Clin Oncol (Meeting Abstracts) 2009 27: e11603. [Abstract]  

J. Menard, Sr., J. Extra, J. Jacquemier, M. Buttarelli, E. Lambaudie, M. Bannier, I. Brenot Rossi, and G. Houvenaeghel

Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy
J Clin Oncol (Meeting Abstracts) 2009 27: e11604. [Abstract]  

S. Lee, J. Yang, S. Nam, J. Lee, W. Kim, J. Choi, G. Kim, and G. Kim

Triple detection method for sentinel lymph node detection
J Clin Oncol (Meeting Abstracts) 2009 27: e11605. [Abstract]  

Y. Suh, S. Oh, B. Song, and S. Jung

TAC (docetaxel, doxorubicin, and cyclophosphamide) adjuvant chemotherapy supported by G-CSF without dose-reduction in node-positive breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11606. [Abstract]  

Y. Tian, D. Hua, Y. Ji, X. Li, J. Liu, B. Wang, and D. Yu

The patterns of care studies for operable breast cancer in China
J Clin Oncol (Meeting Abstracts) 2009 27: e11607. [Abstract]  

P. Martin, C. Mazouni, F. André, and P. Bonnier

Impact of the mode of estrogen receptor determination on breast cancer prognosis
J Clin Oncol (Meeting Abstracts) 2009 27: e11609. [Abstract]  

J. Iturbe, Jr., A. Zwenger, J. A. Lacava, P. Perez Verdera, C. Vallejo, A. Romero, J. P. Leone, J. Perez, M. Maccihavelli, and B. Leone

Treatment of early breast cancer (EBC): A long-term follow-up study—GOCS experience
J Clin Oncol (Meeting Abstracts) 2009 27: e11610. [Abstract]  

M. Almubarak, V. Gadiyaram, S. Osman, G. Hobbs, A. Saad, G. Marano, and J. Abraham

Impact of FDG-PET scan on follow-up care in nonmetastatic breast cancer
J Clin Oncol (Meeting Abstracts) 2009 27: e11611. [Abstract]  

M. Moe, M. Almatari, P. Ali, and P. Willshaw

Bisphosphonate therapy requirement during adjuvant aromatase inhibitor therapy in early breast cancer patients according to UK bone health guidelines
J Clin Oncol (Meeting Abstracts) 2009 27: e11612. [Abstract]